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1.1 Preface 
Polymeric materials surround us in our everyday life. These materials are 
composed of  large chain-like molecules called polymers that consist of  small 
building blocks called monomers. There are natural polymers such as wool, rubber, 
silk and starch, and there are synthetic polymers such as nylon, polyester, Teflon, 
poly(ethylene) (PE), poly(vinyl chloride) (PVC), or poly(ethylene terephthalate) 
(PET).  
There is growing concern about the impact of  abundant use, especially of  
synthetic polymers, on environment pollution and large consumption of  non-
renewable resources to create synthetic polymers. Globally, more than 260 million 
tons of  synthetic polymers are produced annually, corresponding to approximately 
8% of  the mineral oil consumption per year [1]. It goes without saying that this 
will not be sustainable in the long run. Obviously, society will have to turn to the 
“three Rs” (reduce, reuse and recycle) or even the “fourth and fifth Rs” (energy recover 
and molecular redesign) to cope with these major problems. These “Rs” continuously 
stimulate industrial and academic researchers to explore and develop eco-friendly 
and sustainable polymers based on green and renewable resources. One prominent 
example of  such a polymer is poly(lactic acid) (PLA), a biodegradable 
thermoplastic polymer derived from sugar, which can be made suitable for many 
applications.  
PLA played a central role in the research leading to this thesis. This chapter 
provides a general introduction to PLA, with a focus on synthesis, properties and 
biomedical applications of  PLA, followed by the scope and impetus of  the thesis, 
and concludes with an outline of  the thesis.  
1.2 An Overview of  PLA  
Synthesis of  PLA  
PLA is an aliphatic polyester synthesized from lactic acid derived from renewable 
sources, such as wheat, corn starch and sugarcane [2-4]. Among several production 
techniques for PLA, direct polycondensation of  lactic acid and ring-opening 
polymerization (ROP) of  lactide (the dimer of  lactic acids) are the most commonly 
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used [5]. Lactide is a chiral molecule and three stereoisomers exist: L,L-lactide, 
D,D-lactide and meso-lactide, as shown in Figure 1.  
 
Figure 1. Stereoisomers of  lactide, showing the three variants. 
The synthesis routes of  PLA are illustrated in Figure 2. Direct condensation 
of  lactic acid usually produces low to intermediate polymers due to breakdown of  
polymer chains caused by water generated during the polymerization process [6]. 
Removal of  water helps to increase the molecular weight, but simultaneously 
requires high temperature and high vacuum with risk of  darkening and 
racemization of  PLA [7]. The resultant PLA (low to intermediate) can be coupled 
by chain extenders, e.g. isocyantes and peroxide, to produce a range of  different 
molecular weights [8]. ROP allows high controllability of  the polymerization and 
provides PLA of  defined molecular weight and structure (i.e. ratio and sequence 
of  D- and L-unit) [9-13].  
Cargill Dow Polymers and Mitsui Chemicals are two of  the leading companies 
in the development of  PLA. These two companies produce high-molecular-weight 
PLA through different routes. Cargill utilizes direct condensation to first synthesize 
low-molecular-weight PLA, which is then depolymerized to obtain lactide. The 
resultant lactide is purified by distillation, followed by ROP to produce PLA with 
controlled molecular weights [8]. Mitsui produces high-molecular-weight PLA 
though a solvent-based direct condensation route, in which water is removed 
continuously by azeotropic distillation [14]. These two processes are displayed in 
Figure 2. 
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Figure 2. Synthesis routes of  PLA. Adapted from [15] with permission. 
Properties of  Poly(lactic acid) 
The physical, mechanical and thermal properties of  PLA are closely related to its 
composition, stereochemistry, molecular weight, molecular weight distribution and 
crystallinity [16-17]. The steric structures of  PLA can be easily controlled by 
polymerization of  different lactides through the use of  special catalysts [5]. 
Different steric structures, thermal history and processing technologies directly 
affect PLA crystallinity, and thus its properties [18-20]. In general, there are four 
PLA variants: poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(D,L-
lactic acid) (PDLLA) and PLA made from meso-lactide. PLLA and PDLA are 
semi-crystalline polymers with a regular chain structure, while PDLLA is 
amorphous. The content of  L-lactic acid has a significant effect on the degree of  
crystallinity of  PLA, e.g. when the content of  L-lactic acid is lowered from 100% 
to 92%, crystallinity of  PLA decreases from 57% to 32% [18]. Some properties of  
PLA are summarized in Table 1. 
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Table 1. Properties of  PLA [21-22]. 
Poly(lactic acid) 
Glass Transition 
Temperature  
[oC] 
Melting Temperature 
[oC] 
Density 
[g/cm3] 
PLLA 55-80 ~180 1.290 
PDLA 50-60 ~180 1.248 
PDLLA 43-53 120-170 1.250 
PLA has four outstanding advantages over other polymeric materials – 
renewability, biocompatibility, processability and energy saving [23]. These four 
aspects will be further explained. 
(i) Renewability. Consumption of  non-renewable resources and serious 
environment pollutions are great concerns for utilization of  petrochemical-based 
conventional polymeric materials such as PE, PET and poly(propylene) (PP). 
These concerns prompt academia and industry to develop eco-friendly polymers 
based on renewable resources like PLA [24]. PLA is made from renewable 
agricultural raw materials, is fully compostable and provides low environmental 
pollution and toxicity [25-26].  
(ii) Biocompatibility. PLA has been proven biocompatible and has been 
approved by US Food and Drug Administration (FDA) for biomedical use [21, 27-
29]. In vivo, PLA can degrade by hydrolysis into short chains and finally to lactic 
acid. Thereafter, lactic acid is converted to pyruvate by lactate dehydrogenase, 
followed by decarboxylation and oxidization towards acetyl-coA, which can enter 
the Krebs cycle (tricarboxylic acid cycle, TCA cycle) and finally will be excreted 
[30]. The degradation rate is affected by various factors including PLA crystallinity, 
molecular weight, purity and morphology [31-34]. The good biocompatibility and 
biodegradability of  PLA lead to wide applications of  PLA in the biomedical field, 
e.g. sutures, scaffolds and drug delivery systems [4-5, 35-40].  
(iii) Processability. PLA has good thermal processability and can be processed 
by extrusion, stretch blow molding, injection molding, film casting, and fiber 
spinning [15, 20, 23].  
(iv) Energy saving. 5%-55% less energy is required for the production of  PLA 
compared with classical petroleum-based polymers (42 MJ/kg PLA vs. 70 MJ/kg 
for PET) [7, 41]. New technological developments on PLA production still allow 
lowering energy cost to synthesize PLA. For instance, energy consumption of  PLA 
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produced by NatureWorks, a leading company in PLA industry, was reduced from 
50 MJ/kg polymer in 2005 to 42 MJ/kg polymer in 2009 [41]. NatureWorks has 
even targeted an energy reduction to achieve 35 MJ/kg polymer in the near future 
[41]. 
Although PLA is an attractive biomaterial with excellent properties it also has 
some disadvantages, which may limit its utilization in certain fields. Brittleness is a 
general drawback of  PLA [15]. PLA has high tensile strength (53 MPa) and high 
tensile modulus (3.4 GPa) comparable to those of  PET (54 MPa and 2.8 GPa). 
However, PLA is much more brittle than PET, showing a smaller elongation at 
break (6% for PLA vs. 130% for PET) [42]. The inherent brittleness of  PLA 
impedes its use in applications requiring high toughness. Considering these 
limitations of  PLA, researchers have made considerable efforts on strategies of  
bulk and surface modifications of  PLA, e.g. copolymerization, blending, coating, 
entrapment and photografting, to modulate the properties of  PLA (hydrophobicity, 
toughness, reactive functionalities and biodegradability), thereby making PLA meet 
the requirements of  specific applications [15, 23, 43-45]. 
Biomedical Applications of  PLA  
Sutures 
Surgical sutures are a class of  medical devices developed to (mechanically) stitch 
body tissues together after injury or surgery. In principal, suture materials must be 
strong enough and provide sufficient support until healing has occurred. The study 
on bioresorbable PLA sutures started from 1960s. In 1966, Kulkarni et al. [27] 
synthesized PLLA of  high molecular weight and implanted PLLA powder and 
films in the abdominal wall of  several guinea pigs. The PLLA powder and films 
were found to be tissue receptive and degrade slowly in vivo, causing only mild 
inflammatory reactions. These results prompted the use of  PLA as a surgical 
suture material. Thereafter, Kulkarni et al. [46] set out to develop sutures based on 
PLLA and PDLLA. In their experiments, PDLLA was first molded into rods, 
which were then processed into fibers with appropriate tensile properties by melt 
spinning. Subsequently, fibers were plied and twisted into 520 deniers yarn. 
PDLLA sutures implanted intramuscularly revealed tissue responses similar to 
stainless steel and Dacron (PET suture). 
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The good biocompatibility of  PLA makes it a potential material for sutures, 
however utilization of  PLA fibers as bioresorbable sutures is rather limited due to 
slow degradation rates of  PLA homopolymers (50% in 1 – 2 years) [47]. 
Consequently, copolymers of  PLA, which degrade faster than PLA homopolymers, 
are commercially used for sutures. One example is Vicryl®, a suture composed of  
poly(glycolide-co-L-lactide) (PGLA, 90/10). The complete absorption time for 
Vicryl® is between 56 and 70 days [48]. The slow degradation and good mechanical 
properties of  PLA make it suitable for applications requiring long retention of  
strength. Lam et al. [49] studied the potential of  reinforced PLLA fibers as long-
term degradable suture material. The reinforced PLLA fibers had higher tensile 
strength than poly(dioxanone) (PDS®) or Vicryl® sutures after 12 weeks in vitro 
degradation. In addition, inflammatory response against the PLLA fibers 
implanted intramuscularly was comparable to Ethilon® (nylon sutures). Mäkelä et al. 
[36] compared the mechanical properties of  self-reinforced PLLA (SR-PLLA) 
sutures with poly(glyconate) (MaxonTM) and PDS® sutures in vitro; SR-PLLA 
sutures maintained their tensile strength for the longest time. 
Implants 
Kulkarni et al. introduced the concept of  biodegradable implants in the late 1960s 
[27, 46, 50]. PLA is preferred for use in applications requiring good mechanical 
performance, such as implants in orthopedics (e.g. shoulder lesions repair, meniscal 
repair, bone fixation, fracture fixation, ligament augmentation, and tendon 
reconstruction) and vascular stents [35, 37, 51-57]. 
Fully absorbable bone or ligament fixation devices made of  alpha-hydroxy 
polyesters, i.e. poly(glycolic acid) (PGA) and PLLA, were introduced clinically by 
Rokkanen et al. in 1984 [52]. In the last three decades, numerous efforts have been 
made to develop biodegradable orthopedic implants in the form of  rods, plates, 
screws, cages and wires. There are two main advantages of  biodegradable implants 
compared with metal ones. Firstly, biodegradable implants eliminate the need for a 
second surgery to remove the device; secondly, they can reduce the long term 
biohazard concerns on retained implants, e.g. corrosion, osteoporosis resulting 
from stress shielding and negative interference with imaging modalities (X-ray, CT 
and MRI) [29, 54, 58-59]. PLA, PGA and their copolymer PLGA are the most 
widely used materials in this field. There is a big difference between the 
degradation profiles of  these polymers, ranging from a few months for PGA [60], 
to more than 12 weeks for PLGA 85/15 [61] and more than five years for PLLA 
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[62]. The degradation rate of  the polymer has a direct relation with the foreign-
body reactions triggered by the implant [63]. A more severe foreign-body reaction 
can occur when by-products and particles from the polymer degradation exceed 
the clearing mechanism in the body [50]. As a consequence, the adverse reaction 
rates with PLA implants are usually lower than that with PGA implants. For 
example, in a clinical study with 2,500 patients, 2.3 % of  the patients with PGA 
bone fixation implant had foreign-body reactions, whereas none of  patients with 
relatively slow degrading PLA implants built up a reaction [52]. Although for short 
and intermediate implantation time foreign-body reaction for PLA implants is low, 
adverse tissue reactions can be found with PLLA implants as late as 4 or 5 years 
after operation [62, 64]. Bergsma et al. [62] reported foreign body reactions to 
PLLA implants due to degradation towards highly crystalline PLLA particles that 
took place after an implantation period of  5.7 years. These particles were resistant 
to hydrolysis and were internalized by phagocytic cells.  
PLA is also applied to construct biodegradable vascular stents, which are 
devices that support vascular lesion after angioplasty and gradually disappear. 
PLLA and PDLLA have been utilized to build stents [65]. One example is 
ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA), the first drug-eluting 
biodegradable stent composed of  PLLA and PDLLA. This stent is made of  PLLA 
scaffold and a PDLLA coating that controllably elutes everolimus, an 
immunosuppressant to prevent restenosis of  the vessel. Clinical studies of  this 
stent showed promising results, indicating that biodegradable stents could be an 
alternative to traditional non-degradable metal stents [66-68]. 
Tissue Engineering 
Tissue engineering is a technique to create implantable living tissues by combining 
cells with supportive scaffolds, also referred to as matrices or constructs. Cells can 
adhere or settle on these scaffolds, allowing them to proliferate and to finally 
develop into functional tissues under certain physiological conditions. Tissue 
engineering has attracted great attention because of  its potential to serve as 
alternative for tissue transplantation in treating organ failure and tissue loss. PLA 
and PLA-based copolymers, such as PLGA, are the most commonly used synthetic 
polymeric materials in tissue engineering. This is directly related to their 
biocompatibility, biodegradability, good mechanical strength as scaffolds, and 
controllability of  various properties (e.g. degradation time, porosity and mechanical 
properties) to match special tissue and/or physical requirements [28, 40, 69]. 
 General Introduction 
15 
The strong hydrophobicity of  PLA results in low binding affinity for cells 
when using it as a scaffold for tissue engineering [70]. Modifications are required to 
bypass this non-favorable characteristic. To improve cell adhesion, Sultana et al. [71] 
fabricated poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV)/PLLA-based 
composite scaffolds with a collagen coating. The coating increased wettability of  
the scaffold and thereby improved attachment of  osteoblastic cells. Pu et al. [72] 
constructed oxidized collagen-PLLA hybrid scaffolds for abdominal wall repair. 
These hybrid scaffolds showed higher bladder smooth muscle cell adhesion and 
proliferation in comparison with bare PLLA scaffolds. The higher dose of  
oxidized collagen resulted in better cell adhesion and tissue integration. Ju et al. [73] 
produced porous acrylic acid grafted PLLA scaffolds for tissue-engineering 
cartilage. The surface modification substantially improved adhesion and 
proliferation of  chondrocytes. PLLA microfibers have been evaluated for the 
creation of  a vascular network as well [74]. RGD (peptides)-biofunctionalized 
PLLA microfibers (diameter 10 µm) were prepared and incubated in a 
HUVEC/HFF (endothelial cells/fibroblasts) co-culture system for at least 21 days. 
Capillary-like structures were found adjacent to the fibers at the end of  the 
incubation, which demonstrated the feasibility of  PLLA microfibers as a guide 
system to direct vascularization.  
The acidic degradation products of  PLA-based polymers are immunogens for 
tissue reactions owning to the resulting decrease in local pH, hence degradation 
behavior of  the building materials of  scaffolds is essential for surrounding cells 
and tissues [63]. Asawa et al. [75] compared PLLA scaffolds with PLGA scaffolds 
for the production of  tissue-engineered cartilage in a canine autologous cartilage 
transplantation model. PLLA scaffolds possessed abundant cartilage at the early 
stage of  transplantation, but no cartilage was found in PLGA scaffolds. They 
attributed the superiority of  PLLA to its slow degradation which could have led to 
a decrease in severe tissue reactions. PLGA degraded much faster and the 
degradation products may have evoked a more severe tissue response.  
Apart from these fields of  tissue engineering, PLA and PLA-based materials 
also find their application in many other regions, like bone regeneration [76-77], 
neural repair [78-79] and periodontal regeneration [80]. 
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Drug Delivery System  
Polymeric microspheres and nanoparticles have been investigated as delivery tools 
to achieve targeted delivery and sustained release of  drugs. Microspheres can be 
defined as spherical particles ranging in size from 1 to 1000 µm. Particles smaller 
than 100 nm are called nanoparticles. These microspheres and nanoparticles, can 
preserve bioactivity of  the drug cargo, improve the therapeutic efficacy and 
minimize side effects in vivo. PLA and PLA-based copolymers are widely used as 
building materials for these delivery systems due to their good biocompatibility, 
biodegradability and solubility in various organic solvents [81]. 
Drug-loaded PLA microspheres are conventionally prepared through solvent 
based methods - single emulsion or double emulsion method. In recent years, 
development of  new manufacturing technologies have enabled encapsulation of  
biological molecules, such as proteins, RNA/DNA and vaccines in microspheres 
[82-83]. One important application of  PLA and PLA-based microspheres is their 
use for cancer therapy. In vivo studies of  microspheres loaded with anti-tumor 
compounds, like cisplatin [38-39] or 5-fluorouracil [84], showed maintenance of  
anticancer potency of  the drug applied and reduction of  acute renal toxicity as 
compared to systemic administration.  
The release of  drug (or other biological agents) from PLA-based 
microspheres is controlled by two processes: (i) drug diffusion; and (ii) polymer 
degradation. Physical properties of  the microspheres, e.g. average size, size 
distribution, inner structure and surface morphology, greatly influence their drug 
release profile. These properties can be tailored by formulation variables of  the 
fabrication process [85]. For example, a decrease in size of  microspheres will 
accelerate the drug release process, because larger surface areas of  smaller particles 
will enable higher water absorption and thereby facilitate drug diffusion [81]. Pore-
forming in microspheres can increase the drug release rate as well, since the drug 
can diffuse through the water-filled pores, which will be much faster than diffusion 
through the dense polymer matrix [86]. Considering the slow degradation of  PLA 
homopolymers, PGLA is generally preferred when faster degradation rate is 
required.  
Apart from microspheres, various nanoparticles based on PLA or PLA-based 
copolymers have also been studied [87-90]. Two most interesting aspects of  
nanoparticles are: (i) their small size allows nanoparticles to permeate some 
biological barriers (e.g. blood-brain barrier); (ii) delivery targetors can be bound to 
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nanoparticles to achieve targeted drug release. For example, Rencan et al. [90] 
prepared PLA particles for transepidermal drug delivery. These particles 
penetrated into 50% of  the vellus hair follicles in vitro and formed aggregates and 
clusters in the follicles. Hu et al. [91] prepared lactoferrin (Lf) conjugated 
poly(ethylene glycol)-PLA nanoparticle (Lf-NP) for brain drug delivery. Lactoferrin 
is a brain delivery targetor. In vivo results showed that both Lf-NP and 
unconjugated nanoparticles successfully permeated through the blood-brain barrier. 
The brain up-take of  Lf-NP was significantly higher than that of  unconjugated 
nanoparticles. 
1.3 Scope and Impetus of  the Thesis 
This thesis focuses on PLA-derived biomaterials with two biomedical applications 
in mind: biodegradable vascular stents and biodegradable embolic microspheres 
for transarterial chemoembolization (TACE). Section 1.3.1 provides an 
introduction to biodegradable vascular stents and the impetus for the studies 
presented in Chapters 2 and 3. Section 1.3.2 addresses the current state of  
development in embolic microspheres and also the impetus for the research of  
Chapters 4 and 5. 
Biodegradable Vascular Stents 
Percutaneous transluminal coronary angioplasty (PTCA) has become an important 
treatment for coronary disease in the past three decades [92]. The first PTCA was 
performed in 1977 and later clinical reports demonstrated acceptable safety of  this 
procedure [93-94]. The major limitations of  PTCA included high early abrupt 
closure rates (up to 6%) and high restenosis rates (up to 30%), leading to the 
development of  bare metal stents [95-96]. Bare metal stents are tubular mesh 
devices, which allow maintenance of  vascular patency at the site of  the 
atherosclerotic lesion after coronary angioplasty. The implantation of bare metal 
stents by PTCA reduced early procedural complications (e.g. acute closure), but 
bare metal stents were not effective in reducing late event restenosis and stent 
thrombosis [97]. These concerns prompted the development of drug-eluting stents 
(DES), in which the bare metal stent is coated with a polymer-layer containing 
anti-proliferative agents. Its mechanism of  action has two components: (i) the 
scaffold provides mechanical support to the balloon-dilated blood vessel at the site 
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of  the lesion; (ii) an anti-proliferating drug slowly releases from the polymeric 
coating of  the scaffold, inhibiting migration and proliferation of  neighboring 
smooth muscle cells [98-99]. DES has significantly reduced restenosis rates (< 2%) 
[100], still clinical practice and long-terms clinical studies on DES reveal safety 
issues related to late stent thrombosis [100-101]. By using bioresorbable stents 
these late events may eventually be overcome. 
Bioresorbable stents, also called bioresorbable vascular scaffolds, are a 
relatively new generation of stents. These stents support the vascular lesions after 
angioplasty for a certain period of time (depending on the properties of building 
materials), can release anti-atherosclerotic drugs and gradually dissolve [102-104]. 
The bioresorbability of bioresorbable stents makes it a promising device with 
several advantages over non-degradable stents: (i) avoid the need for long-term 
antiplatelet therapy; (ii) reduce or eliminate the adverse effects of non-degradable 
DES, e.g. neo-atherosclerosis, chronic inflammation (foreign body response) and 
the increased risk of late stent-associated thrombosis [68, 105-106]; (iii) enable 
follow-up with non-invasive imaging, e.g. MRI and CT [107-109].  
Several types of  bioresorbable DES have been described. While some consist 
of  biodegradable metal or alloys (e.g. magnesium) [110-111], most of  them are 
polymer devices [103, 112]. Some of  these devices are still in an early phase of  
development, while others have already entered the market and have been used to 
treat human patients.  
An interesting version of  a bioresorbable metal-based scaffold is the AMS 
stent (Biotronik, Berlin, Germany). This device is largely composed of  magnesium, 
and its physical properties closely match those of  other metallic stents. The 
resorption kinetics, thrombogenicity and inflammatory responses in vivo were 
found to be acceptable [113]. The original version of  AMS has been re-engineered 
into a drug (paclitaxel)-eluting version called AMS-3/DREAMS. Clinical results 
from first-in-man trial of  DREAMS showed 100% procedural success, and no 
cardiac death or stent thrombosis up to 12 months follow-up [114].  
The first-developed biodegradable vascular scaffold was the Igaki-Tamai stent 
(Igaki Medical Planning Co., Kyoto, Japan) [115]. The device had a zig-zag helical 
coil design, and it consisted of  PLLA. The stent did not contain any drug. 
Implantation of  the Igaki-Tamai stent required an 8 French guiding catheter, as 
well as pre-heated contrast medium (necessary to achieve full expansion of  the 
stent in situ) [116]. The first implantation in man was done successfully in 1998 and 
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the study comprised 15 patients with 19 lesions that were treated with 25 scaffolds. 
Igaki Medical recently re-engineered the design of  the stent. The newest version 
can be implanted using a more narrow catheter (6 French), and it is no longer 
necessary to heat the contrast agent to achieve full stent expansion.  
The third example of  a degradable stent is the ReZolve stent (Reva Medical 
Inc., San Diego, CA, USA), which is still in clinical trials. This polymer stent is 
made out of  tyrosine-derived polycarbonate polymer. The stent is both resorbable 
and radiopaque. The stent resorption produces water, carbon dioxide, ethanol as 
well as amino acids [35, 117]. The resorption process is completed in around two 
years depending on the molecular weight of  the polymer applied.  
Perhaps the most prominent example of  a bioresorbable vascular scaffold is 
the CE-marked Absorb BVS (Abbott Vascular, Santa Clara, CA, USA). It consists 
of  a backbone of  crystalline PLLA and a surface coating of  amorphous PDLLA 
that is impregnated with the drug everolimus. Numerous studies on clinical 
performance of  Abbott’s BVS have been published during the last years (so-called 
ABSORB Cohort A or B studies) [118-123]. The clinical performance of  this 
scaffold was generally found to be excellent. In the ABSORB Cohort A trial, 
evolving 30 patients, four-year follow-up demonstrated a sustained low rate of  
adverse clinical events (3.4 %) and complete absence of  late complications such as 
stent thrombosis [118-121]. The ABSORB Cohort B trial, focusing on the impact 
of  vessel size on long-term outcomes, enrolled 101 patients. Two-year clinical 
results revealed a significant late lumen increase and positive vessel remodeling in 
vessels smaller than 2.5 mm for the BVS treated individuals [122-123].  
Based on the available data on clinical performance, it is currently believed 
that bioresorbable vascular scaffolds have the potential to overcome the drawbacks 
of  traditional metallic stents, particularly the problem of  late stent-associated 
thrombosis. Perhaps the only drawback that most of  current PLA-based scaffolds 
still exhibit is their radiolucency, i.e. these implants are transparent to X-radiation. 
The scaffolds are therefore invisible on the real-time X-ray images that normally 
provide guidance during metal stent implantation. This is a real drawback, as the 
precise deployment of  the stent inside the lesion is critical to the success of  the 
procedure. The currently applied solution to this problem is incorporation of  small 
metallic markers, usually at the distal and proximal ends of  the stent. These 
markers are used to navigate the stent precisely into the lesion. Nonetheless, 
monitoring of  the expansion process remains difficult.  
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Chapters 2 and 3 present a new solution to the translucency problem of  
biodegradable PLA stents by working on the development of  a new X-ray contrast 
agent. This agent not only provides the capacity to absorb X-radiation throughout 
the entire scaffold, it is also perfectly miscible with the PLA matrix. The latter is a 
necessary boundary condition, since otherwise (i.e. in the case of  phase separation), 
bioresorption would be largely uncontrolled, and physical-mechanical properties 
of  the stent would be inadequate.  
Biodegradable Embolic Particles 
TACE is a minimally invasive therapy used in oncology to treat unresectable 
tumors, e.g. hepatocellular carcinoma. During TACE, a mixture of  lipiodol and 
chemotherapeutic drugs is injected via a catheter into the feeding vessel bed of  a 
tumor, followed by embolization with spherical or nonspherical embolic agents 
[124-125]. Most commonly used chemotherapeutics are doxorubicin, cisplatin, 
epirubicin and mitomycin C [126-129]. Optimal results are achieved when drug-
eluting microspheres are used as embolic agents, i.e. the chemotherapeutic drugs 
are loaded to embolic microspheres [129-131]. TACE of  a solid tumor with drug-
eluting embolic particles combines two mechanisms of  action: (i) induction of  
local ischemia by particles blocking the arterial blood supply to parts of  the tumor; 
(ii) local delivery of  chemotherapy. 
DC-Bead® (Biocompatibles, Farnham, UK) is the most well-known device for 
embolization based on drug-eluting embolic microspheres. DC Bead® has been 
used successfully in the treatment of  liver tumors [132-136]. These polyvinyl 
alcohol (PVA) microspheres can be loaded with the well-known anti-cancer agents 
irinotecan or doxorubicin [137-140]. Irinotecan, a semisynthetic derivative of  
camphotecin (a quinoline alkaloid), inhibits the enzyme topoisomerase 1, thereby 
hampering unwinding of  DNA and subsequently cell proliferation. Doxorubicin 
(also known as adriamycin) works by nucleotide intercalation (i.e. the drug “sits” in 
between adjacent DNA or RNA nucleotide bases) and, eventually, initiates the cell 
death cascade. Drug loading of  the beads is clinically performed in the vascular 
suite prior to injection. In situ, there is a controlled and sustained release of  the 
cytostatic agent directly into the tumor tissue. This also implies that systemic side 
effects are practically eliminated. Notably, positively charged drug molecules can be 
loaded to the beads by ion exchange and then controllably released. Drugs without 
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positive charge cannot be immobilized to these beads, and thus these drugs are 
released instantaneously [141].  
The polymeric microparticles of  the product DC Bead® are not 
biodegradable, because they consist of  PVA, a stable polymeric material. Currently, 
a clear trend to search for biodegradable alternative embolic microspheres exists. 
These biodegradable variants would eliminate the concern of  possible late 
inflammatory foreign-body responses to the presence of  the microspheres [142]. 
The use of  biodegradable embolic particles could also be advantageous in 
situations requiring repeated embolization (e.g. to control growth of  a tumor).  
Weng et al. [143-144] recently described biodegradable embolic microspheres 
prepared from carboxymethyl chitosan (a biodegradable polysaccharide) and 
oxidized carboxymethyl cellulose. These microspheres contain abundant carboxylic 
groups which enable loading of  doxorubicin through an ion-exchange mechanism. 
Doxorubicin was shown to be released from the microspheres in a controlled 
manner and the release profile was tunable. The empty microspheres were 
certificated to be biocompatible and biodegradable both in vitro and in vivo. In vivo 
embolization experiments revealed that the empty microspheres could occlude 
arteries and therefore have the potential to be used as biodegradable embolic agent 
for transarterial embolization.  
Chapters 4 and 5 describe the use of  PDLLA for preparing new 
biodegradable (multiple) drug-eluting embolic microspheres. PDLLA, an 
amorphous PLA, is biocompatible and biodegradable, and has been well studied 
for biomedical applications. Two anti-cancer drugs were impregnated in these 
PDLLA microspheres: cisplatin and sorafenib tosylate. The hypothesis is that these 
PDLLA particles can be used in TACE, and that they will, once arrested inside the 
tumor, start to degrade and concomitantly release the drug payload into the 
neighboring tissue.  
Cisplatin is one of  the classical cytostatic agents, which is used to treat 
numerous human cancers (e.g. lung, ovarian, testicular and bladder) [145-146]. The 
cytotoxicity of  cisplatin is introduced through binding to nuclear DNA to form 
DNA adducts, mainly intrastrand crosslink adducts. These DNA adducts 
subsequently interfere with the normal mechanism of  DNA transcription and/or 
replication, and finally activate apoptosis [147-148]. Sorafenib tosylate (developed 
and marketed by Bayer and Onyx Pharmaceuticals) is a synthetic, non-selective 
multiple kinase inhibitor with proven anti-tumoral effects in thyroid and renal 
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cancers, and hepatocellular carcinoma [149-151]. Sorafenib tosylate inhibits 
proliferation and angiogenesis of  tumor tissues. The action mode of  this drug is 
mediated by targeting vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) related pathways [152]. The combination treatment 
of  TACE and sorafenib tosylate (intravenous administration of  sorafenib tosylate 
after TACE) appears to compare favorably with TACE or sorafenib tosylate 
monotherapies in time to progression, overall survival and tumor response [153-
155]. The combination therapy, however, also increases the risk of  adverse 
reactions, such as diarrhea, hypertension, rash and desquamation [153, 155].  
PDLLA microspheres containing cisplatin and sorafenib tosylate prepared in 
Chapters 4 and 5 have ideally the following features: (i) drugs are controllably 
released from the polymer matrix; (ii) high dose drugs can be delivered to the 
tumor site thereby eliminating adverse reactions; (iii) synergistic effect might be 
introduced by the combination of  cisplatin and sorafenib tosylate; (iv) the X-ray 
contrast of  cisplatin might enable visualization of  the microspheres in situ; (v) 
these drug-eluting microspheres can be potentially used as embolic materials in 
TACE. 
1.4 Outline of  the Thesis 
This thesis presents novel approaches to formulate new biomaterials derived from 
PLA which have the potential to be utilized for biodegradable vascular stents and 
biodegradable embolic microspheres for TACE. Chapters 2 and 3 describe the 
preparation and properties of  a series of  radiopaque PLA blends, as well as their 
potential utilization in the construction of  radiopaque bioresorbable vascular stents. 
Chapters 4 and 5 center on drug-carrying embolic microspheres made of  PDLLA. 
Chapter 4 describes the fabrication and in vitro drug release behavior of  these 
microspheres; the in vitro and in vivo therapeutic efficacies of  these microspheres 
are evaluated in Chapter 5.  
In particular, Chapter 2 describes the study on the new X-ray contrast agent, 
which was designed to be structurally compatible with PLA, and also contained 
iodine bounded covalently in a stable manner. This new agent was an 
enantiomerically pure organic structure that has not been described hitherto. The 
compound was used to manufacture two different physical blends with medical-
grade PDLLA. The resulting blends were homogeneous, revealing that the contrast 
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agent was indeed well accommodated by the polymer matrix. These blends were 
investigated further to determine their thermal properties, cytotoxicity and 
hemocompatibility. Although the glass transition temperature of  both blends were 
actually too low for stent application, it could be concluded preliminarily that the 
new contrast agent offers novel possibilities to manufacture PLA based vascular 
scaffolds that combine biodegradation and X-ray traceability.  
Chapter 3 describes further research with the new contrast agent, focusing 
on physical blending with PLLA. It is hypothesized that such blends would have 
higher glass transition temperatures as compared to their counterparts described in 
Chapter 2, an essential requirement for use at body temperature. Results in this 
chapter show that our new blends had higher glass transition temperatures and, 
hence, that they might be suitable for further development of  bioresorbable 
radiopaque vascular scaffolds. 
Chapter 4 deals with the fabrication and characterization of  the PDLLA 
microspheres. Different formulations were manufactured and tested: PDLLA 
microspheres per se, PDLLA microspheres containing cisplatin (12.4% by mass), 
PDLLA microspheres loaded with sorafenib tosylate (15.7% by mass), and 
PDLLA microspheres with cisplatin and sorafenib tosylate (each 4.8% and 7.3% 
by mass). These particles were spherical with diameters ranging from 200 µm to 
400 µm (after sieving), and drug molecules/crystals dispersed throughout the 
polymer matrix of  the microspheres. Drug release behavior of  the microspheres 
was studied in vitro. The bioactivity of  released cisplatin and sorafenib tosylate was 
investigated in vitro as well. 
Chapter 5 describes the degradation profile of  the microspheres prepared in 
Chapter 4, as well as further detailed studies on the release of  cisplatin and 
sorafenib tosylate from the microspheres. First, degradation of  the microspheres 
was determined in vitro in aqueous medium at pH 7.4. Secondly, in vitro cytotoxicity 
experiments on endothelial cells, fibroblast cells, and Renca tumor cells were 
performed to study the effect of  cisplatin released from the microspheres. In vitro 
classical matrigel endothelial tube assay was applied to study the anti-angiogenic 
effect of  released sorafenib tosylate. Then therapeutic efficacies of  these 
microspheres were evaluated in a mouse Renca tumor model by intratumoral 
injection. 
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Chapter 6 discusses the main conclusions of  the thesis as well as the future 
directions for research on the application of  PLA for coronary stents and embolic 
microspheres. 
References 
[1] R. C. Thompson, S. H. Swan, C. J. Moore and F. S. vom Saal. Our plastic age. Philos Trans R 
Soc Lond B Biol Sci 2009, 364, 1973-1976. 
[2] M. G. Adsul, A. J. Varma and D. V. Gokhale. Lactic acid production from waste sugarcane 
bagasse derived cellulose. Green Chemistry 2007, 9, 58-62. 
[3] K. J. Jem, J. van der Pol and S. de Vos. Microbial Lactic Acid, Its Polymer Poly(lactic acid), and 
Their Industrial Applications. Plastics from Bacteria. Vol. 14 (Ed.: G. G.-Q. Chen). Springer 
Berlin Heidelberg. 2010, 323-346. 
[4] A. J. R. Lasprilla, G. A. R. Martinez, B. H. Lunelli, A. L. Jardini and R. M. Filho. Poly-lactic 
acid synthesis for application in biomedical devices — A review. Biotechnology Advances 2012, 30, 
321-328. 
[5] B. Gupta, N. Revagade and J. Hilborn. Poly(lactic acid) fiber: An overview. Progress in Polymer 
Science 2007, 32, 455-482. 
[6] M. Okada. Chemical syntheses of biodegradable polymers. Progress in Polymer Science 2002, 27, 
87-133. 
[7] E. T. H. Vink, K. R. Rábago, D. A. Glassner and P. R. Gruber. Applications of life cycle 
assessment to NatureWorks™ polylactide (PLA) production. Polymer Degradation and Stability 
2003, 80, 403-419. 
[8] J. Lunt. Large-scale production, properties and commercial applications of polylactic acid 
polymers. Polymer Degradation and Stability 1998, 59, 145-152. 
[9] H. R. Kricheldorf, I. Kreiser-Saunders, C. Jürgens and D. Wolter. Polylactides - synthesis, 
characterization and medical application. Macromolecular Symposia 1996, 103, 85-102. 
[10] C. P. Radano, G. L. Baker and M. R. Smith. Stereoselective Polymerization of a Racemic 
Monomer with a Racemic Catalyst:  Direct Preparation of the Polylactic Acid Stereocomplex 
from Racemic Lactide. Journal of the American Chemical Society 2000, 122, 1552-1553. 
[11] M. P. Shaver and D. J. A. Cameron. Tacticity Control in the Synthesis of Poly(lactic acid) 
Polymer Stars with Dipentaerythritol Cores. Biomacromolecules 2010, 11, 3673-3679. 
[12] N. Nomura, R. Ishii, M. Akakura and K. Aoi. Stereoselective Ring-Opening Polymerization of 
Racemic Lactide Using Aluminum-Achiral Ligand Complexes:  Exploration of a Chain-End 
Control Mechanism. Journal of the American Chemical Society 2002, 124, 5938-5939. 
[13] M. Ajioka, K. Enomoto, K. Suzuki and A. Yamaguchi. The basic properties of poly(lactic acid) 
produced by the direct condensation polymerization of lactic acid. J Environ Polym Degr 1995, 3, 
225-234. 
[14] K. Enomoto, M. Ajioka and A. Yamaguchi. Google Patents, 1994. 
[15] H. Liu and J. Zhang. Research progress in toughening modification of poly(lactic acid). Journal 
of Polymer Science Part B: Polymer Physics 2011, 49, 1051-1083. 
[16] G. Perego, G. D. Cella and C. Bastioli. Effect of molecular weight and crystallinity on 
poly(lactic acid) mechanical properties. Journal of Applied Polymer Science 1996, 59, 37-43. 
 General Introduction 
25 
[17] A. Södergård and M. Stolt. Properties of lactic acid based polymers and their correlation with 
composition. Progress in Polymer Science 2002, 27, 1123-1163. 
[18] M. S. Reeve, S. P. McCarthy, M. J. Downey and R. A. Gross. Polylactide stereochemistry: 
effect on enzymic degradability. Macromolecules 1994, 27, 825-831. 
[19] A. Celli and M. Scandola. Thermal properties and physical ageing of poly (l-lactic acid). Polymer 
1992, 33, 2699-2703. 
[20] L. T. Lim, R. Auras and M. Rubino. Processing technologies for poly(lactic acid). Progress in 
Polymer Science 2008, 33, 820-852. 
[21] L. Xiao, B. Wang, G. Yang and M. Gauthier. Poly(Lactic Acid)-Based Biomaterials: Synthesis, 
Modification and Applications. Biomedical Science, Engineering and Technology (Ed.: D. N. Ghista). 
InTech, Morn Hill, UK. 2012, 247-282. 
[22] K. Madhavan Nampoothiri, N. R. Nair and R. P. John. An overview of the recent 
developments in polylactide (PLA) research. Bioresource Technology 2010, 101, 8493-8501. 
[23] R. M. Rasal, A. V. Janorkar and D. E. Hirt. Poly(lactic acid) modifications. Progress in Polymer 
Science 2010, 35, 338-356. 
[24] A. Khare and S. Deshmukh. Studies Toward Producing Eco-Friendly Plastics. Journal of Plastic 
Film and Sheeting 2006, 22, 193-211. 
[25] R. E. Drumright, P. R. Gruber and D. E. Henton. Polylactic Acid Technology. Advanced 
Materials 2000, 12, 1841-1846. 
[26] D. J. Sawyer. Bioprocessing – no longer a field of dreams. Macromolecular Symposia 2003, 201, 
271-282. 
[27] R. K. Kulkarni, K. C. Pani, C. C. Neuman and F. F. Leonard. Polylactic acid for surgical 
implants. Archives of Surgery 1966, 93, 839-843. 
[28] L. S. Nair and C. T. Laurencin. Biodegradable polymers as biomaterials. Progress in Polymer 
Science 2007, 32, 762-798. 
[29] S. Suzuki and Y. Ikada. Medical Applications. Poly(Lactic Acid). John Wiley & Sons, Inc. 2010, 
443-456. 
[30] K. A. Athanasiou, G. G. Niederauer and C. M. Agrawal. Sterilization, toxicity, biocompatibility 
and clinical applications of polylactic acid/ polyglycolic acid copolymers. Biomaterials 1996, 17, 
93-102. 
[31] I. Grizzi, H. Garreau, S. Li and M. Vert. Hydrolytic degradation of devices based on poly(dl-
lactic acid) size-dependence. Biomaterials 1995, 16, 305-311. 
[32] X. Zhang, U. P. Wyss, D. Pichora and M. F. A. Goosen. An Investigation of Poly(lactic acid) 
Degradation. Journal of Bioactive and Compatible Polymers 1994, 9, 80-100. 
[33] T. G. Park. Degradation of poly(d,l-lactic acid) microspheres: effect of molecular weight. 
Journal of Controlled Release 1994, 30, 161-173. 
[34] H. Cai, V. Dave, R. A. Gross and S. P. McCarthy. Effects of physical aging, crystallinity, and 
orientation on the enzymatic degradation of poly(lactic acid). Journal of Polymer Science Part B: 
Polymer Physics 1996, 34, 2701-2708. 
[35] D. M. Martin and F. J. Boyle. Drug-eluting stents for coronary artery disease: A review. Medical 
Engineering & Physics 2011, 33, 148-163. 
[36] P. Makela, T. Pohjonen, P. Tormala, T. Waris and N. Ashammakhi. Strength retention 
properties of self-reinforced poly L-lactide (SR-PLLA) sutures compared with polyglyconate 
(Maxon) and polydioxanone (PDS) sutures. An in vitro study. Biomaterials 2002, 23, 2587-2592. 
[37] L. Durselen, M. Dauner, H. Hierlemann, H. Planck, L. E. Claes and A. Ignatius. Resorbable 
polymer fibers for ligament augmentation. J Biomed Mater Res 2001, 58, 666-672. 
Chapter 1 
26 
[38] L. Kuang, D. J. Yang, T. Inoue, W. C. Liu, S. Wallace and K. C. Wright. Percutaneous 
intratumoral injection of cisplatin microspheres in tumor-bearing rats to diminish acute 
nephrotoxicity. Anticancer Drugs 1996, 7, 220-227. 
[39] Y. Nakamura, Y. Hamabe, H. Ikuta, S. H. Hyon and Y. Kuroda. An experimental study of 
regional chemotherapy using CDDP-loaded microspheres for esophageal cancer. Surg Today 
2002, 32, 335-342. 
[40] M. S. Lopes, A. L. Jardini and R. M. Filho. Poly (Lactic Acid) Production for Tissue 
Engineering Applications. Procedia Engineering 2012, 42, 1402-1413. 
[41] E. T. H. Vink, S. Davies and J. J. Kolstad. ORIGINAL RESEARCH: The eco-profile for 
current Ingeo® polylactide production. Industrial Biotechnology 2010, 6, 212-224. 
[42] Z. Cygan. Improving processing and properties of polylactic acid, Avaibable at: http://www.plasticstren
ds.net/index.php/last-months-mainmenu-28/218-improving-processing-and-properties-of-pol
ylactic-acid, 05 May 2009.  
[43] T.-M. Wu and C.-Y. Wu. Biodegradable poly(lactic acid)/chitosan-modified montmorillonite 
nanocomposites: Preparation and characterization. Polymer Degradation and Stability 2006, 91, 
2198-2204. 
[44] C. Rouzes, R. Gref, M. Leonard, A. De Sousa Delgado and E. Dellacherie. Surface 
modification of poly(lactic acid) nanospheres using hydrophobically modified dextrans as 
stabilizers in an o/w emulsion/evaporation technique. J Biomed Mater Res 2000, 50, 557-565. 
[45] A. V. Janorkar, A. T. Metters and D. E. Hirt. Modification of Poly(lactic acid) Films:  
Enhanced Wettability from Surface-Confined Photografting and Increased Degradation Rate 
Due to an Artifact of the Photografting Process. Macromolecules 2004, 37, 9151-9159. 
[46] R. K. Kulkarni, E. G. Moore, A. F. Hegyeli and F. Leonard. Biodegradable poly(lactic acid) 
polymers. Journal of Biomedical Materials Research 1971, 5, 169-181. 
[47] Y. Ikada and H. Tsuji. Biodegradable polyesters for medical and ecological applications. 
Macromolecular Rapid Communications 2000, 21, 117-132. 
[48] See: http://www.ethicon.com/healthcare-professionals/products/wound-closure/absorbable-
sutures/coated-vicryl-polyglactin-910-suture#!description-and-specs 
[49] K. H. Lam, A. J. Nijenhuis, H. Bartels, A. R. Postema, M. F. Jonkman, A. J. Pennings and P. 
Nieuwenhuis. Reinforced poly(L-lactic acid) fibres as suture material. J Appl Biomater 1995, 6, 
191-197. 
[50] A. R. Amini, J. S. Wallace and S. P. Nukavarapu. Short-Term and Long-Term Effects of 
Orthopedic Biodegradable Implants. J Long Term Eff Med Implants 2011, 21, 93-122. 
[51] A. Majola, S. Vainionpaa, K. Vihtonen, M. Mero, J. Vasenius, P. Tormala and P. Rokkanen. 
Absorption, biocompatibility, and fixation properties of polylactic acid in bone tissue: an 
experimental study in rats. Clin Orthop Relat Res 1991, 268, 260-269. 
[52] P. Rokkanen, O. Bostman, Vainionpaa, E. A. Makela, E. Hirvensalo, E. K. Partio, K. 
Vihtonen, H. Patiala and P. Tormala. Absorbable Devices in the Fixation of Fractures. Journal 
of Trauma and Acute Care Surgery 1996, 40, 123S-127S. 
[53] M. Aoki, S. Miyamoto, K. Okamura, T. Yamashita, Y. Ikada and S. Matsuda. Tensile properties 
and biological response of poly(L-lactic acid) felt graft: an experimental trial for rotator-cuff 
reconstruction. J Biomed Mater Res B Appl Biomater 2004, 71, 252-259. 
[54] W. J. Ciccone, C. Motz, C. Bentley and J. P. Tasto. Bioabsorbable Implants in Orthopaedics: 
New Developments and Clinical Applications. Journal of the American Academy of Orthopaedic 
Surgeons 2001, 9, 280-288. 
 General Introduction 
27 
[55] S. J. Nho, M. T. Provencher, S. T. Seroyer and A. A. Romeo. Bioabsorbable Anchors in 
Glenohumeral Shoulder Surgery. Arthroscopy: The Journal of Arthroscopic & Related Surgery 2009, 
25, 788-793. 
[56] Y. Kocabey, H. C. Chang, J. C. Brand, Jr., A. Nawab, J. Nyland and D. N. Caborn. A 
biomechanical comparison of the FasT-Fix meniscal repair suture system and the RapidLoc 
device in cadaver meniscus. Arthroscopy 2006, 22, 406-413. 
[57] C. Landes, A. Ballon, S. Ghanaati, A. Tran and R. Sader. Treatment of malar and midfacial 
fractures with osteoconductive forged unsintered hydroxyapatite and poly-L-lactide composite 
internal fixation devices. J Oral Maxillofac Surg 2014, 72, 1328-1338. 
[58] O. Böstman and H. Pihlajamäki. Clinical biocompatibility of biodegradable orthopaedic 
implants for internal fixation: a review. Biomaterials 2000, 21, 2615-2621. 
[59] M. C. Kennady, M. R. Tucker, G. E. Lester and M. J. Buckley. Histomorphometric evaluation 
of stress shielding in mandibular continuity defects treated with rigid fixation plates and bone 
grafts. International Journal of Oral and Maxillofacial Surgery 1989, 18, 170-174. 
[60] G. W. Hastings and P. Ducheyne. Bioresorbable plastic material for bone surgery. 
Macromolecular Biomaterials. CRC Press, Boca Raton, Fla. 1984, 119-142. 
[61] L. Lu, S. J. Peter, M. D. Lyman, H. L. Lai, S. M. Leite, J. A. Tamada, S. Uyama, J. P. Vacanti, R. 
Langer and A. G. Mikos. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic 
acid) foams. Biomaterials 2000, 21, 1837-1845. 
[62] J. E. Bergsma, W. C. de Bruijn, F. R. Rozema, R. R. M. Bos and G. Boering. Late degradation 
tissue response to poly(l-lactide) bone plates and screws. Biomaterials 1995, 16, 25-31. 
[63] M. Vert, S. Li and H. Garreau. New insights on the degradation of bioresorbable polymeric 
devices based on lactic and glycolic acids. Clin Mater 1992, 10, 3-8. 
[64] E. J. Bergsma, F. R. Rozema, R. R. Bos and W. C. de Bruijn. Foreign body reactions to 
resorbable poly(L-lactide) bone plates and screws used for the fixation of unstable zygomatic 
fractures. J Oral Maxillofac Surg 1993, 51, 666-670. 
[65] A. S. Puranik, E. R. Dawson and N. A. Peppas. Recent advances in drug eluting stents. Int J 
Pharm 2013, 441, 665-679. 
[66] Y. Onuma, K. Nieman, M. Webster, L. Thuesen, D. Dudek, J. Ormiston and P. W. Serruys. 
TCT-37 Five-year Clinical Outcomes and Non-invasive Angiographic Imaging Results With 
Functional Assessment After Bioresorbable Everolimus-eluting Scaffold Implantation in 
Patients with De Novo Coronary Artery Disease. Journal of the American College of Cardiology 2012, 
60. 
[67] P. W. Serruys, Y. Onuma, H. M. Garcia-Garcia, T. Muramatsu, R. J. van Geuns, B. de Bruyne, 
D. Dudek, L. Thuesen, P. C. Smits, B. Chevalier, D. McClean, J. Koolen, S. Windecker, R. 
Whitbourn, I. Meredith, C. Dorange, S. Veldhof, K. M. Hebert, R. Rapoza and J. A. Ormiston. 
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting 
bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. 
EuroIntervention 2014, 9, 1271-1284. 
[68] J. Iqbal, Y. Onuma, J. Ormiston, A. Abizaid, R. Waksman and P. Serruys. Bioresorbable 
scaffolds: rationale, current status, challenges, and future. Eur Heart J 2014, 35, 765-776. 
[69] H. Tian, Z. Tang, X. Zhuang, X. Chen and X. Jing. Biodegradable synthetic polymers: 
Preparation, functionalization and biomedical application. Progress in Polymer Science 2012, 37, 
237-280. 
Chapter 1 
28 
[70] P. B. van Wachem, T. Beugeling, J. Feijen, A. Bantjes, J. P. Detmers and W. G. van Aken. 
Interaction of cultured human endothelial cells with polymeric surfaces of different 
wettabilities. Biomaterials 1985, 6, 403-408. 
[71] N. Sultana and M. Wang. PHBV/PLLA-based composite scaffolds fabricated using an 
emulsion freezing/freeze-drying technique for bone tissue engineering: surface modification 
and in vitro biological evaluation. Biofabrication 2012, 4, 1758-5082. 
[72] F. Pu, N. P. Rhodes, Y. Bayon and J. A. Hunt. In vitro cellular response to oxidized collagen-
PLLA hybrid scaffolds designed for the repair of muscular tissue defects and complex 
incisional hernias. J Tissue Eng Regen Med 2013, 15. 
[73] Y. M. Ju, K. Park, J. S. Son, J. J. Kim, J. W. Rhie and D. K. Han. Beneficial effect of 
hydrophilized porous polymer scaffolds in tissue-engineered cartilage formation. J Biomed Mater 
Res B Appl Biomater 2008, 85, 252-260. 
[74] S. Weinandy, S. Laffar, R. E. Unger, T. C. Flanagan, R. Loesel, C. J. Kirkpatrick, M. van 
Zandvoort, B. Hermanns-Sachweh, A. Dreier, D. Klee and S. Jockenhoevel. Biofunctionalized 
microfiber-assisted formation of intrinsic three-dimensional capillary-like structures. Tissue Eng 
Part A 2014, 20, 1858-1869. 
[75] Y. Asawa, T. Sakamoto, M. Komura, M. Watanabe, S. Nishizawa, Y. Takazawa, T. Takato and 
K. Hoshi. Early stage foreign body reaction against biodegradable polymer scaffolds affects 
tissue regeneration during the autologous transplantation of tissue-engineered cartilage in the 
canine model. Cell Transplant 2012, 21, 1431-1442. 
[76] Y. Liu, Q. Huang and Q. Feng. 3D scaffold of PLLA/pearl and PLLA/nacre powder for bone 
regeneration. Biomed Mater 2013, 8, 1748-6041. 
[77] A. Sadiasa, T. H. Nguyen and B. T. Lee. In vitro and in vivo evaluation of porous PCL-PLLA 
3D polymer scaffolds fabricated via salt leaching method for bone tissue engineering 
applications. J Biomater Sci Polym Ed 2014, 25, 150-167. 
[78] M. Alessandri, G. Lizzo, C. Gualandi, C. Mangano, A. Giuliani, M. L. Focarete and L. Calza. 
Influence of biological matrix and artificial electrospun scaffolds on proliferation, 
differentiation and trophic factor synthesis of rat embryonic stem cells. Matrix Biol 2014, 33, 
68-76. 
[79] L. Jin, Z. Q. Feng, M. L. Zhu, T. Wang, M. K. Leach and Q. Jiang. A novel fluffy conductive 
polypyrrole nano-layer coated PLLA fibrous scaffold for nerve tissue engineering. J Biomed 
Nanotechnol 2012, 8, 779-785. 
[80] W. Liao, M. Okada, F. Sakamoto, N. Okita, K. Inami, A. Nishiura, Y. Hashimoto and N. 
Matsumoto. In vitro human periodontal ligament-like tissue formation with porous poly-L-
lactide matrix. Mater Sci Eng C Mater Biol Appl 2013, 33, 3273-3280. 
[81] S. H. Hyon. Biodegradable poly (lactic acid) microspheres for drug delivery systems. Yonsei Med 
J 2000, 41, 720-734. 
[82] S. Mao, C. Guo, Y. Shi and L. C. Li. Recent advances in polymeric microspheres for parenteral 
drug delivery--part 2. Expert Opin Drug Deliv 2012, 9, 1209-1223. 
[83] V. Lassalle and M. L. Ferreira. PLA nano- and microparticles for drug delivery: an overview of 
the methods of preparation. Macromol Biosci 2007, 7, 767-783. 
[84] J. Li, Y. Pu, S. Wang, M. Ding, D. Chen and M. Zhu. Pharmacokinetic study and effectiveness 
evaluation of slow-release PLGA-5-fluorouracil microsphere. Cancer Chemother Pharmacol 2013, 
71, 351-359. 
[85] M. Li, O. Rouaud and D. Poncelet. Microencapsulation by solvent evaporation: State of the art 
for process engineering approaches. International Journal of Pharmaceutics 2008, 363, 26-39. 
 General Introduction 
29 
[86] H. K. Kim and T. G. Park. Comparative study on sustained release of human growth hormone 
from semi-crystalline poly(l-lactic acid) and amorphous poly(d,l-lactic-co-glycolic acid) 
microspheres: morphological effect on protein release. Journal of Controlled Release 2004, 98, 115-
125. 
[87] K. Kataoka, A. Harada and Y. Nagasaki. Block copolymer micelles for drug delivery: design, 
characterization and biological significance. Advanced Drug Delivery Reviews 2001, 47, 113-131. 
[88] N. Nasongkla, E. Bey, J. Ren, H. Ai, C. Khemtong, J. S. Guthi, S.-F. Chin, A. D. Sherry, D. A. 
Boothman and J. Gao. Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-
Ultrasensitive Drug Delivery Systems. Nano Letters 2006, 6, 2427-2430. 
[89] T. Riley, T. Govender, S. Stolnik, C. D. Xiong, M. C. Garnett, L. Illum and S. S. Davis. 
Colloidal stability and drug incorporation aspects of micellar-like PLA–PEG nanoparticles. 
Colloids and Surfaces B: Biointerfaces 1999, 16, 147-159. 
[90] F. Rancan, D. Papakostas, S. Hadam, S. Hackbarth, T. Delair, C. Primard, B. Verrier, W. 
Sterry, U. Blume-Peytavi and A. Vogt. Investigation of polylactic acid (PLA) nanoparticles as 
drug delivery systems for local dermatotherapy. Pharm Res 2009, 26, 2027-2036. 
[91] K. Hu, J. Li, Y. Shen, W. Lu, X. Gao, Q. Zhang and X. Jiang. Lactoferrin-conjugated PEG–
PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. Journal of 
Controlled Release 2009, 134, 55-61. 
[92] W. Khan, S. Farah and A. J. Domb. Drug eluting stents: developments and current status. J 
Control Release 2012, 161, 703-712. 
[93] K. M. Kent, L. G. Bentivoglio, P. C. Block, M. J. Cowley, G. Dorros, A. J. Gosselin, A. 
Gruntzig, R. K. Myler, J. Simpson, S. H. Stertzer, D. O. Williams, L. Fisher, M. J. Gillespie, K. 
Detre, S. Kelsey, S. M. Mullin and M. B. Mock. Percutaneous transluminal coronary 
angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute. Am J 
Cardiol 1982, 49, 2011-2020. 
[94] L. T. Newsome, M. A. Kutcher and R. L. Royster. Coronary Artery Stents: Part I. Evolution of 
Percutaneous Coronary Intervention. Anesthesia & Analgesia 2008, 107, 552-569. 
[95] A. F. Parisi, E. D. Folland and P. Hartigan. A comparison of angioplasty with medical therapy 
in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. 
N Engl J Med 1992, 326, 10-16. 
[96] Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention 
Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997, 350, 461-468. 
[97] T. Hinohara. Percutaneous coronary intervention: current perspective. The Keio Journal of 
Medicine 2001, 50, 152-160. 
[98] B. D. Gogas, M. McDaniel, H. Samady and S. B. King, 3rd. Novel drug-eluting stents for coronary 
revascularization, Trends Cardiovasc Med. 2014 Oct;24(7):305-313.  
[99] R. O. Escarcega, N. C. Baker, M. J. Lipinski, M. A. Magalhaes, S. Minha, A. F. Omar, R. 
Torguson and R. Waksman. Current application and bioavailability of drug-eluting stents. 
Expert Opin Drug Deliv 2014, 11, 689-709. 
[100] G. G. Biondi-Zoccai, C. Moretti, M. Lotrionte and I. Sheiban. Safety of drug-coated stents. 
Expert Opinion on Drug Safety 2008, 7, 597-606. 
[101] Y. Levy, D. Mandler, J. Weinberger and A. J. Domb. Evaluation of drug-eluting stents' coating 
durability—Clinical and regulatory implications. Journal of Biomedical Materials Research Part B: 
Applied Biomaterials 2009, 91B, 441-451. 
Chapter 1 
30 
[102] S. Brugaletta, H. M. Garcia-Garcia, Y. Onuma and P. W. Serruys. Everolimus-eluting 
ABSORB bioresorbable vascular scaffold: present and future perspectives. Expert Rev Med 
Devices 2012, 9, 327-338. 
[103] J. Iqbal, J. Gunn and P. W. Serruys. Coronary stents: historical development, current status and 
future directions. Br Med Bull 2013, 106, 193-211. 
[104] J. P. Oberhauser, S. Hossainy and R. J. Rapoza. Design principles and performance of 
bioresorbable polymeric vascular scaffolds. EuroIntervention 2009, 15. 
[105] P. W. Serruys, J. A. Ormiston, Y. Onuma, E. Regar, N. Gonzalo, H. M. Garcia-Garcia, K. 
Nieman, N. Bruining, C. Dorange, K. Miquel-Hébert, S. Veldhof, M. Webster, L. Thuesen and 
D. Dudek. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year 
outcomes and results from multiple imaging methods. The Lancet, 373, 897-910. 
[106] A. V. Finn, M. Joner, G. Nakazawa, F. Kolodgie, J. Newell, M. C. John, H. K. Gold and R. 
Virmani. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a 
marker of endothelialization. Circulation 2007, 115, 2435-2441. 
[107] J. J. Wykrzykowska, Y. Onuma and P. W. Serruys. Advances in stent drug delivery: the future 
is in bioabsorbable stents. Expert Opin Drug Deliv 2009, 6, 113-126. 
[108] C. Di Mario and G. Ferrante. Biodegradable drug-eluting stents: promises and pitfalls. Lancet 
2008, 371, 873-874. 
[109] N. Nikam, T. B. Steinberg and D. H. Steinberg. Advances in stent technologies and their effect 
on clinical efficacy and safety. Med Devices 2014, 7, 165-178. 
[110] H. Kitabata, R. Waksman and B. Warnack. Bioresorbable metal scaffold for cardiovascular 
application: current knowledge and future perspectives. Cardiovasc Revasc Med 2014, 15, 109-116. 
[111] C. M. Campos, T. Muramatsu, J. Iqbal, Y. J. Zhang, Y. Onuma, H. M. Garcia-Garcia, M. 
Haude, P. A. Lemos, B. Warnack and P. W. Serruys. Bioresorbable drug-eluting magnesium-
alloy scaffold for treatment of coronary artery disease. Int J Mol Sci 2013, 14, 24492-24500. 
[112] C. Costopoulos, T. Naganuma, A. Latib and A. Colombo. Looking into the future with 
bioresorbable vascular scaffolds. Expert Rev Cardiovasc Ther 2013, 11, 1407-1416. 
[113] R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, 
B. Heublein, M. Horrigan, C. Ilsley, D. Bose, J. Koolen, T. F. Luscher, N. Weissman and R. 
Waksman. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a 
prospective, non-randomised multicentre trial. Lancet 2007, 369, 1869-1875. 
[114] M. Haude, R. Erbel, P. Erne, S. Verheye, H. Degen, D. Bose, P. Vermeersch, I. Wijnbergen, N. 
Weissman, F. Prati, R. Waksman and J. Koolen. Safety and performance of the drug-eluting 
absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month 
results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013, 381, 836-
844. 
[115] H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, S. Matsui, H. Komori, T. Tsuji, S. 
Motohara and H. Uehata. Initial and 6-month results of biodegradable poly-l-lactic acid 
coronary stents in humans. Circulation 2000, 102, 399-404. 
[116] S. Nishio, S. Takeda, K. Kosuga, M. Okada, E. Kyo, T. Tsuji, E. Takeuchi, T. Terashima, Y. 
Inuzuka, T. Hata, Y. Takeuchi, T. Harita, J. Seki and S. Ikeguchi. Decade of histological 
follow-up for a fully biodegradable poly-L-lactic acid coronary stent (Igaki-Tamai stent) in 
humans: are bioresorbable scaffolds the answer? Circulation 2014, 129, 534-535. 
[117] N. Gonzalo and C. Macaya. Absorbable stent: focus on clinical applications and benefits. 
Vascular Health and Risk Management 2012, 8, 125-132. 
 General Introduction 
31 
[118] J. A. Ormiston, P. W. Serruys, E. Regar, D. Dudek, L. Thuesen, M. W. Webster, Y. Onuma, H. 
M. Garcia-Garcia, R. McGreevy and S. Veldhof. A bioabsorbable everolimus-eluting coronary 
stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective 
open-label trial. Lancet 2008, 371, 899-907. 
[119] Y. Onuma, P. W. Serruys, J. A. Ormiston, E. Regar, M. Webster, L. Thuesen, D. Dudek, S. 
Veldhof and R. Rapoza. Three-year results of clinical follow-up after a bioresorbable 
everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. 
EuroIntervention 2010, 6, 447-453. 
[120] P. W. Serruys, J. A. Ormiston, Y. Onuma, E. Regar, N. Gonzalo, H. M. Garcia-Garcia, K. 
Nieman, N. Bruining, C. Dorange, K. Miquel-Hebert, S. Veldhof, M. Webster, L. Thuesen and 
D. Dudek. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year 
outcomes and results from multiple imaging methods. Lancet 2009, 373, 897-910. 
[121] D. Dudek, Y. Onuma, J. A. Ormiston, L. Thuesen, K. Miquel-Hebert and P. W. Serruys. Four-
year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in 
patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2012, 7, 1060-
1061. 
[122] R. Diletti, V. Farooq, C. Girasis, C. Bourantas, Y. Onuma, J. H. Heo, B. D. Gogas, R. J. van 
Geuns, E. Regar, B. de Bruyne, D. Dudek, L. Thuesen, B. Chevalier, D. McClean, S. 
Windecker, R. J. Whitbourn, P. Smits, J. Koolen, I. Meredith, X. Li, K. Miquel-Hebert, S. 
Veldhof, H. M. Garcia-Garcia, J. A. Ormiston and P. W. Serruys. Clinical and intravascular 
imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting 
bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption 
matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013, 99, 98-105. 
[123] S. Nakatani, Y. Onuma, Y. Ishibashi, T. Muramatsu, J. Iqbal, Y. J. Zhang, R. J. van Geuns, J. 
A. Ormiston and P. W. Serruys. Early (before 6 months), late (6-12 months) and very late 
(after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. 
EuroIntervention 2014, 27, 20130829-20130809. 
[124] A. J. Richardson, J. M. Laurence and V. W. Lam. Transarterial chemoembolization with 
irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv 
Radiol 2013, 24, 1209-1217. 
[125] C. Davis, T. Boyett and J. Caridi. Renal Artery Embolization: Application and Success in 
Patients with Renal Cell Carcinoma and Angiomyolipoma. Seminars in Interventional Radiology 
2007, 24, 111-116. 
[126] S. W. Shin. The current practice of transarterial chemoembolization for the treatment of 
hepatocellular carcinoma. Korean J Radiol 2009, 10, 425-434. 
[127] A. Basile, G. Carrafiello, A. M. Ierardi, D. Tsetis and E. Brountzos. Quality-improvement 
guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol 2012, 35, 765-
774. 
[128] L. Marelli, R. Stigliano, C. Triantos, M. Senzolo, E. Cholongitas, N. Davies, J. Tibballs, T. 
Meyer, D. W. Patch and A. K. Burroughs. Transarterial therapy for hepatocellular carcinoma: 
which technique is more effective? A systematic review of cohort and randomized studies. 
Cardiovasc Intervent Radiol 2007, 30, 6-25. 
[129] E. Liapi and J. F. Geschwind. Transcatheter arterial chemoembolization for liver cancer: is it 
time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent 
Radiol 2011, 34, 37-49. 
Chapter 1 
32 
[130] J. Lammer, K. Malagari, T. Vogl, F. Pilleul, A. Denys, A. Watkinson, M. Pitton, G. Sergent, T. 
Pfammatter, S. Terraz, Y. Benhamou, Y. Avajon, T. Gruenberger, M. Pomoni, H. 
Langenberger, M. Schuchmann, J. Dumortier, C. Mueller, P. Chevallier and R. Lencioni. 
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of 
hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 
33, 41-52. 
[131] K. Malagari, M. Pomoni, A. Kelekis, A. Pomoni, S. Dourakis, T. Spyridopoulos, H. 
Moschouris, E. Emmanouil, S. Rizos and D. Kelekis. Prospective randomized comparison of 
chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock 
for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010, 33, 541-551. 
[132] M. J. Song, H. J. Chun, S. Song do, H. Y. Kim, S. H. Yoo, C. H. Park, S. H. Bae, J. Y. Choi, U. 
I. Chang, J. M. Yang, H. G. Lee and S. K. Yoon. Comparative study between doxorubicin-
eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular 
carcinoma. J Hepatol 2012, 57, 1244-1250. 
[133] R. Sacco, I. Bargellini, M. Bertini, E. Bozzi, A. Romano, P. Petruzzi, E. Tumino, B. Ginanni, 
G. Federici, R. Cioni, S. Metrangolo, M. Bertoni, G. Bresci, G. Parisi, E. Altomare, A. Capria 
and C. Bartolozzi. Conventional versus doxorubicin-eluting bead transarterial 
chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011, 22, 1545-1552. 
[134] M. Burrel, M. Reig, A. Forner, M. Barrufet, C. R. de Lope, S. Tremosini, C. Ayuso, J. M. 
Llovet, M. I. Real and J. Bruix. Survival of patients with hepatocellular carcinoma treated by 
transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical 
practice and trial design. J Hepatol 2012, 56, 1330-1335. 
[135] K. Malagari, M. Pomoni, H. Moschouris, E. Bouma, J. Koskinas, A. Stefaniotou, A. Marinis, A. 
Kelekis, E. Alexopoulou, A. Chatziioannou, K. Chatzimichael, S. Dourakis, N. Kelekis, S. 
Rizos and D. Kelekis. Chemoembolization with doxorubicin-eluting beads for unresectable 
hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012, 35, 1119-
1128. 
[136] H. J. Prajapati, R. Dhanasekaran, B. F. El-Rayes, J. S. Kauh, S. K. Maithel, Z. Chen and H. S. 
Kim. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in 
patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013, 24, 307-315. 
[137] J. D. Hecq, A. L. Lewis, D. Vanbeckbergen, A. Athanosopoulos, L. Galanti, J. Jamart, P. 
Czuczman and T. Chung. Doxorubicin-loaded drug-eluting beads (DC Bead(R)) for use in 
transarterial chemoembolization: a stability assessment. J Oncol Pharm Pract 2013, 19, 65-74. 
[138] A. L. Lewis, M. V. Gonzalez, A. W. Lloyd, B. Hall, Y. Tang, S. L. Willis, S. W. Leppard, L. C. 
Wolfenden, R. R. Palmer and P. W. Stratford. DC bead: in vitro characterization of a drug-
delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006, 17, 335-342. 
[139] J. Kaiser, J. Thiesen and I. Kramer. Stability of irinotecan-loaded drug eluting beads (DC Bead) 
used for transarterial chemoembolization. J Oncol Pharm Pract 2010, 16, 53-61. 
[140] R. R. Taylor, Y. Tang, M. V. Gonzalez, P. W. Stratford and A. L. Lewis. Irinotecan drug 
eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release 
properties. Eur J Pharm Sci 2007, 30, 7-14. 
[141] A. L. Lewis. DC Bead: a major development in the toolbox for the interventional oncologist. 
Expert Rev Med Devices 2009, 6, 389-400. 
[142] C. Senturk, V. Cakir, K. Yorukoglu, O. Yilmaz and A. Y. Goktay. Looking for the ideal 
particle: an experimental embolization study. Cardiovasc Intervent Radiol 2010, 33, 336-345. 
 General Introduction 
33 
[143] L. Weng, N. Rostambeigi, N. D. Zantek, P. Rostamzadeh, M. Bravo, J. Carey and J. Golzarian. 
An in situ forming biodegradable hydrogel-based embolic agent for interventional therapies. 
Acta Biomaterialia 2013, 9, 8182-8191. 
[144] L. Weng, P. Rostamzadeh, N. Nooryshokry, H. C. Le and J. Golzarian. In vitro and in vivo 
evaluation of biodegradable embolic microspheres with tunable anticancer drug release. Acta 
Biomaterialia 2013, 9, 6823-6833. 
[145] B. Desoize and C. Madoulet. Particular aspects of platinum compounds used at present in 
cancer treatment. Critical Reviews in Oncology/Hematology 2002, 42, 317-325. 
[146] S. Dasari and P. Bernard Tchounwou. Cisplatin in cancer therapy: Molecular mechanisms of 
action. European Journal of Pharmacology 2014, 740, 364-378. 
[147] M. A. Fuertes, J. Castilla, C. Alonso and J. M. Perez. Cisplatin biochemical mechanism of 
action: from cytotoxicity to induction of cell death through interconnections between 
apoptotic and necrotic pathways. Curr Med Chem 2003, 10, 257-266. 
[148] Z. H. Siddik. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 
2003, 22, 7265-7279. 
[149] L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, D. Wilkie, S. Wilhelm, M. Lynch and C. 
Carter. Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and 
Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5. Cancer 
Research 2006, 66, 11851-11858. 
[150] Y. S. Chang, J. Adnane, P. A. Trail, J. Levy, A. Henderson, D. Xue, E. Bortolon, M. 
Ichetovkin, C. Chen and A. McNabola. Sorafenib (BAY 43-9006) inhibits tumor growth and 
vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer 
chemotherapy and pharmacology 2007, 59, 561-574. 
[151] D. Strumberg, J. W. Clark, A. Awada, M. J. Moore, H. Richly, A. Hendlisz, H. W. Hirte, J. P. 
Eder, H.-J. Lenz and B. Schwartz. Safety, pharmacokinetics, and preliminary antitumor activity 
of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. 
The Oncologist 2007, 12, 426-437. 
[152] L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, D. Wilkie, S. Wilhelm, M. Lynch and C. 
Carter. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and 
induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 
66, 11851-11858. 
[153] L. Zhang, P. Hu, X. Chen and P. Bie. Transarterial chemoembolization (TACE) plus sorafenib 
versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. 
PLoS One 2014, 9. 
[154] A. Erhardt, F. Kolligs, M. Dollinger, E. Schott, H. Wege, M. Bitzer, C. Gog, F. Lammert, M. 
Schuchmann, C. Walter, D. Blondin, C. Ohmann and D. Häussinger. TACE plus sorafenib for 
the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES 
trial. Cancer chemotherapy and pharmacology 2014, 74, 947-954. 
[155] O. Abdel-Rahman and Z. A. Elsayed. Combination Trans Arterial Chemoembolization 
(TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A 
Systematic Review of the Literature. Digestive Diseases and Sciences 2013, 58, 3389-3396. 
 
  
 
 
 
  
 
 
Chapter 2  
 
 
A non-toxic additive to introduce X-ray 
contrast into poly(lactic acid). 
Implications for transient medical 
implants such as bioresorbable coronary 
vascular scaffolds 
 
 
 
 
 
 
 
This chapter has been published: Yujing Wang, Nynke M.S. van den Akker, Daniël 
G.M. Molin, Mick Gagliardi, Cees van der Marel, Martin Lutz, Menno L.W. 
Knetsch and Leo H. Koole. Advanced Healthcare Materials. 2014, 3, 290-299.
Chapter 2 
36 
Abstract 
Bioresorbable coronary vascular scaffolds are about to revolutionize the landscape 
of  interventional cardiology. These scaffolds, consisting of  a poly(L-lactic acid) 
interior and a poly(D,L-lactic acid) surface coating, offer a genuine alternative for 
metallic coronary stents. Perhaps the only remaining drawback is that monitoring 
during implantation is limited to two X-ray contrast points. Here, a new approach 
to make the biodegradable scaffolds entirely radiopaque is explored. A new 
contrast agent was designed and synthesized. This compound is miscible with 
poly(D,L-lactic acid) matrix, and non-toxic to multiple cell types. Blends of  
poly(D,L-lactic acid) and the contrast agent were found to be hemocompatible, 
non cytotoxic and radiopaque. The data show that it is possible to manufacture 
fully radiopaque bioresorbable coronary vascular scaffolds. Whole-stent X-ray 
visibility helps interventionalists to ensure that the scaffold deploys completely. 
This important advantage may translate into improved safety, accuracy and clinical 
performance of  cardiac stents. 
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2.1 Introduction 
The coronary stent, an implanted metallic mesh structure that provides mechanical 
support to a dilated atherosclerotic lesion in one of  the coronary arteries after 
percutaneous coronary intervention, is the most-investigated implant medical 
device. Anno 2013, the most sophisticated coronary stent carries a drug-eluting 
polymer surface coating [1-3]. The drug prevents proliferation of  smooth muscle 
cells adjacent to the stent in situ. This explains why drug-eluting stents feature 
markedly decreased rates of  in-stent restenosis, compared to bare metal stents [4-
6]. Despite this success, there are growing concerns about the fact that a metallic 
drug-eluting stent is not bioresorbable. In other words, a stent is essentially a 
permanent foreign body, which may cause so-called late stent thrombosis [7-8]. 
Moreover, it is well known that individual struts in metallic stents may break, and 
that metallic stents can have persistent or acquired mal-apposition [9].  
These concerns have stimulated the development of  biodegradable stent 
versions, which are also called drug-eluting transient bioresorbable vascular 
scaffolds. These, too, are balloon-expandable tubular structures that support the 
vascular wall, but they are built from one or more biodegradable polymers, with 
the drug impregnated therein. The drug is released in situ, concerted with the 
biodegradation. The beauty of  this concept is that the scaffold performs its 
essential tasks (structural support and drug release) only for as long as it is needed. 
Afterwards, the scaffold degrades and disappears altogether. The absence of  any 
foreign material may also reduce the requirements for long-term antiplatelet 
therapy, resulting in lower risks for bleeding complications [10]. 
Probably the best demonstration of  the technical and clinical feasibility of  the 
drug-eluting transient bioresorbable vascular scaffold concept was delivered by the 
ABSORB A and B trials, which tested the everolimus eluting bioresorbable 
vascular scaffolds ABSORB (1.0) (first generation) and ABSORB (1.1) (second 
generation), respectively [11-15]. These devices were developed by Abbott Vascular 
(Santa Clara, CA, USA). The ABSORB trials made clear that drug-eluting 
bioresorbable scaffolds may drastically change the landscape of  percutaneous 
coronary intervention in the near future. 
The struts of  the ABSORB scaffolds consist of  poly(L-lactic acid), and they 
are covered by a coating consisting of  poly(D, L-lactic acid). Actually, the 
ABSORB scaffolds are a tribute to the many hundreds of  research man-years that 
have been devoted to poly(lactic acids) during the last decades. Extensive 
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knowledge of  these polymers made it possible to engineer the scaffold properties 
precisely. The second generation (ABSORB (1.1)) resulted from a slight re-design 
in order to slow down in vivo degradation. This device ensures that sufficient radial 
support is provided to the lesion during a period of  6 months at least.   
An important characteristic of  the ABSORB scaffolds is that they contain 
two radiopaque markers. These are small platinum particles, which appear as clear 
dots on the pre- and post-procedural X-ray fluoroscopic images. The marker 
points allow the interventionalist to steer the stent exactly into the lesion. It is, 
however, not possible to really witness the deployment of  the stent. This is a 
significant difference with metallic stents; the radiolucency of  the ABSORB 
scaffolds must be regarded as a drawback. 
Triggered by this limitation, we decided to explore a methodology to impart 
radiopacity into poly(lactic acid). Here, we describe a new approach, which is based 
on a novel X-ray contrast agent. We designed this molecule with two boundary 
conditions in mind: (i) the molecule should contain covalently bound iodine; (ii) 
mixing of  the contrast agent into poly(lactic acid) should afford a homogeneous 
blend. In other words: the contrast additive should be miscible with the poly(lactic 
acid) matrix, thus avoiding phase separation. We hypothesize that accurate 
engineering of  the physical/mechanical properties, as well as the degradation 
kinetics, is possible only for homogeneous blends. In the case of  phase-separation, 
premature crack initiation and mechanical failure may occur at the boundaries 
between the polymer matrix and dispersed contrast particles. Herein, we describe a 
new contrast agent that fulfills our boundary conditions: (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid. We characterized this new compound, including its 
X-ray crystal structure, and an analysis of  its in vitro cytotoxicity for various cell 
types. Furthermore, we prepared two blends of  the contrast agent with poly(D, L-
lactic acid) (5% and 10% by mass) through micro-extrusion/mixing. The poly(D, 
L-lactic acid) is a commercial medical grade biomaterial with the viscosity-average 
molecular weight 1.34 × 105 [16-17]. The blends were homogeneous, and the 
materials were studied with respect to their microstructure, thermal behavior, X-
ray contrast, thrombogenicity and biocompatibility in vitro. Potential applications 
of  bioresorbable blends of  this type with regard to endovascular stents and other 
medical devices are briefly discussed.  
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2.2 Experiment Section 
Materials 
All chemicals were purchased from Aldrich (Zwijndrecht, The Netherlands) or 
Acros (Landsmeer, The Netherlands), unless stated otherwise. Dimethylformamide 
(DMF) was dried by calcium hydride and then distilled. Boc-L-serine (98%, ABCR 
GmbH & Co. KG, Germany), 4-iodobenzylbromide (98%, Amplachem, America) 
and other chemicals were used as received. Human coronary arterial endothelial 
cells (HCAECs) were purchased from Lonza (Lonza, Verviers, Belgium). Porcine 
skin fibroblasts (PSFs) and aortic smooth muscle cells (PSMCs) were isolated from 
porcine tissue (Dutch Landrace pig; IDDLO, Lelystad, The Netherlands). All 
animal experiments and handling were conducted according to NIH principles of  
animal care. Cell culture medium (SmGM-2 BulletKit and EGM-2-MV BulletKit) 
were from Lonza (Lonza, Verviers, Belgium). Cell culture medium (DMEM/F-12, 
Glutamax and MCDB 131), fetal bovine serum (FBS), antibiotics, calcein AM and 
ethidium homodimer-1 (EthD-1) were from Invitrogen (Breda, The Netherlands). 
Hoechst 33342 was purchased from Life Technologies (Merelbeke, Belgium). The 
fluorescent thrombin-specific substrate Z-Gly-Gly-Arg-AMC was bought from 
Bachem (Weil am Rhein, Germany). Poly(D,L-lactic acid) (PURASORB PDL 20) 
was supplied by Purac Biochem (Gorinchem, The Netherlands) and dried at 40 oC 
overnight before use. According to the supplier, the inherent viscosity of  poly(D,L-
lactic acid) was measured in chloroform at 25 oC and the viscosity-average 
molecular weight was calculated using equation (1) [16-17]: [𝜂] = 2.21 × 10−4𝑀v0.77 (dL g⁄ )      (1) 
Mv value for poly(D,L-lactic acid) was obtained as 1.34×105. 
Synthesis of  (S)-2-hydroxy-3-(4-iodobenzyloxy) Propanoic Acid 
Synthesis of  (S)-2-Hydroxy-3-(4-iodobenzyloxy) propanoic acid comprised three 
steps. The first reaction was a nucleophilic addition of  4-iodobenzylbromide and 
Boc-L-serine. The second reaction was removal of  the protective Boc group and 
the third was substitution of  the amine group with an alcohol group to complete 
the lactic acid structure.  
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First step: sodium hydride (NaH; 11.98 g in a 60% dispersion of  mineral oil, 
299.6 mmol) and DMF (450 mL) were placed in a flask (1 L) and stirred at 0 °C. In 
another flask, Boc-L-serine (15.00 g, 73.1 mmol) was dissolved in DMF (115 mL). 
This solution was stirred at 0 oC, and then added carefully to the NaH suspension. 
The resultant mixture was kept stirring at 0 oC and the evolution of  a gas 
(hydrogen) was noted. Then, 4-iodobenzylbromide (23.00 g, 77.5 mmol) was added 
and the mixture was stirred for 4 h at room temperature. The reaction progress 
was tracked through thin layer chromatography (TLC) using 
dichloromethane/methanol (CH2Cl2/MeOH; v/v = 9:1) as eluent. When TLC 
confirmed that the reaction was complete, the mixture was poured into ice water 
(400 mL) and extracted with ether (Et2O) three times. The aqueous phase was then 
acidified to pH 3 with citric acid, saturated with sodium chloride (NaCl) and 
extracted with ethyl acetate (EtOAc) five times. The combined organic layers were 
washed with ammonium acetate (NH4OAc) solution (0.01 M) twice and distilled 
water (H2O) twice. Then the organic phase was dried with magnesium sulfate 
(MgSO4), filtered and evaporated under reduced pressure. O-benzyl-4-iodine-Boc-
L-serine was obtained as an orange oil/solid in almost 100% yield (30.78 g, 73.1 
mmol) and was used without further purification. TLC (CH2Cl2/MeOH; v/v = 
9:1): Rf = 0.32; 1H NMR (300 MHz, CDCl3, δ): 7.58 (d, J = 8.3, 2H; CHAr), 6.96 (d, 
J = 8.1, 2H; CHAr), 4.40 (s, 2H; –O–CH2–C6H4I), 4.05 (q, J = 7.1, 1H; –CH–CH2–
O), 3.93 – 3.50 (m, 2H; –CH–CH2–O), 1.38 (s, 9H; –O–C–(CH3)3).  
Second step: o-benzyl-4-iodine-Boc-L-serine (30.78 g, 73.1 mmol) was 
dissolved in CH2Cl2 (100 mL). Trifluoroacetic acid (70 mL, 939.3 mmol) was added 
to the solution and the reaction mixture was stirred for 3.5 h at room temperature. 
The reaction was monitored by TLC in butanol/acetic acid/ H2O 
(BuOH/AcOH/H2O; v/v/v = 4:1:1). Volatile components of  the reaction 
mixture were removed under reduced pressure and the residue was precipitated 
into Et2O. The precipitate, o-benzyl-4-iodine-L-serine, was isolated by filtration. 
This intermediate was obtained as a white powder in 94% yield (22.06 g, 68.7 
mmol). TLC (BuOH/AcOH/H2O; v/v/v = 4:1:1): Rf = 0.47; 1H NMR (300 MHz, 
DMSO-d6, δ): 7.73 (d, J = 8.2, 2H; CHAr), 7.17 (d, J = 8.2, 2H; CHAr), 4.57 – 4.44 
(m, 2H; –O–CH2–C6H4I), 4.22 (t, 1H; –CH–CH2–O), 3.80 (ddd, J = 13.5, 10.5, 3.7, 
2H; –CH–CH2–O).  
Third step: o-benzyl-4-lodine-L-serine (22.06 g, 68.7 mmol) was dissolved in 
sulfuric acid (H2SO4; 1 M, 210 mL) and acetonitrile (210 mL) in a round-bottomed 
flask. Sodium nitrite (NaNO2; 19.00 g, 274.9 mmol) dissolved in H2O (150 mL) 
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was added dropwise. The reaction mixture was stirred for 20 h at room 
temperature. The aqueous layer was extracted with CH2Cl2 four times. The 
combined organic layers were dried with sodium sulfate (Na2SO4), filtered and 
concentrated in vacuum. The raw residue was dissolved in acetonitrile/chloroform 
(8:2, 225 mL). Subsequently the mixture was heated to boiling point and filtered. 
The resultant solution was kept at room temperature for 3 days and then at 0 oC 
for 1 day to crystalize. The iodine containing contrast agent (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid was obtained by filtration as a white crystalline 
solid (needle-shape crystals) in 38% yield (8.46 g, 26.11 mmol). TLC 
(BuOH:AcOH:H2O, v/v/v = 4:1:1): Rf = 0.66; 1H NMR (300 MHz, DMSO-d6, δ): 
7.61 (d, J = 8.2, 2H; CHAr), 6.99 (d, J = 8.1, 2H; CHAr), 4.54 – 4.40 (m, 2H; –O–
CH2–C6H4I), 4.32 (t, J = 4.0 Hz, 1H; –CH–CH2–O), 3.80 – 3.67 (m, J = 9.9, 4.1, 
2H; –CH–CH2–O). 
Preparation of  Blends and Films 
Poly(D,L-lactic acid) was blended with sodium diatrizoate and (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid respectively in a DSM XPlore 15cc Twin Screw 
Micro-Compounder [18] under N2 atmosphere to minimize the risk of  degrading 
the poly(D,L-lactic acid). The temperature was 180 oC and the blending time was 5 
min. The melt was cooled in room temperature after blending. Five different 
blends were prepared: pure poly(D,L-lactic acid) blend, poly(D,L-lactic acid) with 5% 
sodium diatrizoate, with 10% sodium diatrizoate, with 5% (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid and with 10% (S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid. The blends were compressed into films using an Atlas Manual 15T 
Hydraulic Press. The temperature was set at 150 oC and pressure was 2 ton. The 
compressing time was 5 min and the thickness of  each film was 250 μm. 
Characterization of  (S)-2-hydroxy-3-(4-iodobenzyloxy) Propanoic 
Acid 
1H NMR spectroscopy (300 MHz) was recorded at room temperature on a Bruker 
Avance 300 NMR spectrometer, using deuterated chloroform (CDCl3) or 
deuterated dimethyl sulfoxide (DMSO-d6) as solvent. Tetramethylsilane was used as 
an internal standard. 22237 Reflections were measured on a Bruker Kappa ApexII 
diffractometer with sealed tube and Triumph monochromator (λ = 0.71073 Å) at a 
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temperature of  150(2) K up to a resolution of  (sin θ/λ)max = 0.65 Å-1. Intensity 
data were integrated with the Eval15 software [19]. An analytical absorption 
correction and scaling was performed with SADABS [20] (correction range 0.48-
0.91). 2548 Reflections were unique (Rint = 0.015), of  which 2518 were observed 
[I>2σ(I)]. The structure was solved with the program SHELXT [21]. Least-squares 
refinement was performed with SHELXL-97 [22] against F2 of  all reflections. 
Non-hydrogen atoms were refined freely with anisotropic displacement parameters. 
All hydrogen atoms were located in difference Fourier maps. The hydrogen atoms 
of  the O-H groups were refined freely with anisotropic displacement parameters. 
C-H hydrogen atoms were refined with a riding model. 145 Parameters were 
refined with no restraints. R1/wR2 [I > 2σ(I)]: 0.0103 / 0.0254. R1/wR2 [all refl.]: 
0.0105 / 0.0255. S = 1.111. Flack parameter [23] x = -0.001(12). Residual electron 
density between -0.30 and 0.23 e/Å3. Geometry calculations and checking for 
higher symmetry was performed with the PLATON program [24]. (C10H11IO4, Fw 
= 322.09, colourless needle, 0.60 × 0.13 × 0.10 mm3, orthorhombic, P212121 (no. 
19), a = 5.85106(13), b = 8.8776(3), c = 21.2974(5) Å, V = 1106.26(5) Å3, Z = 4, 
Dx = 1.934 g/cm3, µ = 2.89 mm-1.) CCDC 920524 contains the supplementary 
crystallographic data for this paper. These data can be obtained free of  charge 
from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Characterization of  Materials 1 – 6 
Differential scanning calorimetry analysis was carried out using a Perkin-Elmer 
instrument under nitrogen flow (20 mL/min). All samples were first heated from 0 
oC to 200 oC at 10 oC /min and held for 3 min to erase the thermal history, then 
cooled to 0 oC at 10 oC /min, and finally heated to 200 oC at 10 oC /min. 
Morphology of  the films was characterized by scanning electron microscopy 
(SEM). Small film samples were coated with carbon and examined under a Philips 
XL 30 SEM in the backscattered electron imaging (BEI) mode. X-ray 
photoelectron spectroscopy (XPS) was done on a Quantera SXMTM from Ulvac-
PHI (Q1). The measurements were performed using monochromatic AlKα-
radiation and a spot size of  100 µm. Narrow-scans were measured of  the main 
peaks of  C, O and I. Cross-sections were made by breaking the blends (with a 
typical diameter between 1 and 2 mm) into two parts. Surface measurements were 
carried out at eleven positions per cross-section. X-ray visibility of  the blends was 
determined by a Philips X-ray inspection system [25], which has a microfocus X-
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ray tube with a small focal spot and a CCD camera in combination. The films of  
materials 2 – 6 were cut into small round films with a diameter of  approximately 6 
mm. X-ray visibility of  both the single-layer film (with a thickness of  250 μm) and 
double-layer films (with a thickness of  500 μm) as well as aluminum films (with a 
thickness of  120 μm) were investigated. The test was operated at 75 kV and all 
images were taken under the same condition. 
Cytotoxicity of  (S)-2-hydroxy-3-(4-iodobenzyloxy) Propanoic Acid 
Human coronary arterial endothelial cells (HCAECs) were cultured in Lonza 
EGM-2-MV BulletKit cell medium. Porcine skin fibroblasts (PSFs) and aortic 
smooth muscle cells (PSMCs) were isolated from porcine tissue by standard 
collagen digestion and cultured in Lonza SmGM-2 BulletKit or EGM-2-MV 
BulletKit [26], respectively. Cells mentioned above were used for all experiments. 
To define the cytotoxicity of  L-lactic acid/(S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid monomers, cells were seeded in BD Falcon 96 wells HTS Imaging 
microplates (BD, Erembodegem, Belgium) and cultured for 24 h in standard 
culture medium at high confluency (>85%) before the monomers (end 
concentrations 0-10 mM in 0.25% DMSO) were added. Corresponding DMSO 
concentration (end concentration 0.25%) was added to the negative controls to 
exclude cytotoxicity of  the solvent used. As positive control cells were incubated 
with 2.5% DMSO (end concentration) to induce cytotoxicity. After culturing 
samples for 24 h together with the monomers, Hoechst 33342 (800 nM) and 
ethidium homodimer-1 (EtHD-1, 4 μM) were added to distinguish for cell 
numbers (Hoechst positive nuclei) and number of  dead cells (EtHD-1 positive 
nuclei). Finally, cells were imaged and analyzed fully automated by using a BD 
Pathway 855 high content analyzer (BD Biosciences, Heidelberg, Germany). BD 
Attovision software (BD Biosciences, version 1.6) was used for both image 
acquisition and individual cell segmentation. Obtained numeric data was further 
analyzed with flow cytometry software (Kaluza 1.2, Beckman Coulter, Mijdrecht, 
The Netherlands) to define the number of  total (Hoechst) and dead cells (EtHD-
1). Number of  viable cells was calculated as fraction of  number of  adherent cells 
with Hoechst positive nuclei minus the number of  EtHD-1 (dead) positive nuclei 
per well, and averaged for replicates (n=6 per condition). Data was plotted as 
average viable cell numbers per well for the different monomer concentrations, 
and t-test was performed to define statistic differences, with p-value below 0.05 
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considered significantly different (Microsoft Office 2010, Excel; Microsoft, 
Redmond, WA, USA). 
Gene Expression of  L-lactic Acid and (S)-2-hydroxy-3-(4- 
iodobenzyloxy) Propanoic Acid Treated Primary Cells with Reverse 
Transcriptase Quantitative Polymerase Chain Reaction 
HCAECs, PSMCs and PSFs were seeded in 6-wells plates (seeding density 20,000 
cells/cm2) and cultured for 48 h. Next, cells were subjected 24 h to L-lactic acid, 
(S)-2- hydroxy-3-(4-iodobenzyloxy) propanoic acid (both 7.5 mM) or DMSO 
(control) added to new medium. To collect total RNA cells were washed once with 
HEPES. Qiagen RNeasy micro-kit with DNAse treatment (Qiagen, GmbH, 
Hilden, Germany) was used according to protocol of  the manufacture to lyse cells, 
collect and purify RNA. RNA quantity and quality were determined with 
NanoDrop microspectrophotometer (NanoDrop Products, Wilmington, DE, 
USA). A total of  100 ng RNA/sample was subjected to reverse transcription (RT) 
with QScript cDNA synthese kit and quantitative PCR (QPCR) was performed by 
using PerfeCTa SYBR Green kit for Biorad MiQ (both kits Quanta Biosciences, 
Gaithersburg, MD, USA) with primer concentration 10 µM. qPCR reactions were 
run on a BioRad MyiQ Single-Color Real Time QPCR system (Bio-Rad, 
Veenendaal, The Netherlands). Primers were designed with OligoperfectTM 
Designer (Invitrogen), Primer3 and Mfold [27] and synthesized by Eurogentec 
(Eurogentec, Seraing, Belgium). Samples were normalized for input based on beta-
actin (β-ACTIN), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and hypoxanthine-
guanine phosphoribosyltransferase (HPRT) values. Gene expression levels of  control 
groups were used as reference and set at 1.0. Statistical significance was defined by 
applying one-way ANOVA/Tukey (GraphPad Prism 5.0, GraphPad Software, San 
Diego, CA, USA) testing on the dataset, containing a total of  4 replicates per 
group. All data presented as mean relative expression ± SEM. Graphs were 
generated with GraphPad Prism 5.0. 
MTT Assay 
MTT assay was used to determine the cytotoxicity of  blends on mouse fibroblast 
cells (3T3 cells). Culture medium used for 3T3 cells was DMEM/F-12 medium 
containing Glutamax, 10% FBS and antibiotic/antimycotic solution (1x). 0.2 g of  
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each blend was cut into small pieces which were then sterilized with ethanol for 20 
min. Sterilized blends were subsequently incubated in culture medium (2 mL for 
each blend) at 37 oC for 48 h. 3T3 cells were transferred to a 96-well tissue culture 
plate (TCP) with a seeding density of  about 103 cells/well and cultured in an 
incubator at 37 oC with 5% CO2 and high humidity for 24 h. Then the medium 
was replaced by supernatants extracted from blends and cells were incubated for 
another 48 h. Then 20 μL medium containing thiazolyl blue (MTT, 3mg/mL) was 
added to each well. After culturing for 2 h, medium was removed and 100 μL 
isopropanol was added to dissolve the precipitated formazan. The absorbance of  
samples was measured in a microtiter plate reader at 570 nm. TCP wells with 
medium were used as negative control and those with medium extracted form latex 
were used as positive control. 
LIVE/DEAD Assay 
Both mouse 3T3 cells and human microvascular endothelial cells (HMECs) were 
used in the live/dead cells test. The culture medium of  3T3 cells was the same as 
that used in MTT assay. For HMECs the culture medium was MCDB-131 medium 
supplemented with 10% FBS, 2 mm L-glutamine, 1 μg/mL hydrocortisone, 10 
ng/mL epidermal growth factor and antibiotics (100 U/mL penicillin, 100 μg/mL 
streptomycin and 0.25 μg/mL amphothericin B). Films of  blends were cut into 
small triangle films with each side around 8 mm and sterilized with ethanol for 20 
min. Then the sterilized films were placed in a 24-well TCP and 50 μL medium 
containing 104 3T3 cells or HMECs was added on each film. The films were 
incubated at 37 oC with 5% CO2 and high humidity for 2 h. Next, 2 mL medium 
was added to each well and the films were incubated for another 24 h. Afterwards, 
the films were rinsed in phosphate buffered saline (PBS) and each film was stained 
with 50 μL dye solution (1.25 μL calcein-AM and 5 μL EthD-1 in 2.5 mL PBS) for 
20 min in the dark. Images were immediately acquired using a Nikon Diaphot 200 
inverted fluorescence microscope.  
Thrombin Generation Test 
Films of  blends were cut into small round films with a diameter of  approximately 
6 mm and placed in an Immulon 2 HB 96-well plate. Blood was obtained by 
venipuncture from healthy donors. The blood (approximately 20 mL) was collected 
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in Na-citrate tube followed by centrifuging the blood at 200 G for 15 min at 22 oC. 
Then platelets rich plasma (PRP) was removed with plastic pipette and 
supplemented with fluorescent thrombin-specific substrate and 40 μL/mL 0.5 M 
calcium chloride solution. 200 μL recalcified PRP was added to each well. 
Fluorescence spectroscopies of  the samples were measured with a microtiter plate 
reader at 37 oC. The measure time was 1 h and interval time was 30 sec. For each 
blend, six samples were tested. The concentration of  thrombin was average of  six 
determinations and plotted against time. 
2.3 Results and Discussion  
Preparation and Physical Analysis 
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid was synthesized in three steps 
from Boc-L-serine and 4-iodobenzyl bromide. Purity and identity of  the crystalline 
compound were established by NMR spectroscopy (vide infra), and the X-ray crystal 
structure was determined. Figure 1a shows the crystal structure in detail. The 
molecules in the crystal are hydrogen-bonded to form a one-dimensional chain 
along the crystallographic a-axis (Figure 1b). Alternatively stated, the crystal 
consists of  hydrogen-bonded linear polymers in a parallel arrangement. Bijvoet 
analysis (Figure 1c) proved that the crystal was enantiomerically pure, with the 
asymmetric C atom in an S-configuration.  
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid was blended with medical-
grade poly(D,L-lactic acid) (commercial brand name PURASORB PDL 20), using 
a mini-extrusion system, set at 180 oC. Two mixing ratios were used: 5% and 10% 
(by mass). Throughout this article, these blends are referred to as materials 5 and 6, 
respectively (viz. Table 1). The 5% and 10% (by mass) blends of  sodium 
diatrizoate and poly(D,L-lactic acid) were prepared for comparison. These blends 
are referred to as materials 3 and 4, respectively (viz. Table 1). Sodium diatrizoate is 
a commercially available iodine-containing X-ray contrast agent that is widely used 
for diagnostic imaging in the clinic. The extrusion + film compression procedure 
was also done with the poly(D,L-lactic acid) per se. This material is called material 2 
(viz. Table 1). Poly(D,L-lactic acid) as received was also studied in several of  our 
analyses; this material is referred to as material 1 (viz. Table 1). Circular films were 
pressed out of  materials 2 – 6 (diameter 40 mm, thickness 250 μm). Films of  
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material 2, blends 5 and 6 (containing (S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid) were optically transparent, while the others were white-opaque. 
 
Figure 1. a) Displacement ellipsoid plot of  (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic 
acid in the crystal (50% probability level). Selected bond distances [Å], angles and torsion 
angles [º]: C1-O1 1.3158(18), C1-O2 1.2052(18), C2-O3 1.4092(17), C3-O4 1.4159(17), C4-
O4 1.4370(17), C8-I1 2.1013(14), O1-C1-O2 125.97(14), C3-O4-C4 113.07(12), O1-C1-C2-
C3 -58.45(15), C1-C2-C3-O4 -51.29(15), C2-C3-O4-C4 -167.94(13), C3-O4-C4-C5 -
65.97(19), O4-C4-C5-C6 101.43(18). b) Hydrogen bonding interactions in (S)-2-hydroxy-3-
(4-iodobenzyloxy) propanoic acid. C-H hydrogen atoms are omitted for clarity. The one-
dimensional chain in the direction of  the a-axis is characterized by C(5) graph sets [28]. Red: 
O; green: I; black: C; dotted lines indicate hydrogen bonding. c) Scatter plot of  the Bijvoet 
differences in (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid, calculated by the 
PLATON software [24]. 968 pairs are plotted with ∆obs > 0.25σ(∆obs). 897 pairs confirm 
the absolute structure (black). 71 pairs with the wrong signs (red) have only weak intensities 
and are found in the center of  the plot. Likelihood calculations on all reflections according 
to the Hooft method [29] give a probability of  1.000 for the correct absolute structure. 
Hooft parameter y = -0.005(6). 
a) 
b) 
c) 
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Table 1. Experimental data from differential scanning calorimetry and average surficial 
atomic compositions measured by XPS with a travelling measurement spot. 
Material Tg
a) 
[oC] 
C1s         
[Atom 
%] 
O1s       
[Atom 
%] 
I3d      
[Atom 
%] 
1. Poly(D,L-lactic acid) untreated 
(PURASORB PDL 20) 47.8 - - - 
2. Poly(D,L-lactic acid), after extrusion 
and film pressing 46.3 62.9 37.1 0 
3. Blend containing sodium diatrizoate 
(5%) 48.0 62.9 36.9 0.20 
4. Blend containing sodium diatrizoate 
(10%) 45.4 63.5 35.9 0.48 
5. Blend containing (S)-2-hydroxy- 3-
(4-iodobenzyloxy) propanoic acid 
(5%) 
41.1 62.9 37.1 -b) 
6. Blend containing (S)-2-hydroxy- 3-
(4-iodobenzyloxy) propanoic acid 
(10%) 
34.4 62 37.1 -b) 
a) Tg denotes the peak temperature in the second heating run on each curve. 
b) Iodine was detectable, but the resulting numbers are inaccurate because of  the 
experimental error. Blends 5 and 6 were studied further with elemental analysis (in triple). 
This led to experimental mass % values for I of  1.92, 1.98 and 1.94 for blend 5, and 3.88, 
3.85 and 3.95 for blend 6. These values are in excellent agreement with calculated values 
(calculated mass % I is 1.97 % for blend 5 and 3.94 % for blend 6).  
Differential scanning calorimetry experiments were performed on materials 1 
– 6 (Table 1). The data revealed that: (i) the Tg-values of  materials 3 and 4 
(containing sodium diatrizoate) are close (48.0 and 45.4 oC), and comparable to 
both Tg-values found for materials 1 and 2 (47.8 and 46.2 oC), indicating that 
blends 3 and 4 are phase-separated structures; (ii) the Tg-values found for materials 
5 and 6 are significantly lower (41.1 and 34.4 oC, respectively), which indicates that 
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid has a plasticizing effect due to 
structural compatibility with the poly(D,L-lactic acid) matrix. In addition, we 
determined the molecular masses of  materials 1 – 6 via viscosity measurements. 
This showed: Mv(1) = 1.38 × 105; Mv(2) = 1.32 × 105; Mv(3) = 1.29 × 105; Mv(4) = 
1.32 × 105; Mv(5) = 1.27 × 105 and Mv(6) = 1.30 × 105. These data reveal that the 
processing resulted in less than 10% decrease of  Mv.  
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The pressed films of  materials 2 – 6 were studied further with SEM in the 
backscatter mode (Figure 2). Materials 2, 5 and 6 appeared as homogeneous 
surfaces. On a grey scale, they differ as follows: material 2 (darkest) < material 5 < 
material 6 (lightest). Blends 3 and 4, on the other hand, were clearly heterogeneous: 
white dots (contrast agent) are scattered over the surface, thus revealing phase-
separation. Figures 2a and 2b show SEM micrographs (backscatter mode) of  
materials 4 and 6 to illustrate this difference. 
 
Figure 2. a) SEM (backscatter mode) images of  poly(D, L-lactic acid) (2), and the four 
blends (3 through 6). b) Blend 4; particles of  sodium diatrizoate (light grey) are dispersed 
throughout the poly(D,L-lactic acid) matrix (black). c) Blend 6; a uniformly grey image is 
obtained. This is due to the compatibility of  (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic 
acid with the polymer matrix. 
XPS was further used to study the distribution of  iodine at the surface of  the 
blends. These experiments were done with freshly fractured surface, in order to 
eliminate effects of  possible impurities as much as possible. The measurement 
spot (size 100 μm) was moved linearly and stepwise over the surface of  each 
specimen, with intervals of  100 μm. The surface-iodine concentration was 
measured at each point. As expected, materials 3 and 4 showed substantial 
variations of  the atomic composition, with average I-atom percentages (Table 1) 
of  0.20 and 0.48 respectively. Obviously, the big scatter reflects that sodium 
diatrizoate is unevenly distributed at the surface, due to phase separation. Materials 
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5 and 6 showed constant surface atomic composition, with lower average I-atom 
percentages. The small scatter reveals the homogeneous, non-phase separated 
nature of  these two blends. 
 
Figure 3. X-ray images of  aluminum specimens and materials 2 – 6. Radiation absorption 
of: a) 10 stacked circles cut out of  aluminum foil (thickness of  the stack: 120 μm); b) two 
partially overlapping specimens of  material 2 (poly(D,L-lactic acid); thickness per specimen: 
250 μm); c) idem for material 3 (blend containing 5% of  sodium diatrizoate); d) idem for 
material 4 (blend containing 10% of  sodium diatrizoate); e) idem for material 5 (blend 
containing 5% of  (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid); f) idem for material 6 
(blend containing 10% of  (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid).  
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Materials 2 - 6 were analyzed further for their capacity to absorb X-radiation. 
Figure 3 combines X-ray images of  two partially overlapping specimens per 
material (circles with a diameter of  6 mm, cut out of  the pressed films). The grey 
values (scored on a 256-unit scale with white = 0 and black = 255) are compiled in 
Table 2. Note that the images in Figure 3 were measured simultaneously, i.e. grey 
values can be compared. Figure 3a refers to 10 stacked circles which were cut out 
of  aluminum foil with a thickness of  12 μm (i.e. stack thickness in Figure 3a is 120 
μm). The data (Table 2) reveal that the intrinsic attenuation coefficients (i.e. the 
capacity of  the materials to absorb X-radiation) increase in the order: poly(D,L-
lactic acid) < blend with 5% sodium diatrizoate < blend with 5% (S)-2-hydroxy-3-
(4-iodobenzyloxy) propanoic acid < blend with 10% (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid < blend with 10% sodium diatrizoate. 
Table 2. Experimental data from the X-ray contrast experiments. 
Material 
Grey Levela) Attenuation 
[%] 
per μm 
Thickness 
Linear 
Attenuation 
Coefficient b) 
Houns-
field 
Units 
Single 
Layer 
Double 
Layers 
 Ten 
Layers 
Aluminum  - - 82.8±3.6 0.271 0.75 c) 2640 c 
2 22.5±5.3 44.9±5.9 - 0.035 0.10 340 
3 33.2±5.1 65.4±3.9 - 0.052 0.14 507 
4 49.0±5.6 99.7±4.6 - 0.077 0.21 750 
5 33.5±5.1 70.2±4.4 - 0.053 0.15 516 
6 47.3±4.8 93.1±4.5 - 0.074 0.20 721 
a) Grey scale = gray scale of  single/double layer – gray scale of  background; the gray scale 
of  white is 0 and black is 255. 
b) The linear attenuation coefficient and the Hounsfield unit are measures for the capacity 
of  a material to absorb X-radiation.  
c) The data for aluminum (at 60 keV) were abstracted from the literature. The linear 
attenuation coefficients for materials 2 – 6 were calculated from the attenuation/μm 
thickness data.  
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Cytotoxicity of  the Contrast Agent and Biocompatibility of  the 
Blends 
Evidently, it is a conditio sine qua non that the new contrast agent will not invoke any 
toxic effect on neighboring cells or tissues. We studied cellular toxicity of  (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid through comparison with L-lactic 
acid. Different concentrations of  both compounds (range 0-10 mM end 
concentration) were added to cultured human coronary arterial endothelial cells 
(HCAECs), porcine skin fibroblast cells (PSFs) or porcine aortic smooth muscle 
cells (PSMCs), and incubated for 24 h. A low but negligible cytotoxicity was found 
for most monomer concentrations and cell types tested as compared with negative 
control (0 mM), whereas the positive condition (2.5% DMSO) revealed 
considerable cytotoxicity (Figure 4). Only HCAECs treated with 10 mM (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid showed significant lower average 
viable cell numbers/well, with merely 10% reduction (p<0.01, n=6) as compared 
with control. Also, cytotoxicity of  10 mM (S)-2-hydroxy-3-(4- iodobenzyloxy) 
propanoic acid was significantly higher than 10 mM L-lactic acid (p<0.01, n=6). 
HCAECs incubated with 2.5% DMSO presented with a considerable 75% 
reduction in viable cell numbers as compared with the 0.25% DMSO conditions 
of  the 0 mM control (Figure 4a). For PSFs (Figure 4b) and PSMCs (Figure 4c) 
cytotoxicity was apparent neither for both monomers as compared with their 
respective negative controls, nor between monomer types. The cytotoxic effect of  
2.5% DMSO for PSFs was the lowest of  all cell types analyzed, though still 
inducing significant reduction of  44% (p<0.01, n=6) as compared with control. 
Also for PSMCs, the positive control showed a considerable reduction of  76% in 
viable cell number (p<0.01, n=6). Concentrations above 10 mM monomer could 
not be tested due to formation of  precipitates in the culture. 
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Figure 4. Cytotoxic effects of  different L-lactic acid (columns with slashes) and (S)-2-
hydroxy- 3-(4-iodobenzyloxy) propanoic acid (black columns) concentrations and 2.5% 
DMSO (positive control, white columns) on HCAECs (a) , PSFs (b) and PSMCs (c) 
viability. A low to absent cytotoxicity is present for both L-lactic acid and (S)-2-hydroxy-3-
(4-iodobenzyloxy) propanoic acid, showing comparable average viable cell numbers per 
well for most polymer conditions tested as compared with control (0 mM monomer, 0.25% 
DMSO; a-c). Only for HCAECs cultured with 10 mM (S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid a significant increase in viable cell loss compared with both control and 10 
mM L-lactic acid (a, single asterisks) is apparent. For all cell types 2.5% DMSO significantly 
reduces the average viable cell numbers per well as compared with 0.25% DMSO present 
in controls (a-c, double asterisks). Abbreviations: *, p<0.05 and **, p<0.01; t-test, all n=6.  
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To test the effect of  L-lactic acid (7.5 mM) and (S)-2-hydroxy-3- (4-
iodobenzyloxy) propanoic acid (7.5 mM) on gene expression of  primary cells, 
HCAECs, PSMCs and PSFs were subjected to gene expression analysis by using 
standard RT-QPCR. For HCAECs (Figure 5A) the differentiation markers CD31 
and Vegfr2 were not differently expressed between conditions tested, whereas both 
L-lactic acid and (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid groups showed 
a moderate higher endothelial nitric oxide synthesis (eNOS) expression that was 
significantly different from control (1.62+/-0.032, 1.7+/-0.38, L-lactic acid and 
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid, respectively). The pro-coagulant 
factor Von Willebrand factor (VWF) was significantly lower expressed in (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid treated endothelial cells as compared 
to both control and L-lactic acid condition. PSMCs (Figure 5B) did not show any 
marked differences in expression of  the extracellular matrix genes collagen 1A1 and 
1A2 (Coll1A1, Coll1A2). In contrast, smooth muscle marker alpha actin (aSMA) was 
significantly lower expressed in both monomer groups and was even significantly 
lower expressed in (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid treated cells 
as compared with L-lactic acid (0.36+/-0.0022, 0.019+/-0.00048, L-lactic acid and 
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid, respectively). The anti- and pro-
apoptotic genes BCL2 and BAX were not significantly different between 
conditions tested. In line with the effect of  L-lactic acid and (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid on aSMA expression in PSMCs a significant lower 
expression was apparent for PSFs (0.27+/-0.023, 0.17+/-0.020, L-lactic acid and 
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid, respectively; Figure 5C), being 
lowest expressed for (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid treated 
cells (approx. 5.9 times lower than control). Both monomers showed a significant 
lower expression of  Coll1A2 and only (S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid treated samples revealed lower expression of  Coll1A1 (0.26+/-
0.040) as compared with control. Also for the PSFs L-lactic acid and (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid did not affect the expression levels of  
BCL2 and BAX. For aSMA, Coll1A1 and Coll1A2 the expression of  the 
corresponding genes was significantly lower in the (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid group as compared with L-lactic acid. 
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Figure 5. Effects of  L-lactic acid and (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid 
on relative gene expression of  (A) HCAECs , (B) PSMCs and (C) PSFs as compared with 
DMSO control. All cells were treated with 7.5 mM L-lactic acid (white bars) or (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid (black bars). mRNA expression was analyzed 
with standard RT-QPCR and relative expression was compared with corresponding DMSO 
control (with expression set at 1). A) HCAECs treated with L-lactic acid show a 
significantly higher expression of  eNOS, and (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic 
acid presents a significant lower VWF expression as compared to both control and L-lactic 
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acid. B) PSMCs incubated with L-lactic acid show significantly lower a-smooth muscle actin 
(aSMA) than control. (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid also gives a 
significantly lower aSMA expression, being lower than both control and L-lactic acid. C) 
For PSFs aSMA and collagen 1A2 (Coll1A2) expression in both L-lactic acid and (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid conditions are lower than in control. Only (S)-
2-hydroxy-3-(4-iodobenzyloxy) propanoic acid treatment presents with significantly lower 
expression of  Coll1A1 compared with both control and L-lactic acid conditions. Error bars 
present SEM (n = 4); with * p < 0.05 vs. DMSO control and # p < 0.05 L-lactic acid vs. 
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid. 
(S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid revealed no clear negative 
effects on gene expression of  HCAECs, once more excluding a cytotoxic response. 
For PSMCs a considerable lower aSMA expression was apparent for both L-lactic 
acid and (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid conditions that could 
relate to dedifferentiation of  PSMCs, although expression levels were still 
comparable to moderate expressed genes (i.e. HPRT, data not shown). As 
concomitantly no increase in collagen expression levels occurred, dedifferentiation 
of  the PSMCs in a synthetic phenotype can be excluded. The unaltered expression 
of  the pro- and anti-apoptotic genes BCL2 and BAX eliminates an effect of  (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid on apoptosis. For fibroblast (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid showed a different effect on aSMA, 
COLL1A1 and 1A2 gene expression as compared to both L-lactic acid and control. 
Especially the lower expression of  COLL1A1 indicates that this monomer 
represses COLLAGEN 1 expression. It remains unclear how this difference 
between L-lactic acid and (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid is 
regulated and why PSMCs are not differently affected by (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid. From our data it can be stated that (S)-2-hydroxy-
3-(4-iodobenzyloxy) propanoic acid predominantly alters the phenotype of  PSMCs 
and PSFs, causing lowering of  cellular contractility (aSMA) in both cell types and 
reducing extracellular matrix production (COLLAGEN 1) in PSFs. It is difficult to 
say whether reduced expression of  these genes is advantageous or not. Regarding 
the foreseen application of  our blends for the manufacture of  endovascular stents, 
it is desirable to suppress fibrosis (scar formation). The occurrence of  fibrosis 
increases the risk for restenosis (re-narrowing of  the stented atherosclerotic lesion). 
Cytotoxicity of  blends 2 – 6 was studied by two methods in vitro. First, the 
MTT test [30] was used (3T3 cells, protocol according to ISO 10993-5:2009, 
Biological evaluation of  medical devices - Part 5: Tests for in vitro cytotoxicity). The 
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cells that had been in contact with material 2 (poly(D, L-lactic acid)) had a viability 
score of  97.2 ± 13.5%. For materials 3 and 4, viability percentages were: 92.7 ± 
12.0 and 88.9 ± 9.4, respectively; for materials 5 and 6: 92.4 ± 12.0 and 83.3 ± 12.1, 
respectively. Viability was only 4.5% for cells that had been in contact with latex 
(positive control). These data reveal that materials 2 – 6 were not cytotoxic in the 
MTT test. Secondly, in vitro cytotoxicity of  materials 2 – 6 was investigated by 
live/dead assay [31] on HMECs and 3T3 cells. Figure 6 shows representative 
examples: the fluorescence microscopic fields for materials 2 - 6 are dominated by 
living HMECs (green), with almost no red dots (dead cells). The HMECs attached 
to materials 2 - 6 behaved the same as the cells that were attached to glass (non-
toxic control). The same results were also obtained for 3T3 cells. 
 
Figure 6. Fluorescence microscopic images provided by the live/dead viability test of  
HMECs incubated on glass, PURASORB PDL 20 film and the four experimental blends 
films for 24 h. a) glass; b) material 2; c) material 3; d) material 4; e) material 5; f) material 6.  
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Figure 7. Thrombin generation curves measured for materials 2 – 6 in contact with 
aliquots of  fresh human blood plasma. Parallel experiments were run in which stainless 
steel stent, or a commercial vascular catheter were incubated with the plasma (both the 
stent and the catheter were cut to 4-mm long pieces, and experiments were run in which 1 
or 2 pieces of  the stent or catheter were incubated). All experiments were performed in 6-
fold. The experimental thrombin-generation lag times decreased as follows: empty wells 
polystyrene (21.0 min) > 1 catheter piece (15.5 min) > 2 catheter pieces (13.5 min) > 
material 2 (10.5 min) ≈ 1 stent piece (10.4 min) > 2 stent pieces (9.6 min) ≈ material 6 (9.5 
min) ≈ material 4 (9.0 min) ≈ material 5 (8.8 min) ≈ material 3 (8.6 min).  
Furthermore, hemocompatibility of  materials 2 - 6 was assessed. This was 
done via an in vitro thrombin generation assay [32-33], using fresh human blood 
plasma. For each material, a thrombin-generation curve was measured (in 4-fold) 
(Figure 7). Each curve is characterized by: (i) a lag-phase (no thrombin is formed 
during the first few minutes of  the test, which starts on the moment of  
“recalcification” of  the plasma that is in contact with the biomaterial); (ii) a steep 
rise of  the thrombin concentration; (iii) a maximum; (iv) decline of  the thrombin 
concentration due to inactivation of  the enzyme by antithrombin-III and 
complexation with 2-macroglobulin [34]. In this assay, thrombin formation is 
triggered exclusively by the contact between the material and the plasma, i.e. no 
tissue factor is used. The lag time (tlag), i.e. the interval between the start of  the test 
and the onset of  the steep rise of  the thrombin concentration, provides a measure 
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for the material’s thrombogenicity (i.e. a more thrombogenic material has a shorter 
tlag than a less thrombogenic material). Figure 7 shows the thrombin generation 
curves measured for materials 2 – 6. Furthermore, we included two other materials 
for comparison: (i) a commercial diagnostic catheter [35] that is used in direct 
contact with blood (samples were 4-mm pieces cut from the catheter tube; 
experiments were done with 1 or 2 catheter pieces per well); (ii) stainless steel 
stents (samples were cut from non-expanded stents, sample length = 4 mm; 
experiments were done with 1 or 2 stent pieces per well). The thrombin generation 
lag times decreased in the following order: empty wells polystyrene (21.0 min) > 1 
catheter piece (15.5 min) > 2 catheter pieces (13.5 min) > material 2 (10.5 min) ≈ 1 
stent piece (10.4 min) > 2 stent pieces (9.6 min) ≈ material 6 (9.5 min) ≈ material 4 
(9.0 min) ≈ material 5 (8.8 min) ≈ material 3 (8.6 min). 
2.4 Conclusions 
The aim of  this study, developing a method to impart radiopacity into poly(lactic 
acids), led to the design of  a novel contrast agent: (S)-2-hydroxy-3- (4-
iodobenzyloxy) propanoic acid. This compound bears structural resemblance to L-
lactic acid and contains covalently bound iodine. (S)-2-hydroxy-3-(4- 
iodobenzyloxy) propanoic acid appeared to be miscible with poly(D,L-lactic acid), 
at least up to a mass percentage of  10%. The compound’s X-ray crystal structure 
provides a plausible explanation for the miscibility: the molecule forms an intricate 
H-bonded network in its own crystal, and it will also be able to engage in H-
bonding when residing in a poly(D,L-lactic acid) matrix. These blends are non-
cytotoxic for endothelial cells, vascular smooth muscle cells and fibroblasts 
(cultured in vitro), hemocompatible, and radiopaque. Furthermore, the contrast 
agent per se was found to be non-cytotoxic, and hardly affecting gene expression. 
Only at high concentration (> 10 mM) a slightly higher cytotoxicity was measured 
for (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid, in comparison with L-lactic 
acid. In view of  the slow degradation of  poly(D,L-lactic acid) in vivo and the mass 
percentage of  maximal 10%, the concentration of  (S)-2-hydroxy-3- (4-
iodobenzyloxy) propanoic acid in the tissues surrounding the stent will certainly be 
much lower than the 10 mM concentration tested.  
From the perspective of  biomaterials science, the presence of  5% or 10% of  
the contrast agent in our blends represents an interesting situation, since this more 
or less resembles the situation after 5% or 10% degradation in vivo. Alternatively 
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stated: a stent that is built from a blend as described here, must be considered to 
be degraded already for 5% (or 10%) at the moment of  implantation. It is noted 
that the Tg-values of  the 5% and 10 % blends are low (41 and 34 oC, respectively), 
i.e. the blends are clearly too soft for use as stent building materials. Increased Tgs 
can be achieved by using poly(L-lactic acid) as the matrix material, rather than 
PURASORB PDL 20. A very promising material is medical grade PURASORB PL 
18 with Tg = 58 - 60 oC [36-37]. Work to prepare and characterize these new 
blends is already in progress in our laboratory. Taken together, the physical and 
biological properties of  the new blends indicate that it is possible to build a 
biodegradable radiopaque coronary stent from these materials. There is no doubt 
that the extra feature (X-ray visibility of  the entire scaffold) will be helpful during 
placement and follow-up of  the scaffold. Hence, the new approach as described 
herein has the potential to enhance accuracy and safety, associated with clinical use 
of  bioabsorbable vascular scaffolds. Evidently, more research and development 
work (particularly in vivo studies) will be required to address the following issues: (i) 
kinetics of  degradation in vivo; (ii) physical-mechanical behavior in vivo (strength, 
fatigue, etc); (iii) biocompatibility of  the blends and their degradation products in 
vivo; (iv) clearance of  the degradation products in vivo; (v) changes occurring with 
regard to (i), (ii) and (iii) when an anti-proliferative drug (such as everolimus) is 
mixed into the biomaterial. Research along these lines is currently ongoing in our 
laboratory.  
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Abstract 
The clinically undesired translucency of  biodegradable poly(lactic acid) vascular 
stents prompted us to investigate a new approach to introduce X-ray contrast to 
poly(lactic acid). In previous work we developed the new contrast agent (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic acid, which is miscible with poly(D,L-lactic 
acid) and non-cytotoxic in vitro. However, the resultant homogeneous radiopaque 
poly(D,L-lactic acid) blends have too low glass transition temperatures (Tg, 34 and 
41 oC, respectively) for stent application. This prompted us to study the 
compatibility of  the new contrast agent with semi-crystalline poly(L-lactic acid) 
(PLLA). In this study, blends of  PLLA with (S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid (5 wt% and 10 wt%) were prepared by a twin-screw extruder. 
PLLA blends containing sodium diatrizoate (5 wt% and 10 wt%), a commercial 
contrast agent for medical imaging, were prepared for comparison. Properties of  
PLLA and blends were characterized by differential scanning calorimetry, scanning 
electron microscopy (in backscatter mode) and tensile test. Blends with sodium 
diatrizoate were phase-separated, while blends containing the new contrast agent 
were homogeneous with Tg-values higher than the previous poly(D,L-lactic acid) 
blends and well above human body temperature. Homogeneity of  these blends 
would allow for accurate engineering of  their degradation kinetics. Addition of  the 
new contrast agent and sodium diatrizoate did not have a significant negative effect 
on mechanical properties of  the blends. In vitro biocompatibility and thrombin 
generation experiments prove that PLLA blends containing the new contrast agent 
were both bio- and hemo-compatible. Results in this study certificated the good 
compatibility of  the new contrast agent with PLLA. Physical and biological 
properties of  the homogeneous PLLA blends underline their potential to 
construct radiopaque versions of  biodegradable vascular stents. The contrast agent 
we synthesized could provide a new approach to develop poly(lactic acid) materials 
with controllable degradation and radiopacity for biomedical application. 
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3.1 Introduction 
Coronary stents are tubular devices that are used to treat patients with obstructive 
coronary artery disease [1]. Choices for coronary stents comprise bare metal stents, 
drug-eluting metal stents, and completely biodegradable drug-eluting stents [1-3]. 
Drug-eluting metal stents have a polymer surface coating with an anti-proliferative 
drug therein [2]. The polymer serves as a reservoir, to enable controlled and 
sustained local release of  the drug. The introduction of  drug-eluting metal stents 
has significantly reduced restenosis rates (< 2%) compared with bare metal stents 
(16% - 44%) [4-5]. However, widespread clinical applications of  drug-eluting stents 
and long-term clinical studies have revealed safety issues related to late-stent 
thrombosis [4, 6]. The presence of  stable polymers after complete drug elution 
poses a high thrombogenic risk and has been associated with delayed vascular 
healing and sustained inflammation in the arterial wall [7-13]. Moreover, the 
remaining stent-body is accountable for several complications, e.g. incomplete 
endothelialization, stent fracture and late-acquired mal-apposition [13-15], which 
could ultimately lead to restenosis and late stent thrombosis. 
These insights have urged the need to develop completely biodegradable 
drug-eluting stents. The most important representative of  this stent-class is the CE 
marked Bioresorbable Vascular Scaffold (BVS; Abbott Vascular, Santa Clara, CA, 
USA) [3]. The BVS consists of  semi-crystalline poly(L-lactic acid) (PLLA), carrying 
a thin polymer coating of  a mixture of  amorphous poly(D,L-lactic acid) and 
everolimus (1:1). A single-blinded multicenter randomized trial indicated that the 
everolimus-eluting BVS and the everolimus-eluting metallic stents performed 
similarly over a period of  1 year [16]. Studies on both the first- and second-
generation BVS device demonstrated biosafety of  these stents with no occurrence 
of  scaffold thrombosis events [17-18]. 
The BVS is radiolucent (i.e., transparent to X-radiation), and the device is 
localized on angiography and other imaging modalities via 2 platinum markers at 
each end. Our specific interest in bioresorbable vascular scaffolds is primarily 
focused on modification to allow X-ray imaging of  the device in situ. In our 
previous work, we described the synthesis and performance of  a new X-ray 
contrast agent: (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid [19]. This 
compound could be physically blended with poly(D,L-lactic acid) in a twin-screw 
extruder without phase-separation, i.e. the contrast agent is miscible with the 
polymer matrix. We found in our previous work that the blends of  poly(D,L-lactic 
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acid) and the new contrast agent have glass transition temperatures that are too low 
(34 and 41 oC) for vascular applications. At body temperature, these blends would 
be soft and pliable and thus unable to provide adequate radial strength. This 
concern drives us to further investigate compatibility of  the new contrast agent 
with other poly(lactic acid).  
In this research, PLLA (PURASORB PL 18), with higher Tg (58 – 60 oC) than 
the poly(D,L-lactic acid) (48 oC) used in our previous work, was used as polymer 
matrix to construct radiopaque blends. PLLA blends containing the new contrast 
agent (5 wt% and 10 wt%) were prepared. Blends with sodium diatrizoate (5 wt% 
and 10 wt%), a well-known contrast agent in angiography, were prepared for 
comparison. The aim of  this study was to investigate the compatibility of  the new 
contrast agent with semi-crystalline PLLA and to analyze the potential applicability 
of  the resulting blends for stent application. Thermal behavior, microstructures, 
tensile properties as well as in vitro biocompatibility and thrombogenicity of  the 
blends were characterized. PLLA containing sodium diatrizoate was found to be 
phase-separated. For these heterogeneous blends failure and crack may occur at 
the interface between polymer matrix and the contrast particles. Especially as 
sodium diatrizoate is water-soluble, this would facilitate water absorption, which 
could significantly affect the mechanical properties and degradation kinetics of  
PLLA in vivo. It can be concluded that the heterogeneity of  these blends hampers 
their use for biomedical application. PLLA blended with the new contrast agent 
were homogeneous and their Tg values were well above human body temperature, 
which makes these materials potentially interesting to construct radiopaque 
versions of  the BVS. This characteristic opens a route to develop poly(lactic acid) 
biomaterials that combine controlled biodegradation and whole-body X-ray 
visibility. In case of  a vascular stent the intervention cardiologist will be able to 
monitor deployment of  a radiopaque poly(lactic acid) BVS during the procedure. 
3.2 Experimental Section 
Materials 
Boc-L-serine (98%; ABCR GmbH & Co. KG, Germany) and 4-iodobenzyl 
bromide (98%; Amplachem, USA) were used as received. PLLA (PURASORB PL 
18) was supplied by Corbion (Gorinchem, The Netherlands) and dried at 40 oC 
overnight before use. According to the supplier, the inherent viscosity of  PLLA (η) 
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was measured in chloroform at 25 oC and the viscosity-average molecular weight 
(Mv) was calculated using equation (1) [20-21]: 
𝑀𝑣 =  � 𝜂5.45×10−40.73       (1) 
Mv value for PLLA was obtained as 7.1×104. Sodium diatrizoate and thiazolyl blue 
tetrazolium bromide were purchased from Aldrich (Zwijndrecht, The Netherlands). 
Human microvascular endothelial cells (HMECs) and mouse fibroblasts (L929 
cells) were purchased from Lonza (Verviers, Belgium). Cell culture medium 
(DMEM/F12, Glutamax and MCDB 131), fetal bovine serum (FBS), antibiotics 
(i.e. penicillin, streptomycin and amphotericine), calcein AM and ethidium 
homodimer-1 (EthD-1) were from Invitrogen (Bleiswijk, The Netherlands). The 
fluorescent thrombin-specific substrate Z-Gly-Gly-Arg-AMC was bought from 
Bachem (Weil am Rhein, Germany).  
Synthesis of  (S)-2-hydroxy-3-(4-iodobenzyloxy) Propanoic Acid 
The contrast agent (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid (designated 
as ILA) was synthesized in three steps from Boc-L-serine and 4-iodobenzyl 
bromide according to the procedures described previously (Scheme 1) [19].  
 
Scheme 1. Synthesis of  (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid (product 3). 
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Preparation of  Blends and Films 
PLLA (PURASORB PL 18) was blended with sodium diatrizoate or the new 
contrast agent in a DSM XPlore 15cc Twin Screw Micro-Compounder under N2 
atmosphere. The heating temperature was 210 oC and the blending time was 5 min 
at screw speed of  100 rpm. The melt was cooled at room temperature after 
extrusion. Characteristics of  the two contrast agents, ILA and sodium diatrizoate 
(designated as SD), used in this research are listed in Table 1. Five different 
materials were prepared: pure PLLA, PLLA/SD blends (5 wt% and 10 wt%, 
designated as 5SD and 10SD, respectively) and PLLA/ILA blends (5 wt% and 10 
wt%, designated as 5ILA and 10ILA, respectively). Blends obtained by extrusion 
were compressed into films using an Atlas Manual 15T Hydraulic Press. The 
heating temperature was set at 180 oC and the blends were compressed for 5 min 
under a pressure of  2 ton. The thickness of  each film was 250 μm. 
Table 1. Contrast agents used in this study. 
Contrast agent Designation 
M 
(g/mol) 
Description 
Sodium diatrizoate 
O ONa
II
N
H
N
HI
CH3H3C
O O
 
SD 636 
A commercial contrast 
agent used in 
angiography; soluble in 
water. 
(S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic 
acid 
 
ILA 322 
A new contrast agent 
synthesized in this 
study; insoluble in 
water. 
Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) analysis was carried out with a Perkin 
Elmer Pyris 1 apparatus under nitrogen flow (20 mL/min). All samples were first 
I
O OH
O
OH
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heated from 0 oC to 200 oC at 10 oC/min and held for 3 min to erase the thermal 
history, then cooled to 0 oC at 10 oC/min, and finally heated to 200 oC at 10 
oC/min. The crystallization temperature (Tc) and crystallization enthalpy (ΔHc) 
were determined from the cooling run. The glass transition temperature (Tg), cold 
crystallization temperature (Tcc), cold crystallization enthalpy (ΔHcc) and melting 
point (Tm) were obtained from the second heating run. The degree of  crystallinity 
(χc) and the degree of  cold crystallinity (χcc) were calculated using equation (2): 
𝜒𝑐  (𝑜𝑜 𝜒𝑐𝑐) =  𝛥𝐻𝑐 (𝑜𝑜 𝛥𝐻𝑐𝑐)𝛥𝐻𝑐  0  ×(1 −𝑝 )  × 100      (2) 
where χc is the degree of  crystallinity; χcc is the degree of  cold crystallinity; ΔHc is 
the crystallization enthalpy of  the sample; ΔHcc is the cold crystallization enthalpy 
of  the sample; p is the weight percentage of  contrast agent in the sample; ΔHc0 is 
the melting enthalpy of  100% crystalline poly(lactic acid) (93.0 J/g) [22].  
Scanning Electron Microscopy 
Morphology of  the films was characterized by scanning electron microscopy 
(SEM). Small film samples were coated with carbon and examined under a Philips 
XL 30 SEM (Eindhoven, The Netherlands) in the backscattered electron imaging 
mode.  
Tensile Testing 
Test specimens, with a width of  2.2 mm and a length of  15.0 mm, were cut from 
films prepared by compression. Specimens were examined by an Olympus imaging 
polarized optical microscope to ensure well-defined and sharp rectangular edges. 
Tensile testing was performed on a rheometer, using a gauge length of  6 mm and 
an elongation speed of  3 µm/s. An average of  3 specimens was tested for each 
sample. The fracture surfaces of  all specimens were examined by polarized optical 
microscopy. 
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In Vitro Cytotoxicity 
Cell Culture 
L929 cells were cultured in DMEM/F12 medium containing Glutamax and 
supplemented with 10% FBS and antibiotics (100 U/mL penicillin, 100 µg/mL 
streptomycin and 0.25 μg/mL amphothericin B). HMECs were cultured in MCDB 
131 medium supplemented with 10% FBS, L-glutamine (2 mM/mL), 
hydrocortisone (1 μg/mL), epidermal growth factor (10 ng/mL) and antibiotics 
(100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml amphothericin B). 
Both cell types were incubated at 37 oC with 5% CO2 and high humidity. 
MTT Assay 
MTT assay (protocol according to ISO 10993-5:2009, Biological evaluation of  
medical devices - Part 5: Tests for in vitro cytotoxicity) was used to determine the 
cytotoxicity of  blends. 0.2 g of  each blend was cut into small pieces which were 
then sterilized with ethanol (70%) for 20 min. Subsequently, sterilized pieces were 
incubated in culture medium (2 mL) at 37 oC for 48 h. L929 cells were cultured in 
96-well tissue culture plate (TCP) with seeding density of  103 cells/well and 
incubated for 24 h. Then medium was replaced by extracted supernatants of  
blends, and cells were incubated for another 48 h. Next, 20 μL medium containing 
thiazolyl blue tetrazolium bromide (MTT, 3 mg/mL) was added to each well. After 
culturing for 2 h, medium was removed and 100 μL isopropanol was added to 
dissolve the precipitated formazan. Absorbance of  the samples was measured in a 
Spectra Max M2 microtiter plate reader at 570 nm. TCP wells with medium only 
were used as negative control. Cells treated with medium extracted from latex 
served as positive control. 
LIVE/DEAD Assay 
Both L929 cells and HMECs were used in the live/dead cells test. Films of  blends 
were cut into small triangle films (8 mm each end) and sterilized with ethanol (70%) 
for 20 min. The sterilized films were placed in a 24-well TCP and 50 μL medium 
containing 104 L929 cells or HMECs were added on top of  the films. The films 
were incubated for 2 h to facilitate adherence of  the cells to the film. Subsequently, 
2 mL medium was added to each well and the films were further incubated for 
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another 24 h. Next, the films were rinsed in phosphate buffered saline (PBS) and 
stained with 50 μL dye solution (2.5 mL PBS containing 1.25 μL calcein AM and 5 
μL EthD-1) for 20 min in dark. Afterwards the films were rinsed with PBS and 
then observed with a Nikon Diaphot 200 inverted fluorescence microscope. 
Thrombin Generation Test 
In vitro thrombin generation test was performed using fresh human blood plasma 
[23-25]. Films of  blends were cut into small round films with a diameter of  
approximately 6 mm. Non-expanded steel stents and a 4-Fr diagnostic catheter 
(Cordis) were cut into small pieces with a length of  4 mm. All specimens were 
placed into an Immulon 2 HB 96-well plate: one film per well, or one (or two) 
pieces of  stent or catheter per well. Blood (approximately 20 mL) was obtained by 
venipuncture from healthy donors and collected in Na-citrate tube. Subsequently, 
the blood was centrifuged at 200 G for 15 min (22 oC) and platelets rich plasma 
(PRP) was collected. Then the PRP was supplemented with fluorescent thrombin-
specific substrate (Z-Gly-Gly-Arg-AMC) to a final concentration of  400 μM and 
calcium chloride solution (0.5 M; 40 μL/mL PRP). Recalcified PRP (200 μL) was 
added to each well containing specimens. Fluorescence spectroscopies of  the 
samples were measured by a Spectra Max M2 microtiter plate reader at 37 oC. The 
measurement time was 1 h with interval time of  30 sec. For each blend, six 
samples were tested. The concentration of  thrombin was average of  six 
determinations and plotted against time.  
3.3 Results and Discussion 
Thermal Analysis 
DSC experiments were performed to characterize the thermal properties of  PLLA 
and PLLA blends. Figure 1 shows the DSC curves recorded during cooling and 
the second heating scan. Data derived from DSC analysis are summarized in Table 
2. As shown in Figure 1, pure PLLA had no crystallization peak during cooling 
which might relate to the slow crystallization kinetics of  poly(lactic acid). After 
extrusion PLLA crystallized during cooling and the glass transition temperature (Tg) 
was decreased from 60.1 to 55.4 oC. The difference between pure PLLA and PLLA 
after extrusion could be explained by the increased chain mobility resulting from 
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chain scission during the processing [26-27]. Both pure PLLA and PLLA after 
extrusion crystallized on heating (cold crystallization) but at different temperatures, 
indicating that extrusion had an effect on the crystallization behavior of  PLLA. It 
has been reported that different PLLA crystals, disordered α’-from crystal, ordered 
α-form crystal or a mixture of  both, were produced at different crystallization 
temperatures [28]. The different Tcc-values of  pure PLLA and PLLA after 
extrusion (Table 2) revealed that different forms of  PLLA crystal were developed 
during heating. Pure PLLA crystalized at 134.7 oC and the crystals formed at this 
temperature might be a mixture of  α’- and α-form crystals; PLLA after extrusion 
showed two cold crystallization peaks at 93.9 and 158.2 oC, which may reflect the 
formation of  α’- and α-crystalline phase, respectively [28]. 
 
Figure 1. DSC thermographs of  pure PLLA (untreated), PLLA after extrusion as well as 4 
kinds of  PLLA blends in the cooling run (dotted lines) and in the heating run (solid lines), 
respectively. 
All PLLA blends showed crystallization peaks during cooling (Figure 1). The 
data in Table 2 indicate that both SD and ILA facilitated the crystallization of  
PLLA and the crystallinity (χc) increased with the concentration of  SD and ILA. 
Specifically, χc was increased from 23.6% to 38.9% (5SD), 47.8% (10SD), 37.0% 
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(5ILA) and 48.4% (10ILA), respectively. On the other hand, SD blends and ILA 
blends did not crystallize during heating, implying that crystals have already been 
fully developed during the cooling process.  
Table 2. Experimental data of  PLLA and its blends from differential scanning calorimetry. 
Material Designation 
Cooling 
 
2rd Heating 
Tc 
[oC] 
χc 
[%] 
 Tg a) 
[oC] 
Tcc 
[oC] 
χcc 
[%] 
Tm 
[oC] 
Pure PLLA 
(PURASORB PL 18) 
- - -  60.1 134.7 19. 8 180.3 
PLLA  
(after extrusion)  
- 97.6 23.6 
 
55.4 
93.9 b) 7.8 b) 
177.4 
 158.2 b) 5.8 b) 
PLLA/5 wt% SD 5SD 104.4 38.9  53.5 - - 174.3 
PLLA/10 wt% SD 10SD 106.3 47.8  57.5 - - 175.2 
PLLA/5 wt% ILA 5ILA 98.9 37.0  55.1 - - 172.3 
PLLA/10 wt% ILA 10ILA 92.9 48.4  47.0 - - 166.5 
a) Tg is defined as the midpoint of  the temperature range, bound by the tangents to the two 
flat parts in the region of  glass transition. 
b) PLLA (after extrusion) showed two cold crystallization peaks in the second heating scan 
at 93.9 and 158.2 oC, respectively. Crystallinities correspond to these two peaks are 7.8% 
and 5.8%, respectively.  
Tg and Tm of  all materials were determined from the heating curves. PLLA 
(after extrusion), blend 5SD and blend 10SD showed comparable Tg-values (55.4, 
53.5 and 57.5 oC, respectively), revealing that blends 5SD and 10SD might be 
phase-separated and that SD acted as a filler on PLLA. The Tg-value of  blend 
10ILA was the lowest (47.0 oC), indicating that ILA had a plasticizing effect on the 
polymer matrix. The plasticizing effect is probably due to the good structural 
compatibility of  ILA with PLLA, which reduced intermolecular force among 
polymer chains and increased the chain mobility. The plasticizing effect was not 
distinct when the content of  ILA was low (5 wt%), i.e. the Tg of  blend 5ILA was 
55.1 oC, comparable with PLLA after extrusion (55.4 oC). It is noted from the 
heating curves that the glass transition of  SD blends and ILA blends was less 
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pronounced than that of  PLLA (the pure one and the one after extrusion). This is 
probably due to the fully developed crystals during cooling and a decreased 
amount of  amorphous phase compared with PLLA. Melting point (Tm) was found 
to have the same trend as Tg. 5SD and 10SD had comparable Tm, 174.3 vs. 175.2 
oC. A depression of  Tm (up to 10.9 oC) was observed for ILA blends and this 
depression increased with the increase in ILA content, which is a typical behavior 
for plasticized poly(lactic acid) [29].  
The analysis of  Tg and Tm indicated that SD acted as a filler on PLLA, while 
ILA had a plasticizing effect on PLLA. Their different roles were also 
demonstrated in the cooling process. Both SD and ILA improved the 
crystallization ability of  PLLA to same extent in cooling, but they influenced the 
crystallization temperature differently. As shown in Figure 1 and Table 2, the 
crystallization peaks shifted to higher temperature with the increase of  SD content, 
97.6 (PLLA after extrusion) vs. 104.4 (5SD) vs. 106.3 oC (10SD). This might be 
associated with the increased nucleating ability, i.e. the addition of  SD reduced the 
energy required to nucleate, thus inducing crystallization at higher temperature in 
cooling. In contrast, Tc of  ILA blends decreased with the increase in ILA content, 
i.e. 97.6 (PLLA after extrusion) vs. 98.9 (5ILA) vs. 92.9 oC (10ILA). This might 
result from the plasticizing effect of  ILA, which increased the chain mobility and 
decreased Tg, thus facilitating the crystallization at low temperature upon cooling 
[29-30]. 
Morphology of  Compressed Films 
PLLA (after extrusion), SD blends and ILA blends were compressed into films 
and their microstructures were investigated by scanning electron microscopy (SEM) 
in backscatter mode. As shown in Figure 2. PLLA, 5ILA and 10ILA were 
homogeneous (uniformly grey images), demonstrating the compatibility of  ILA 
with the polymer matrix. In contrast, blends 5SD and 10SD appeared to be 
heterogeneous. SD aggregated into small particles (the light grey dots in Figure 1a 
and b) and dispersed throughout the blends. Figures 1b and 1c further illustrate the 
different microstructures of  blends 10SD and 10ILA.  
These data are consistent with results from our previous research (Chapter 2 
[19]) on poly(D,L-lactic acid) (PURASORB PDL 20) blended with ILA. It is 
known that poly(D,L-lactic acid) and PLLA have different crystalline properties, 
the former being amorphous and the latter semi-crystalline. The homogeneity of  
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both poly(D,L-lactic acid) blends and PLLA blends indicates that ILA has good 
compatibility with both amorphous and semi-crystalline poly(lactic acid).  
 
Figure 2. Scanning electron photographs (backscatter mode) of  PLLA and four blends. a) 
PLLA, blends 5SD, 10SD, 5ILA and 10ILA; b) blend 10SD; c) blend 10ILA. For blends 
5SD and 10SD, SD particles (light grey) are distributed throughout the PLLA matrix. 
Uniformly grey images are obtained for blends 5ILA and 10ILA due to the miscibility of  
ILA and PLLA matrix. 
Tensile Properties 
Tensile properties of  PLLA, SD blends and ILA blends were studied by tensile 
tests. The resulting tensile-strain curves were analyzed to determine elastic 
modulus, tensile strength and elongation at break. The results are compiled in 
Table 3. Table 3 shows that PLLA, 5SD and 10SD had comparable elastic 
modulus (2.10, 2.33 and 2.09 GPa, respectively). The presence of  SD caused a 
reduction of  tensile strength from 59.1 (PLLA) to 34.6 (5SD) and to 40.4 MPa 
(10SD), respectively. The same decreasing trend was found for elongation at break, 
which shifted from 11.5% (PLLA) to 3.0% (5SD) and to 4.3 % (10SD). The data 
of  elastic modulus and tensile strength indicated that SD had no reinforcing effect 
on PLLA. This is probably due to the incompatibility of  SD and PLLA matrix (as 
the phase-separated structure shows in Figure 2), i.e. there was only weak 
interaction between SD and PLLA. Similar trends were also reported in other 
blending systems, in which incompatible blends lead to weakened mechanical 
properties [29, 31-32]. The drop in elongation at break might result from phase 
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separation as well. The aggregations of  SD may cause stress concentration, thus 
reducing toughness. 
Table 3. Tensile properties of  PLLA, SD blends and ILA blends. 
Material 
Elastic  
Modulus a)  
[GPa] 
Tensile Strength 
[MPa] 
Elongation at Break 
[%] 
PLLA 2.10 59.1 11.5 
5SD 2.33 34.6 3.0 
10SD 2.09 40.4 4.2 
5ILA 1.41 59.4 9.5 
10ILA 2.01 29.4 2.5 
a) Elastic modulus was calculated as the slope of  the regression line performed on data set 
between two strain-values, 0.05% and 0.25%.  
The addition of  5 wt% ILA did not have a significant effect on tensile 
strength and elongation at break, i.e. 59.4 (5ILA) vs. 59.1 MPa (PLLA), and 9.5% 
(5ILA) vs. 11.5% (PLLA), respectively. Notably, a reduction in elastic modulus was 
found for 5ILA (1.41 GPa), compared with 2.20 GPa for PLLA. Significant lower 
tensile strength and elongation at break were observed for 10ILA, 29.4 MPa and 
2.5%, respectively. Elastic modulus increased from 1.41 to 2.01 GPa with the 
increase of  ILA content from 5 wt% to 10 wt%. These results for ILA blends 
implied that ILA did not really act like a plasticizer. In general, a plasticizer can 
decrease Tg, the elastic modulus as well as the tensile strength while it 
simultaneously increases elongation at break. By adding 10 wt% ILA to PLLA, the 
Tg decreased from 55.4 to 47.0 oC, demonstrating the plasticizing effect of  ILA. 
However, the tensile properties of  ILA do not fully certify this effect. One 
possible explanation might be that the concentration of  ILA used in our study is 
not sufficient to get plasticized materials, as the efficacy of  a plasticizer is related to 
its concentration [33]. The change of  elastic modulus might be explained by the 
different molecule-molecule interactions for ILA inside the blends. At low ILA 
concentration, ILA-polymer interaction is the dominant one. ILA reduces the 
interaction among polymer chains, leading to a drop of  elastic modulus. At high 
ILA concentration, ILA-ILA interaction (hydrogen bonding) might also become 
important, thus increasing the elastic modulus. Still the tensile strength and 
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elongation at break cannot be fully explained, yet. The function of  plasticizer is to 
reduce secondary forces among polymer chains [34]. On the one hand, the 
miscibility of  ILA and PLLA allows ILA to occupy spaces between chains, 
reducing the interactions among them. On the other hand, hydrogen bonding 
among ILA molecules may increase the secondary forces inside the blends.  
The elongations at break of  all material ranged from 2.5% to 11.5%, revealing 
the brittleness of  these materials. Failure zones of  the specimens were examined 
by polarized optical microscopy (Figure 3). No apparent plastic deformation was 
found in the failure zones (Figure 3), indicating that all specimens failed through a 
brittle fracture mode. Microcracks developed in specimens of  PLLA, blend 5ILA 
and blend 10ILA (Figures 3 a, c and d), which finally led to brittle breaking with 
few filaments. Though specimens of  blend 5SD (Figure 3 b) and blend 10SD (data 
not shown) showed brittle fracture containing few filaments as well, no 
microcracks were found in these specimens. 
 
Figure 3. Polarized light micrographs of  the failure regions fractured by tensile test. a) 
PLLA; b) 5SD; c) 5ILA; d) 10ILA. Black horizontal lines in a), c) and d) indicate 
microcracks. All images have the same scale bars corresponding to 200 µm. 
Taken together, PLLA, SD blends and ILA blends are all brittle materials, 
with elongation at break less than 11.5%. In our tensile tests, the presence of  SD 
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(up to 10 wt%) and ILA ( up to 10 wt%) didn’t have a significant adverse effect on 
the mechanical properties of  PLLA. More research should be done to further 
illustrate the effect of  ILA, especially at high loading (> 10 wt%), on the 
mechanical properties of  PLLA. 
In Vitro Cytotoxicity  
In vitro cytotoxicity of  PLLA, SD blends and ILA blends were characterized by 
MTT assay [35] and live/dead assay. Firstly, the MTT test was carried out using 
L929 cells (Figure 4). For all blends tested cell viability was comparable. Cell 
viability for cells incubated with extracts from PLLA was 88.6% ± 14.0%, 
comparable to negative control (set as 100%). For blend 5SD and blend 10SD, 
survival percentages were 84.3% ± 9.1% and 83.0% ± 8.1%, respectively. For 
blend 5ILA and blend 10ILA, survival percentages were 85.5% ± 12.1% and 82.9% 
± 9.2%, respectively. Cells incubated with extract from latex (positive control) only 
showed a viability of  19.1% ± 5.6%. These results confirmed that the 
incorporation of  either contrast agent did not influence the cell-compatibility of  
PLLA. 
 
Figure 4. Survival percentage of  L929 cells in MTT test.  
Secondly, in vitro cytotoxicity of  PLLA, SD blends and ILA blends was 
studied by live/dead assay on both L929 cells and HMECs to test the toxic effect 
of  polymer–cell contact. Calcein AM is a highly membrane-permeable green 
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fluorescent live-cell labeling dye. Upon entering viable cells esterases cleave the 
AM-ester group, yielding the membrane-impermeable calcein green fluorescent 
dye. EthD-1 can cross only damaged cell membranes and bind to DNA, thereby 
exhibiting a red fluorescence in non-viable cells. Figure 5 shows the results of  
HMECs incubated on glass as well as films of  PLLA and blends (5SD, 10SD, 5ILA 
and 10ILA). Green signal indicates viable cells and red nuclea indicate non-viable 
cells. For all tested materials, viable cells clearly dominated the images, with few 
dead cells randomly distributed. HMECs attached to glass and those attached to 
PLLA and blends (5SD, 10SD, 5ILA and 10ILA) showed similar appearance and 
comparable density. Similar outcome was found for L929 cells (data not shown). 
Taken together, PLLA and the four blends were non-toxic when directly 
contacting with HEMCs or L929 cells. 
 
Figure 5. Fluorescence microscope photographs obtained from live/dead test of  HMEC 
cells incubated on glass as well as films of  PLLA and blends (5SD, 10SD, 5ILA and 10ILA) 
for 24 h. a) glass; b) PLLA; c) 5SD; d) 10SD; e) 5ILA; f) 10ILA. Green dots donate live 
cells and red dots represent dead cells. Scale bars are the same for all images and equal to 
250 µm. 
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In general, ILA blends showed no cytotoxic effect in MTT assay and 
live/dead assay, which is in fact of  no surprise. On the one hand, PLLA is a safe 
material with good biocompatibility and has been approved by US Food and Drug 
Administration (FDA) for medical use. On the other hand, in our previous work 
ILA was shown to be biocompatible, i.e. ILA (< 10 mM) represented no 
cytotoxicity on human coronary arterial endothelial cells (HCAECs), porcine skin 
fibroblast cells (PSFs), or porcine aortic smooth muscle cells (PSMCs) and showed 
no negative effect on gene expression of  these cell types as well [19].  
In Vitro Hemocompatibility 
In vitro hemocompatibility of  PLLA and blends (5SD, 10SD, 5ILA and 10ILA) was 
assessed via a thrombin generation assay [23-25]. All samples were tested in direct 
contact with human platelet-rich plasma to characterize their thrombogenicity. A 
diagnostic catheter and stainless steel stents, both of  which are commercial 
available medical devices used in direct contact with blood, were studied as 
references. For each material, a thrombin generation curve was obtained based on 
six measurements (Figure 6). Thrombin generation lag time is defined as the time 
interval between start of  experiment (i.e. the moment of  recalcification of  plasma) 
and the time point when sudden increase of  thrombin in nanomolar 
concentrations occurs. The lag time provides a measure for the thrombogenicity of  
a material [36-38]: the shorter the lag time the more thrombogenic the material will 
be. Polystyrene wells without any material presented the longest lag time, 25.4 min. 
All materials showed comparable thrombin generation lag times ranging from 10.2 
to 13.2 min, i.e. PLLA (10.2 min), 5SD (11.0 min), 10SD (12.3 min), 5ILA (12.3 
min), 10ILA (12.7 min), 1 catheter piece (13.2 min), 2 catheter pieces (10.5 min), 1 
stent piece (10.6 min), 2 stent pieces (10.2 min). These results indicate that the 
presence of  either contrast agent did not negatively affect hemocompatibility of  
PLLA. 
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Figure 6. Thrombin generation curves for PLLA and blends (5SD, 10SD, 5ILA and 
10ILA). Pieces (4-mm long) from commercial catheter and stainless steel stents were used 
for comparison. All experiments were performed in 6-fold. Average values were plotted. 
Conclusions 
ILA, a new contrast agent with structural resemblance to L-lactic acid, was 
successfully developed in our previous work and is compatible with poly(D,L-lactic 
acid) [19]. In the present study, ILA also showed good compatibility with semi-
crystalline PLLA (PURASORB PL 18), i.e. PLLA blends containing ILA were 
homogeneous. In addition, their Tg-values (55.1 and 47.0 oC, respectively) were 
above body temperature. These Tg-values are higher than those of  poly(D,L-lactic 
acid) blends fabricated in our previous work [19]. Preliminary mechanical tests 
showed that the addiction of  the new contrast agent did not provide a significantly 
negative effect on mechanical properties of  PLLA. In vitro cytotoxicity and 
thrombin generation studies demonstrated the biocompatibility and 
hemocompatibility of  these blends. While the heterogeneity of  PLLA/SD blends 
hampers their use for biomedical application, the physical and biological properties 
of  the new PLLA/ILA blends make them promising materials for biodegradable 
radiopaque coronary stents. 
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We hypothesize that it will be possible to design biomaterials with specific 
physical properties and degradation kinetics from the homogeneous PLLA/ILA 
blends. The new approach presented, using the new contrast agent to introduce X-
ray contrast to poly(lactic acid), could be of  great interest for radiopaque stent 
application and other biomedical application in which radiopacity is desired (e.g. 
radiopaque scaffolds and implants). More research and developmental work must 
be performed to address the following issues in more depth: i) upper load limit of  
the new contrast agent, i.e. the maximum loading capacity in poly(lactic acid) 
matrix without losing mechanical integrity; ii) effect of  the new contrast agent on 
mechanical properties at high load (a filler or a plasticizer); iii) degradation of  
blends in vitro and in vivo; iv) metabolism of  the new contrast agent in vivo.  
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Abstract 
Biodegradable poly(D,L-lactic acid) drug-eluting microspheres containing anti-
tumor drugs, cisplatin and sorafenib tosylate, have been prepared by the emulsion 
solvent evaporation method with diameter between 200 μm and 400 μm. Scanning 
electron microscopy showed that cisplatin microspheres had smooth surfaces, 
while sorafenib tosylate microspheres and cisplatin + sorafenib tosylate 
microspheres were porous at the surface and the pits of  the latter were larger than 
those of  the former. Notably, cisplatin + sorafenib tosylate microspheres had a 
fast drug release rate compared with microspheres containing one drug alone. In 
vitro cytotoxicity experiments and classical matrigel endothelial tube assay 
certificated the maintaining bioactivity of  cisplatin and sorafenib tosylate released 
from the microspheres, respectively. This work provides a useful approach for the 
fabrication of  drug-eluting beads used in transarterial chemoembolization (TACE).  
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4.1 Introduction 
Transcatheter arterial embolization (TAE) is a frequently used technique in the 
treatment of  hepatocellular carcinoma (HCC), one of  the most common liver 
tumors [1-2]. TAE involves precise navigation of  a catheter into an arterial branch 
that feeds the hypervascular tumor, but none of  the surrounding healthy tissues [3]. 
Then, small polymer particles (usually microspheres) are injected via the catheter. 
When the particles leave the catheter’s mouth, the arterial blood flow carries them 
into the tumor. Due to branching, the embolic particles get stuck in the tumor’s 
arterial vessel bed. The consequence is that tumor tissues behind each obstruction 
are no longer perfused. Ideally, this leads to ischemia and necrosis in these parts of  
the tumor. 
It has become clear that TAE per se is generally unsuccessful in HCC 
treatment. Hypoxia leads to upregulation of  vascular endothelial growth factor 
(VEGF) and/or platelet-derived growth factor receptor Beta, and this stimulates 
neo-angiogenisis. New blood vessels are generated as bypasses around the embolic 
particles, and some tumors may even be stimulated to grow faster than they did 
before embolization [4-6]. 
It is for this reason that the search for new strategies to treat HCCs is focused 
on combining embolization with local administration of  cytostatic and/or anti-
angiogenic drugs. Currently, one of  the most promising approaches is the use of  
drug-eluting beads in transarterial chemoembolization (DEB-TACE), followed by 
a daily intravenous administration of  a formulation containing the drug sorafenib 
tosylate which is also known as NEXAVAR® [6-9]. Sorafenib tosylate is a 
multikinase inhibitor targeting several serine/threonine and receptor tyrosine 
kinases. It is shown that sorafenib tosylate is a pronounced anti-angiogenic agent. 
The efficacy of  sorafenib tosylate in DEB-TACE has recently been evaluated in a 
number of  clinical trials around the globe [10-15]. A recent meta-analysis has 
shown that combination of  TACE with sorafenib tosylate in patients with 
advanced stage HCC improves overall survival, time-to-progression and objective 
response rate, although sorafenib tosylate also provoked significant adverse 
reactions [16]. 
From the perspective of  biomaterials science and engineering, the combined 
approach has several interesting features. Firstly, DEB-TACE involves a charging 
step, in which the embolic particles are combined with an aqueous drug 
formulation. For example, in the commercial product DC-Beads (Biocompatibles, 
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Farnham, UK), the particles are loaded (e.g., with doxorubicin) through immersion 
of  the microspheres in an aqueous formulation of  the drug, approximately 20 min. 
prior to the injection [17-18]. Thus, DEB-TACE combines embolization and local 
release of  doxorubicin at the target site. Note that (i), for some drugs there is no 
interaction between the beads and the drug and hence elution is rapid and could 
result in premature loss of  the drug load during embolization [19], and (ii), the 
embolizing particles are stable, i.e., not biodegradable. Secondly, the intravenous 
administration of  sorafenib tosylate leads to spreading and dilution of  the drug. It 
is a drawback that the drug cannot easily reach embolized tissues, since there is 
limited perfusion there. It must be expected that only a minute fraction of  the drug 
actually is absorbed by the tumor. The remainder of  the drug can trigger adverse 
reactions. 
These considerations prompted us to develop ideas about microspheres for 
combined embolization and prolonged local administration of  a drug (e.g., 
sorafenib tosylate). We prepared microspheres from medical-grade biodegradable 
poly(D,L-lactic acid) (PDLLA), in such a way that sorafenib tosylate was dispersed 
in the particles, and we could achieve loading up to 15.7 % by mass. Furthermore, 
we prepared analogous microspheres in which cisplatin was dispersed, again with a 
load of  12.4 mass %. We also prepared biodegradable microspheres containing 7.3 % 
sorafenib tosylate and 4.8 % cisplatin. We describe the preparation of  these drug-
loaded particles, as well as an analysis of  their structures, paying special attention 
to porosity. We studied release of  the drug(s) in vitro and the bioactivity of  the 
drugs released from the microspheres. Finally, we comment on the potential utility 
of  bio-eroding drug-loaded microspheres as described here, in TACE. We also 
discuss the versatility of  the drug charging method: it is possible to charge the bio-
eroding particles with different cytostatic or anti-angiogenic drugs, which provides 
possibilities for personalized therapy. It is also discussed that the drug-loaded 
microspheres represent medical device/drug combinations, which may complicate 
regulatory issues on the pathway to introduction in the clinical practice.   
4.2 Experiment Section 
Materials 
Dichloromethane, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), 
methanol and Tween 20 were purchased from Acros (Landsmeer, The 
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Netherlands). Poly(D,L-lactic acid (PURASORB PDL 20, PDLLA) was purchased 
from Corbion (Gorinchem, The Netherlands), which was the same as the poly 
lactic acid used in our previous paper, having an Mv value of  1.34 × 105 [20]. 
Detergent was bought from Lidl Netherland GmbH (Huizen, The Netherlands). 
Cisplatin and sorafenib tosylate were from SPE Chemicals (Shanghai, China). o-
Phenylenediamine (OPDA) was purchased from Aldrich (Zwijndrecht, The 
Netherlands). Cell culture medium EGM-2-MV BulletKit was obtained from 
Lonza (Verviers, Belgium). Cell culture medium RPMI 1640 with antibiotics 
penicillin and streptomycin (pen-strep), foetal bovine serum (FBS), ethidium 
homodimer-1 (EthD-1) and Hoechst 33342 were all purchased from Life 
Technologies (Merelbeke, Belgium). Human umbilical vein endothelial cells 
(HUVECs) and reducing growth factor matrigel were acquired from BD 
Biosciences (Breda, The Netherlands). Renca tumor cells were purchased from Cell 
Lines Service GmbH (Eppelheim, Germany). 
Preparation of  the Microspheres 
All microspheres were fabricated by the emulsion solvent evaporation method. A 
typical procedure for the preparation of  cisplatin microspheres is as follows. 
PDLLA (1.40g) was dissolved in dichloromethane (20 mL) and stirred overnight. 
Cisplatin powder (280 mg, 20 % w/w) was added and the suspension was stirred 
for 30 min. The suspension was then slowly poured into 1 L of  mechanically 
stirred (500 rpm) solution of  detergent (12 g) in 1 L of  distilled water. Stirring was 
continued for 4 h, to allow complete evaporation of  the dichloromethane. 
Microspheres were isolated via filtration. The microspheres were washed with 
distilled water, until there was no foam left. The wet microspheres were finally 
lyophilized. PDLLA microspheres were prepared by the same procedure. For 
sorafenib tosylate microspheres and cisplatin + sorafenib tosylate microspheres, 
organic phases were produced by different ways. For the former, sorafenib tosylate 
(280 mg, 20% w/w) was first dissolved in 1.4 mL DMSO, which was added to 18.6 
mL dichloromethane solution containing PDLLA (1.4 g), and stirred for 30 min to 
form the organic phase. For the latter one, sorafenib tosylate (140 mg, 10% w/w) 
was dissolved in 0.7 mL DMF and was added to 19.3 mL dichloromethane 
solution containing PDLLA (1.4 g) together with cisplatin (140 mg, 10% w/w). 
Then, the mixture was stirred for 30 min to form the organic phase. After 
lyophilizing, microspheres were sieved by two sieves with mesh diameter of  400 
μm and 200 μm, respectively. Microspheres with diameter between 200 μm and 
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400 μm, which were approximately 60 % of  the yield, were used in subsequent 
experiments. The choice to use microspheres in this diameter range was arbitrary. 
The fabrication process also yielded microspheres with diameter < 200 μm. Larger 
particles (> 400 μm) were found to be non-spherical in many cases.  
Scanning Electron Microscopy 
Surface morphology of  microspheres was characterized by scanning electron 
microscopy (SEM). All samples were sputter-coated with gold before examination. 
SEM images were analyzed with ImageJ [21] software to determine the size of  
microspheres. For each microspheres batch, 100 measurements were taken for the 
calculation and 2 batches were measured for each sample. The cross-sections were 
prepared by embedding microspheres in Epon resin, and then the Epon blocks 
were sliced. The cross-sections were sputter-coated with carbon and examined 
using a Philips XL 30 SEM instrument (Eindhoven, The Netherlands) in the 
backscattered electron imaging (BEI) mode. 
X-ray Visibility 
X-ray visibility of  the microspheres was characterized by a Phoenix Nanomex ultra 
high-resolution nanofocus X-ray inspection system from General Electric, located 
at the Philips High-tech Campus (Eindhoven, The Netherlands). The instrument 
was operated at 80 kV. 
Determination of  Drug Content and Loading Efficiency 
Cisplatin microspheres: Microspheres were dissolved in 1.25 mL DMF. The 
determination was done in 3-fold, with either 4.4 mg, 5.4 mg or 5.8 mg 
microspheres. The concentrations of  cisplatin were measured by a UV-visible 
spectrometer (Spectra Max M2, Wokingham, United Kingdom) at 310 nm at room 
temperature and calculated according to a standard curve [22-23]. 
Sorafenib tosylate microspheres: Microspheres were dissolved in 0.05 mL 
DMF and then 25 mL methanol was added to the solution. The determination was 
done in 3-fold, with either 1.2 mg, 1.5 mg or 2.0 mg microspheres. The mixture 
was centrifuged and the supernatant was measured by a UV-visible spectrometry at 
265 nm at room temperature [24]. The absence of  background for cisplatin, 
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PDLLA and remaining solvents was checked in the experiment. The 
concentrations of  sorafenib tosylate were calculated according to a standard curve. 
Cisplatin + sorafenib tosylate microspheres: The content of  cisplatin was 
determined as follows. First, microspheres were dissolved in 1.00 mL DMF. 
Second, 0.08 mL was transferred to a test tube and diluted with PBS (pH = 7.4) to 
1.00 mL. 1.00 mL OPDA solution (1.4 mg/mL, in DMF) and 2.00 mL PBS (pH = 
6.5) were added to the test tube, which was then put in an oil bath at 100 oC for 10 
min. The mixture was cooled to room temperature and DMF was added to give a 
final volume of  10 mL. The determination was done in 3-fold, with either 5.2 mg, 
5.1 mg or 4.3 mg microspheres. The concentrations of  cisplatin were measured by 
a UV-visible spectrometer at 703 nm at room temperature [25-26]. For sorafenib 
tosylate, the procedure was the same as the one for sorafenib tosylate microspheres. 
In Vitro Drug Release Studies 
The drug-loaded microspheres were immersed in 5 mL PBS (pH = 7.4 or 6.0) and 
put in a shaking water bath (100 rpm) at 37 oC. The drug release solution was 
centrifuged (1500 g, 3 min) and changed periodically (1, 2, 4, 6, 24, 48h…). 
Concentrations of  drugs released from the microspheres were monitored by a UV-
visible spectrometry at room temperature. 1% Tween 20 (w/v) was added to the 
release medium to promote the solubility of  sorafenib tosylate in the release 
medium. All release experiments were carried out in 3-fold, and all data were 
averages of  three determinations. 
Cytotoxicity 
To determine cytotoxicity of  PDLLA microspheres loaded with cisplatin, 
sorafenib tosylate, cisplatin + sorafenib tosylate or unloaded, beads were incubated 
for 24 h in EGM-2-MV medium after which supernatants were collected. 
HUVECs were cultured in EGM-2-MV. RenCa cells were cultured in RPMI1640 
with 10% FBS and pen-strep (100 units/mL penicillin and 100 µg/mL 
streptomycin, respectively). To test cytotoxicity cells were seeded in BD Falcon 96 
wells HTS Imaging microplates (BD, Erembodegem, Belgium) and cultured for 72 
h until high confluency (>85%). Next, bead supernatants were added. After 24 h 
incubation, Hoechst 33342 (800 × 10−9 M) and EtHD-1 (4 × 10−6 M) were added 
to distinguish between viable and non-viable adherent cells. Cells were imaged and 
Chapter 4 
96 
analyzed automatically with a BD Pathway 855 high content analyzer (BD 
Biosciences). BD Attovision software (BD Biosciences, version 1.6) was used for 
both image acquisition and individual cell segmentation and analyses. Numerical 
data were further analyzed with flow cytometry software (Kaluza 1.2; Beckman 
Coulter, Mijdrecht, The Netherlands) to assess total cell numbers (Hoechst) and 
dead cells (EtHD-1). Number of  viable cells was calculated as fraction of  number 
of  adherent cells with Hoechst positive nuclei minus number of  EtHD-1 (dead) 
positive nuclei per well, and averaged for replicates (n = 3 per condition). Data 
were plotted as average viable cell numbers per well for the different conditions 
with untreated wells as control set at 100%. Either Student t–test (Renca 
experiment) or one-way-Anova (all others) were applied to define statistical 
differences, with p-value below 0.05 considered significantly different (GraphPad 
Prism 5.01 for Windows, GraphPad Software, San Diego, CA, USA). 
Classical Matrigel Endothelial Tube Assay 
To determine the effect of  sorafenib tosylate on agniogenesis a classical matrigel 
endothelial tube assay was performed. µ-Slide Angiogenesis (Ibidi, Munich, 
Germany) plate wells were filled with 10 µL reduced growth factor matrigel and 
incubated (37 oC, 5% CO2) for 30 min to polymerize. Next, cells were resuspended 
in appropriate growth medium (EGM-2-MV without bFGF, with 100 ng/mL 
VEGF-A and 2.5% FBS), with additionally for each condition an equal volume of  
bead supernatant (conditions as described previously) or 5 µM SU5416. HUVECs 
were seeded with 10,000 cells/well (n = 5 per condition). Finally, overnight cell 
cultures were imaged under standard bright field microscope conditions with 
EVOS® XL Imaging System (Advanced Microscopy Group, Bothell, WA, USA) 
and analyzed with ImageJ [21] (Version 1.47v) and Angiogenesis Analyzer for 
ImageJ [27] plug-in to quantify total angiogenic tube length per well. 
4.3 Results and Discussion 
Formation and Physical Analysis of  the Microspheres 
Preparation of  the microspheres by solvent evaporation proceeded smoothly in all 
cases. For cisplatin microspheres, the organic phase was a suspension. When using 
suspension as the organic phase for sorafenib tosylate microspheres and cisplatin 
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+ sorafenib tosylate microspheres, the particles stuck with one another and had 
irregular shapes, which indicated that it’s important to have a homogeneous oil 
phase for sorafenib tosylate when making these two kinds of  microspheres. 
DMSO and dichloromethane were used as the organic solvent for sorafenib 
tosylate microspheres. Cisplatin is not stable in DMSO solution [28], so DMF and 
dichloromethane were chosen for microspheres containing the two drugs.  
SEM micrographs of  the different microspheres are shown in Figure 1 and 
diameters of  the microspheres are compiled in Table 1. PDLLA microspheres and 
cisplatin microspheres both had smooth surfaces (Figures 1 a1, a2, b1, b2), while 
sorafenib tosylate microspheres and cisplatin + sorafenib tosylate microspheres 
showed pits at the surface (Figures 1 c1, c2, d1, d2). The pits that were observed 
for the microspheres containing cisplatin and sorafenib tosylate were generally 
larger than those found for the microspheres containing sorafenib tosylate alone. 
The backscatter SEM images shows that cisplatin crystals are dispersed throughout 
microspheres randomly (Figures 1 b3, d3). All microspheres appeared to have 
porous shells (Figures 1 a3, b3, c3, d3) and solid cores except cisplatin + sorafenib 
tosylate microspheres (Figure 1 d3) which also have a porous core.  
The porous shells can be explained by the solvent extraction during the 
formation of  the microspheres. For PDLLA and cisplatin containing microspheres, 
when the organic phase was poured into the continuous water phase, round 
droplets would form due to the existence of  detergent and mechanical stirring and 
their cortical part would immediately become viscous polymer-rich shells because 
of  the fast outward diffusion of  dichloromethane to the water phase. At the same 
time dichloromethane inside the droplets would diffuse though the PDLLA rich 
shells to the water phase and some water may enter into the droplets through the 
polymer rich phase which later become pores with the solidification of  the 
microspheres. However, there are limitations in this path because of  the low 
solubility of  water in dichloromethane and PDLLA. 
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Figure 1. Scanning electron images of  microspheres showing surfaces (the first and second 
lines) and cross-sections (the third line). a) PDLLA microspheres; b) cisplatin microspheres; 
c) sorafenib tosylate microspheres; d) cisplatin + sorafenib tosylate microspheres. The scale 
bars in the three lines of  images correspond to 200 μm, 50 μm and 50 μm, respectively. 
Table 1. Diameters and drug-loading parameters of  microspheres. 
Entry PDLLA Microspheres 
Cisplatin 
Microspheres 
Sorafenib 
Tosylate 
Microspheres 
Cisplatin + 
Sorafenib 
Tosylate 
Microspheres 
Diametera) 
(μm) 280 ± 52 278 ± 50 264 ± 50 259 ± 51 
DLCb)cisplatin - 12.4% - 4.8% 
DLEc)cisplatin - 74.3% - 57.7% 
DLCsorafenib 
tosylate 
- - 15.7% 7.3% 
DLEsorafenib 
tosylate 
- - 94.2% 88.0% 
a) The diameter represents mean diameter ± S.D.  
b) DLC denotes the drug-loading capacity of  microspheres, which is the weight ratio of  
actual drug to drug-loaded microspheres.  
c) DLE denotes the drug loading efficiency of  microspheres, which is the weight ratio of  
actual and added drug content. 
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The path mentioned above also played a role in the generation of  porous 
peripheral layers of  sorafenib tosylate and cisplatin + sorafenib tosylate 
microspheres. Porosity in these particles is probably due to the water solubility of  
DMSO and DMF. Phase separations occurred during the formation of  these 
microspheres: (1) polymer-rich phase containing most PDLLA, dichloromethane; 
(2) polymer-poor phase made up of  most DMSO or DMF, sorafenib tosylate and 
small amount of  cisplatin; (3) non-polymer phase consisting of  cisplatin. The 
porosity of  microspheres is then determined by the amount of  water entrapped 
inside the microspheres. Water soluble cosolvents, DMSO and DMF, in the 
polymer-poor phase may help the uptake of  water to form some water-filled 
DMSO and DMF regions which are the precursors for the pores. During the 
formation of  microspheres, two competitive processes coexist: the uptake of  water 
and the solidification of  the periphery part [29-30]. If  the former dominated, the 
microspheres would be more porous than the case in which the latter dominated. 
The different porosities of  these two microspheres were probably due to the 
different control process in the formation.     
The microspheres were further analyzed for their X-ray visibility (Figure 2). 
As seen from Figures 2 b, c, microspheres containing cisplatin showed good X-ray 
contrast, while PDLLA microspheres (Figure 2 a) were logically-radiolucent and 
invisible by X-ray imaging.  
PDLLA microspheres (200 mg) were mixed with 11 mL contrast agent 
mixture, as shown in Figure 3. They formed a stable suspension for several 
minutes. The suspension easily passed a 4-Fr diagnostic catheter (Cobra, Cordis). 
 
Figure 2. X-ray images of  the microspheres. a) PDLLA microspheres; b) cisplatin 
microspheres; c) cisplatin + sorafenib tosylate microspheres. The scale bar in Figure 2a 
corresponds to 1 mm. The scale bars in Figures 2b and 2c correspond to 500 μm. 
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Figure 3. Suspension of  PDLLA microspheres in contrast agent mixture. 
In Vitro Drug Release Behavior 
The drug-loading parameters are compiled in Table 1. The drug-loading efficiency 
of  sorafenib tosylate (94.2%) was higher than that of  cisplatin (74.3%), which 
reflects the difference of  aqueous solubility of  the two drugs; sorafenib tosylate is 
practically insoluble in aqueous media, while solubility of  cisplatin is approximately 
0.25 g/100 mL (at 25 oC). The drug-loading efficiencies of  microspheres 
containing two drugs were lower than corresponding microspheres with one drug. 
This was probably due to the inclusion of  DMF and the porous structure of  these 
microspheres. 
We decided to study release of  the drug(s) from our microspheres, at two 
different pH values: 7.4 (physiologic pH) and 6.0. The latter pH value may reflect 
the microenvironment of  solid tumors, which is known to be slightly acidic. The 
drug-release curves, measured during a time-interval of  15 days, are shown in 
Figures 4 and 5. In all cases, a biphasic drug-release profile was found, with an 
initial release on the first day and slower release in the next days. At pH 7.4, the 
microspheres containing sorafenib tosylate released 4.2% of  their cargo during the 
first 24 h. Release was similar for the microspheres containing cisplatin (4.0% 
during the first 24 h). After 15 days, 9.3 % of  the sorafenib tosylate cargo was set 
free, versus 6.9% for cisplatin. At pH 6.0, the release from sorafenib microspheres 
was slightly accelerated, with 8.5% of  the cargo released after 24 h and 11.8% after 
15 days. This reflects the fact that sorafenib tosylate is more soluble in acidic 
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medium than in neutral medium [31]. Noteworthy, the release profiles of  cisplatin 
microspheres practically overlapped for pH 7.4 and 6.0 (pH 6.0: 4.2% of  cisplatin 
released after 24 h and 7.2% after 15 days). 
 
Figure 4. Effect of  pH of  the medium on the in vitro drug-release profiles of  cisplatin 
microspheres and sorafenib tosylate microspheres at 37 oC. 
 
Figure 5. Effect of  pH of  the medium on the in vitro drug-release profiles of  cisplatin + 
sorafenib microspheres at 37 oC. The solid lines represent fitting profiles calculated using 
bi-exponential equation. 
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Much faster release rates were found for the microspheres containing both 
drugs together (compare Figures 4 and 5). At pH 7.4, release of  sorafenib tosylate 
is 23% after 24 h, and 91% after 15 days. Simultaneously, release of  cisplatin was 
20% after 24 h and 48% after 15 days. The release profiles in Figure 5 were 
analyzed by a bi-exponential model [32-33]. In this model, the drug release system 
was divided into two parts, and the release profile of  each part obeyed the mono-
exponential model. This model can be expressed equation (1): R (t) = 𝑅1 �1 −  𝑒−𝑘1𝑡� +  𝑅2 �1 −  𝑒−𝑘2𝑡�       (1) 
where R (t) is the amount of  drug released into the solution at time t; R1 and R2 are 
the final amounts of  drugs released from Part 1 and Part 2; k1 and k2 are the 
release rate constants of  Part 1 and Part 2. Equation (1) was fitted to the release 
data (Table 2). 
Table 2. Release parameters of  cisplatin + sorafenib tosylate microspheres using bi-
expotional model based on in vitro release profile a). 
Entry R1 [%] k1 [h-1] R2 [%) k2 [h-1] 
Square of  
Correlation 
Coefficient 
pH 7.4 Sorafenib 
tosylate 9.9 0.2846 90.1 0.0056 0.9924 
Cisplatin 20.2 0.2576 79.8 0.0014 0.9886 
pH 6.0 Sorafenib 
tosylate 27.6 0.2828 72.4 0.0023 0.9923 
Cisplatin 24.1 0.4241 75.9 0.0009 0.9781 
a) R1 + R2 was fixed to 100% if  R1 + R2 was far from 100%. 
The accelerated release of  both drugs can, in opinion, be attributed to the 
more porous nature of  these microspheres, caused by the combined use of  DMF 
and dichloromethane during the fabrication of  the drug-loaded microspheres. 
Interestingly, changing the pH from 7.4 to 6.0 affected the release rates of  
sorafenib tosylate, and cisplatin in a reverse manner, compared to the microspheres 
that contained only sorafenib tosylate or cisplatin. Figure 5 shows that the release 
of  sorafenib tosylate and cisplatin is slowed down upon going from pH 7.4 to pH 
6.0. This is best seen after 15 days, when sorafenib tosylate is released for 91.1% at 
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pH 7.4, and only 66.4% at pH 6.0. Analogously, 15-days release of  cisplatin was 
47.8% at pH 7.4, and 42.1% at pH 6.0. 
To explain these observations, we must consider the factors that govern the 
release of  drugs that are dispersed in biodegradable polymer microspheres. These 
factors are [34-35]: 
a. Initial release from the surface of  the microspheres. 
b. Diffusion through water-filled pores. 
c. Diffusion through the polymer matrix. 
d. Polymer erosion and bulk degradation. 
In vitro degradation experiments (37 oC, pH 7.4) carried out with the four 
kinds of  microspheres, showed no obvious weight loss and morphology changes 
(observed by SEM), even after 3 months. This reveals that the PDLLA is stable 
under these conditions, i.e. hardly any degradation occurs. We did not perform 
analogous experiments at pH 6.0, but based on literature on PDLLA at pH 5.0 
either. For example, Makino et al. studied the degradation of  PDLLA 
microcapsules in buffer solutions with different pH [36]. They observed no 
significant changes of  the degradation behavior between neutral media (pH 7.4) 
and slight acidic media (pH 5.0). 
Hence, in our case, drug releasing processes during the first 2 weeks are not 
controlled by polymer erosion or bulk degradation (mechanism d). The initial burst 
release is probably due to mechanism a: initial release of  drug molecules residing at 
the surface of  microspheres. Subsequently, cisplatin microspheres and sorafenib 
tosylate microspheres both entered a slow release phase according to mechanism c: 
slow diffusion through the relatively dense polymer matrix. Note that the cisplatin-
containing microspheres are smooth (Figure 1 b1), and the sorafenib-tosylate 
containing microspheres are also smooth, with few small pores at their surface 
(Figure 1 c1). For the microspheres containing the two drugs together, the 
morphology was different, as is seen in Figure 1 d1. These particles contain many 
relatively large pores, which are expected to facilitate mechanism b, i.e. relatively 
fast diffusion of  drug molecules through water-filled pores. At this point, it is 
interesting to consider the effect of  changing the pH from neutral to slightly acidic. 
By doing so, the ratio of  COO-/COOH will decrease, the polymer will therefore 
contract, and the pores will become smaller. Proikakis et al. [37] found higher 
swelling index of  poly(lactic acid) tablets in medium of  pH 7.4 than that in 
medium of  pH 5.4, which was due to the dissociation of  carboxylic end groups at 
higher pH, causing strong repulsive electrostatic forces among COO- anions. 
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These forces lead to higher degree of  swelling, increased mesh size in the polymer 
matrix, and finally faster release rate. In our case, the release of  both drugs from 
the microspheres is expected to become slower upon going from pH 7.4 to 6.0, 
and this is what was observed (vide supra and Figure 5).  
Biofunctionality of  Cisplatin and Sorafenib Tosylate 
To evaluate biofunctionality of  the drugs being released by the drug loaded 
PDLLA microspheres, medium supplemented with beads and cultured for 24 h 
was analyzed for cytotoxicity and anti-angiogenic effect (Figure 6).  
 
Figure 6. Effect of  medium incubated for 24 h with PDLLA beads, cisplatin, sorafenib 
tosylate (ST) or cisplatin + ST loaded PDLLA beads on cell viability of  HUVECs (A) or 
Renca tumor cells (B) after 24 h of  culturing, and on endothelial tube formation illustrated 
by total length of  endothelial tubes per condition (left) and representative transmission 
microscope images of  the endothelial tubes in culture (right) (C). Numbers of  cells 
cultured for 24 h in cell medium serve as control and are set at 100%. Error bars represent 
standard deviation, * indicates for a significant difference compared with PDLLA control 
and # between conditions (n=3 A, B; and n=5 for C). Scale bar is 1 mm. 
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As expected supernatants derived from cisplatin loaded PDLLA beads 
resulted in a significant drop in cell viability of  endothelial cells (i.e. HUVECs) as 
compared with PDLLA control (61.7% +/- 0.8% vs 100.4% +/- 1.0%, 
respectively; one-way-Anova, p<0.05, n=3). An augmented effect was found for 
supernatant of  cisplatin + sorafenib tosylate loaded beads compared with PDLLA, 
even presenting a significant higher cytotoxic effect over supernatant of  cisplatin 
loaded PDLLA only (45.1 +/- 9.8% vs 61.7% +/- 0.8%; one-way-Anova, p<0.05, 
n=3), whereas supernatant of  PDLLA beads loaded with sorafenib tosylate 
showed no compromised cell viability (Figure 6A). A considerable cytotoxic effect 
for supernatant of  cisplatin + sorafenib tosylate loaded PDLLA beads was also 
apparent for Renca tumor cells (Figure 6B; 60.0% +/- 8.1% vs. 96.2% +/- 3.8% 
for PDLLA control). Cisplatin is a classical cytostatic drug, which bind to the 
neighboring purine bases in DNA, resulting in DNA damage and the start of  
apoptosis [38]. The drop in cell viability of  endothelial cells and Renca tumor cells 
demonstrated the bioactivity of  cisplatin released from the microspheres.   
To test for the anti-angiogenic effect of  sorafenib tosylate a classical 
endothelial matrigel tube assay was applied with VEGFR2 inhibitor (SU5416) as 
inhibition control (Figure 6C). Significant reduced endothelial total tube length was 
found for supernatant of  all sorafenib loaded beads (8,494 +/- 1,431; 10,921 +/- 
1,557 pixels for sorafenib tosylate and cisplatin + sorafenib tosylate, respectively 
with PDLLA 14,159 +/- 749 pixels, one-way-Anova, all p<0.05, n=5) comparable 
to SU5416 (10,030 +/- 567 pixels). Supernatant of  beads loaded with only 
cisplatin showed no effect. Strongest anti-angiogenic effect was found for 
supernatant of  sorafenib tosylate beads with significantly lower total tube length 
than cisplatin + sorafenib tosylate loaded beads (Figure 6C). Sorafenib tosylate, an 
anti-cancer drug, is a multikinase inhibitor, which acts on vascular endothelial 
growth factor (VEGF) and on platelet-derived growth factor (PDGF) related 
pathways to block tumor cell proliferation and angiogenesis [39]. The results from 
the classical endothelial matrigel tube assay certificated the biofunctionality of  the 
released sorafenib tosylate from the microspheres. 
4.4 Conclusions 
This study shows that biodegradable drug-eluting microspheres can be 
manufactured by the emulsion solvent evaporation technique. Particle diameters in 
the diameter range 200 – 400 μm, as required for transarterial catheter-based 
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embolization of  hypervascular solid tumors (like HCCs), can be manufactured. 
The particles are mostly spherical, and drug molecules or crystals are dispersed 
throughout the volume of  the microspheres. The incorporation of  two different 
drugs in the same microspheres is technically feasible as well. 
Drug release from the particles is a complex interplay between: (i), solubility 
of  the drug(s); (ii), formulation (i.e., drug-to-polymer ratio); (iii), porosity of  the 
particles. Much more engineering is required to optimize all these parameters with 
respect to the therapeutic window of  the medication that is used. Furthermore, 
during embolization therapy, the pH of  the tissue around the microspheres will 
strongly affect the bio-erosion of  the PDLLA, and –hence- the kinetics of  local 
drug release.  
We anticipate that embolization therapy in the oncology field will move 
toward the use of  biodegradable and drug-eluting microparticles, as described in 
this study. While this concept may cause difficulties from a regulatory point of  
view (drug-loaded embolization particles are not simply medical devices, but 
device-drug combinations), efforts to introduce such particles into the clinic are 
likely to be worthwhile. We can imagine that bio-eroding drug-loaded microspheres 
for embolization, and bio-eroding drug-loaded endovascular stents could fall under 
the same regulatory regime.  
In biomaterials science and engineering, there is a clear general trend towards 
the use of  biodegradable biomaterials to construct implants. Applying such 
biomaterials poses technical complications, but can also reduce the risks for 
complications due to chronic inflammatory reactions. While we know that the 
stable embolic particles that are currently on the market are markedly 
“biocompatible” [40], it is also known that inflammatory reactions can be invoked. 
For example, Senturk et al. [41] reported the occurrence of  mild to moderate 
inflammatory reactions to polyvinyl alcohol embolic particles (irregular and 
microspheres), as well as to tris-acryl gelatin microspheres, in a rabbit kidney 
model of  embolization. Furthermore, slow and controlled biodegradation of  the 
polymer carrier provides a mechanism to deliver the drug(s) locally and within the 
therapeutic window, during a prolonged time interval. We agree with previous 
reports [42] that the possibility to use embolization particles containing two 
different drugs (e.g. a cytostatic and an anti-angiogenic drug) provides interesting 
options for personalized therapies in oncology in the future. 
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Abstract 
Poly (lactic acids) are well-studied and widely used polymers for biomedical 
application due to their biocompatibility and biodegradability. In this study, 
poly(D,L-lactic acid) microspheres loaded with cisplatin, or sorafenib tosylate, or a 
combination of  both drugs were developed. Degradation, and release of  cisplatin 
and/or sorafenib tosylate from these microspheres were characterized in detail. 
Incubation of  the microspheres in phosphate buffered saline (pH = 7.4), revealed 
slow degradation of  all microspheres tested. Although degradation was slow, 
significant release of  cisplatin and sorafenib tosylate from microspheres loaded 
with both drugs was apparent in vitro and might relate to their porous structure. 
Supernatants from microspheres loaded with both drugs showed strong cytotoxic 
effect on cells (i.e. endothelial cells, fibroblast cells and Renca tumor cells) and 
potent anti-angiogenic effect in matrigel endothelial tube assay. In vivo anti-tumor 
effect of  the microspheres was evaluated in a Renca tumor mouse model. 
Microspheres containing both cisplatin and sorafenib tosylate revealed highest 
therapeutic efficacy, demonstrating that combined local administration of  cisplatin 
and sorafenib tosylate effectively inhibits tumor growth in situ. In conclusion, this 
study demonstrates the applicability of  biodegradable poly(D,L-lactic acid) 
microspheres loaded with cisplatin and sorafenib tosylate for local drug delivery 
and their potential future use in transarterial chemoembolization. 
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5.1 Introduction 
Minimally invasive therapies are rapidly gaining importance in oncology, in 
particular by transarterial chemoembolization (TACE). The conventional TACE 
involves two steps. First, contrast medium containing anticancer drug(s) is 
administrated via a catheter, which is followed by injection of  embolic agents 
(spherical or nonspherical) into the vessel bed of  the tumor (e.g. primary liver 
tumors, such as hepatocellular carcinoma (HCC), or kidney tumor) [1-2]. Optimal 
results are currently achieved when cytostatic drugs are not directly intra-arterial 
delivered but instead are loaded to the embolic microspheres (i.e. drug-eluting 
beads), which are then slowly released inside the tumor during the first two weeks 
of  the post-embolization phase [3-5]. 
Several commercial products of  embolic drug-eluting microspheres have 
entered the market already. For example, DC Bead® (Biocompatibles, Farnham, 
UK) has been developed to bind, deliver and elute doxorubicin in HCCs during 
and after TACE. Preclinical and clinical studies revealed that this technique leads to 
higher drug concentrations within the tumor (compared with conventional TACE), 
while lower systemic concentrations are maintained [4, 6-7]. Although DC Bead® is 
quite promising, two aspects of  this device deserve further attention. The first item 
deals with the drug loading of  DC Bead®. The embolic beads are charged with the 
drug in course of  the procedure, just prior to injection. The bead-drug interaction 
is critical for drug loading, and for release kinetics as well. Only positively charged 
drugs can be immobilized to DC Bead® through an ion-exchange mechanism and 
the release kinetics is significantly determined by the ionic environment of  the 
medium. Conversely, drugs without positive charge cannot be loaded within these 
beads and are therefore released almost instantaneously [8]. The other issue deals 
with the non-biodegradability of  DC Bead®. Currently, search for biodegradable 
alternative embolic microspheres is eminent [9-12]. These biodegradable particles 
may eliminate the concern of  possible late inflammatory foreign-body response to 
the presence of  non-degradable microspheres [13]. In addition, utilization of  
biodegradable particles might provide more possibilities in device design, such as 
device loaded with different drug types or with combinations of  drugs for 
personalized therapy and device with adjustable drug release kinetics. 
These considerations prompted us to develop drug-carrying microspheres 
that are: (i) preloaded with one or more drugs; (ii) biodegradable; (iii) able to 
provide a sustained drug release rate. These microspheres should allow us to better 
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adjust the loading of  the drug(s) and their release rate. Furthermore, kinetics of  
drug release in situ will depend on the drug diffusion and on the stability of  the 
biodegradable polymer matrix. This provides a tunable mechanism to control the 
kinetics of  the drug release. For final clinical use, it is obvious that the final 
embolic product must be stored in dried form, which should be mixed with an 
injection fluid just prior to injection to prevent any premature drug release.  
Accordingly, we have prepared drug-carrying biodegradable microspheres 
tailored to combine embolization and a controlled local chemotherapy [14]. The 
microspheres consist of  poly(D,L-lactic acid) (PDLLA), a deeply studied, 
frequently used and reliable biodegradable polymer that is found in numerous 
FDA-approved medical devices [15-17]. The microspheres have been loaded with 
the following drugs: cisplatin or sorafenib tosylate, or a combination of  both. 
Cisplatin, a powerful cytostatic agent, is used to treat numerous human cancers (e.g. 
lung, ovarian, testicular, bladder) [18-20]. Cisplatin binds to neighboring purine 
bases in the DNA, facilitating DNA damage and thereby causing growth arrest and 
cell death (apoptosis and necrosis) [21]. Sorafenib tosylate is a multi-kinase 
inhibitor with anti-angiogenic and anti-proliferative capacity with proven efficacy 
for treating liver and kidney tumors in patients [22-24]. Sorafenib tosylate acts on 
the RAF/ERK-kinase pathway and inhibits several receptor tyrosine kinases, 
including vascular endothelial growth factor receptor (VEGFR), platelet-derived 
growth factor receptor (PDGFR) and VEGFR3, thereby arresting tumor induced 
angiogenesis and subsequently, proliferation of  tumor cells, growth of  tumor mass 
and potential metastasis [22, 25]. Though the combination of  targeted 
embolization (with non-drug-carrying embolic microspheres) and systemic 
administration of  sorafenib tosylate has already been proven to be an effective 
treatment for liver tumors, this combination therapy is also associated with 
increased risk of  treatment-related adverse reactions, such as diarrhea, 
hypertension, rash or desquamation [26-28].  
In the present study we aim to characterize degradation, release kinetics and in 
vivo biological efficacy of  cisplatin and/or sorafenib tosylate loaded microspheres 
previously developed [14]. The following 4 types of  microspheres were assessed: (i) 
PDLLA microspheres used as “placebo”, designated as PDLLA; (ii) PDLLA 
microspheres loaded with cisplatin (12.4 % by mass), designated as Cisplatin; (iii) 
PDLLA microspheres with sorafenib tosylate embedded (15.7% by mass), 
designated as ST; (iv) PDLLA microspheres containing cisplatin and sorafenib 
tosylate (4.8% and 4.3% by mass, respectively), designated as Cisplatin + ST. First, 
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kinetics of  the degradation of  microspheres conducted in vitro has been followed 
measuring the following parameters: weight loss, pH change of  the medium, 
morphology of  the particles and molecular weight of  the polyester. Secondly, the 
in vitro biological activity of  the drugs has been assessed on cultured cells (i.e. 
endothelial cells, fibroblast cells, and Renca tumor cells) for cytotoxicity and anti-
angiogenic capacity. Thirdly, the in vivo efficacy of  drug-loaded biodegradable 
microspheres has been explored in a mouse Renca tumor model. These 
experiments provided data in support of  our goal to develop microspheres for 
combined administration of  cytostatic (i.e. cisplatin) and anti-angiogenic agents (i.e. 
sorafenib tosylate) inside a tumor with particularly tumor growth inhibition in situ. 
The dual drug loaded PDLLA microspheres offer an attractive device for 
intratumoral drug delivery and have the potential as alternative embolic agent for 
tumor embolization. 
5.2 Experiment Section 
Materials 
Poly(D,L-lactic acid) with Mv 1.34 × 105 (PDLLA; PURASORB PDL 20) was 
obtained from Corbion (Gorinchem, The Netherlands) [29]. Sorafenib tosylate and 
cisplatin were purchased from SPE Chemicals (Shanghai, China). Dichloromethane, 
dimethyl sulfoxide (DMSO) and dimethylformamide (DMF) were all from Acros 
(Landsmeer, The Netherlands). Cell culture medium EGM-2-MV BulletKit and 
SmGM-2-MV BulletKit were acquired from Lonza (Verviers, Belgium). Cell 
culture medium RPMI 1640, penicillin, streptomycin, fetal bovine serum (FBS), 
ethidium homodimer-1 (EthD-1) and Hoechst 33342 were obtained from Life 
Technologies (Merelbeke, Belgium). Human umbilical vein endothelial cells 
(HUVECs) and reducing growth factor matrigel were acquired from BD 
Biosciences (Breda, The Netherlands). SU5416 was from Sigma (Zwijndrecht, The 
Netherlands). Porcine skin fibroblasts (PSFs) were isolated from porcine tissue 
(Dutch Landrace pig; IDDLO, Lelystad, The Netherlands). Renca tumor cells were 
purchased from Cell Lines Service GmbH (Eppelheim, Germany). 
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Preparation of  the Microspheres 
The 4 types of  microspheres (PDLLA, Cisplatin, ST and Cisplatin + ST) were 
prepared by an emulsion/solvent evaporation method according to our previous 
study [14]. In brief, ST + Cisplatin microspheres were prepared as follows. PDLLA 
(1.4 g) was dissolved in dichloromethane (19.2 mL) and stirred overnight. Cisplatin 
powder (140 mg, 10% w/w) and sorafenib tosylate (140 mg, 10% w/w, dissolved 
in 0.7 mL DMF) were added to the PDLLA solution and stirred for 30 min at 
room temperature. Next, the mixture was poured into 1 L aqueous solution 
containing 1.2% (w/v) detergent (a mixture of  anionic and amphoteric surfactants) 
and stirred at 500 rpm for 4 h. The resulting microspheres were filtered, washed 
with distilled water and lyophilized for 48 h. For PDLLA and Cisplatin 
microspheres, dichloromethane was used as organic solvent, while DMSO and 
dichloromethane were used as the organic solvent for ST microspheres. 
Microspheres were sieved between 200 - 400 µm giving rise to a ~ 60% yield for all 
4 types of  microspheres. 
Characterization of  the Microspheres 
Surface and cross-section morphologies of  the microspheres were analyzed by 
scanning electron microscopy (SEM, Philips XL 30, FEI, Eindhoven, The 
Netherlands). Microspheres and their cross-sections were mounted on a double-
sided carbon tape attached to an aluminum stub and sputter-coated with gold. 
Polydispersity index (weight average molecular weight/number average molecular 
weight : Mw/Mn) and Mw were analyzed by size exclusion chromatography (SEC, 
Agilent 1050 Series) equipped with two nonlinear columns (Polymer Laboratories, 
104 Å and 500 Å; PLgel 5 µm: 30 cm × 7.5 mm). SEC was performed in 
tetrahydrofuran (THF) containing 2.5% triethylamine (TEA) at an elution rate of  1 
mL/min at 30 oC. Relative Mw of  our polymers were determined adopting 
polystyrene standards with Mw ranging between 800 Da and 504 kDa. Polymer 
Laboratories software relying upon the universal calibration method has been 
adopted to calculate relative Mw of  PDLLA. 
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In Vitro Degradation Studies of  the Microspheres 
Degradation studies were performed in glass vials at 37 oC. In each glass vial, 20 
mg microspheres were immersed in 10 mL phosphate buffered saline (PBS, pH = 
7.4 supplemented with 0.02 % NaN3 as preservative) without agitation. For each 
time point, microspheres were collected, washed with distilled water and dried by 
lyophilisation (time points 1 and 2 weeks, 1, 3, 6 and 9 months). Subsequently, 
weights of  dried microspheres were recorded. Weight loss of  the microspheres was 
calculated by equation (1): 
𝑤𝑒𝑤𝑤ℎ𝑡 𝑙𝑜𝑙𝑙 (%) = 𝑊𝑜 − 𝑊𝑑𝑑𝑑
𝑊𝑜
 × 100       (1) 
where Wdry is the weight of  dried microspheres and Wo is the initial weight of  the 
microspheres. Furthermore, pH changes of  aqueous media were monitored during 
degradation. Surface morphology of  all dried samples was analyzed by SEM. Mw 
and polydispersity of  dried microspheres were investigated using size exclusion 
chromatography. 
In Vitro Cytotoxicity Studies 
Cytotoxicity of  the 4 types of  microspheres (PDLLA, Cisplatin, ST and Cisplatin 
+ ST) was determined by using HUVECs, PSFs and Renca tumor cells. HUVECs 
and PSFs were cultured in Lonza EGM-2-MV BulletKit or SmGM-2 BulletKit, 
respectively. Renca tumor cells were cultured in RPMI 1640 supplemented with 10% 
FBS and antibiotics (100 units/mL penicillin and 100 µg/mL streptomycin). Beads 
were incubated in cell culture medium for 24 h (1 day), 5 days and 7 days, 
respectively, after which supernatants were collected. To test cytotoxicity cells were 
seeded in BD Falcon 96 wells HTS Imaging microplates (BD, Erembodegem, 
Belgium) and cultured for 72 h until a confluency > 85%. Next, beads 
supernatants were added. After 24 h incubation, Hoechst 33342 (8 × 10-7 M) and 
EtHD-1 (4 × 10-6 M) were added to distinguish between viable and non-viable 
adherent cells. Cells were imaged and analyzed automatically with a BD Pathway 
855 high content analyzer (BD Biosciences, Heidelberg, Germany). BD Attovision 
software (BD Biosciences, version 1.6) was used for both image acquisition and 
individual cell segmentation and analyses. Numerical data were further analyzed 
with flow cytometry software (Kaluza 1.2; Beckman Coulter, Mijdrecht, The 
Netherlands) to assess total cell numbers (Hoechst) and dead cells (EtHD-1). 
Chapter 5 
118 
Number of  viable cells was calculated as the fraction of  number of  cells in total 
(adherent cells with Hoechst positive nuclei) minus number of  dead cells (cells 
with EtHD-1 positive nuclei) per well, and averaged for replicates (n = 3 per 
condition). Data were plotted as average viable cell numbers per well for the 
different conditions with untreated wells as control set at 100%. Either Student t –
test (Renca experiment) or one-way-Anova test (all others) was applied to define 
statistical differences, with p-value below 0.05 considered significantly different 
(GraphPad Prism 5.01 for Windows, GraphPad Software, San Diego, CA, USA). 
In Vitro Matrigel Studies 
Matrigel endothelial tube assay was performed to determine the effect of  released 
sorafenib tosylate on angiogenesis. µ-Slide Angiogenesis (Ibidi, Munich, Germany) 
plate wells were filled with 10 µL reduced growth factor matrigel (BD Biosciences) 
and incubated (37˚C, 5% CO2) for 30 min polymerization. Next, cells were 
resuspended in appropriate growth medium (EGM-2-MV without bFGF, with 100 
ng/mL VEGF-A and 2.5% FBS), with additionally for each condition an equal 
volume of  beads supernatant (supernatant from microspheres of  5 days identical 
as for section 2.5) or 5 µM SU5416 (VEGFR2 inhibitor, positive control). 
HUVECs were seeded with 10,000 cells/well (n = 5 per condition). After an 
overnight culture cells were imaged under standard bright field microscope 
conditions with EVOS® XL Imaging System (Advanced Microscopy Group, 
Bothell, WA) and analyzed with ImageJ [30] (Version 1.47v) and Angiogenesis 
Analyzer plug-in for ImageJ [31] to quantify angiogenic tube parameters per well. 
One-way-Anova test was applied to define statistical differences, with p-value 
below 0.05 considered significantly different. 
In Vivo Evaluation of  the Microspheres in a Renca Tumor Model 
Animal experiments were performed in female BALB/c mice bearing syngeneic 
Renca tumors according to standard protocols of  the company (ProQinase GmbH; 
Freiburg, Germany) [32]. Animal experiments and protocols were approved by the 
Ethics Committee for Animal Experimentation and registered by the regional 
governmental board of  Freiburg (Regierungspräsidium Freiburg; G-13/23). This 
animal study was designed to evaluate the in vivo anti-tumor efficacy of  PDLLA 
microspheres loaded with cisplatin and/or sorafenib tosylate. 
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Tumor Implantation 
Renca cells were cultured in RPMI 1640 Glutamax 1 medium supplemented with 
10% FCS and 1% penicillin/streptomycin at 37°C with 5% CO2. For tumor 
implantation, Renca tumor cells (1×106/50 µL PBS) were injected subcutaneously 
into 56 female BALB/c mice (4 – 5 weeks old) at the left flank. The day of  
injection was defined as experimental day 0.  
Intratumoral Injection of  the Microspheres 
On day 14, 40 BALB/c mice with tumor size approx. 100 – 200 mm3 were 
randomly divided into 4 groups of  10 animals each. Subsequently, animals in group 
1 – 4 were treated with PDLLA (control), Cisplatin, ST and Cisplatin + ST 
microspheres, respectively. For each animal 5 mg microspheres suspended in 50 - 
70 µL glycerol/contrast mixture were injected intratumorally. Injectable 
suspensions of  the microspheres were prepared in a 1 mL Braun Omnifix-F 
syringe with 25 mg of  microspheres suspended in 200 µL of  injection fluid. The 
content of  each syringe was carefully mixed prior to injection to ensure 
administration of  homogenous suspensions (Figure 1A). Each syringe was 
connected to a sterile 19G needle, to ensure passing of  microspheres through the 
lumen. A total of  50 - 70 µL suspension, containing 4 – 6 mg microspheres 
(according to volume-mass analysis), was injected carefully into the center of  the 
tumor mass (Figure 1B).  
 
Figure 1. (A) Suspension of  Cisplatin microspheres before administration. (B) Injection of  
the microspheres into the tumor mass using a 1-mL syringe connected with a 19G needle. 
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Animal weights were recorded during the experiments. Tumor growth was 
studied by monitoring tumor volumes which were measured by calipering (manual 
caliper, OMC Fontana) and calculated according to equation (2):  
𝑉 =  𝑊2  × 𝐿
2
        (2) 
where V is tumor volume; L and W are length and perpendicular width of  the 
tumor, respectively (L > W). Animals were sacrificed when tumor ulceration or 
excessive tumor burden developed.  
Statistical Analysis 
Statistical analysis was performed using the Student’s t-test, one-way-Anova test or 
Mann Whitney test, as indicated. Statistical significance is defined as p < 0.05. 
5.3 Results and Discussions 
Morphology and Size of  the Microspheres 
The 4 microsphere types were prepared through emulsion/solvent evaporation 
optimised to fit the particle requested size distribution (200 - 400 µm). Size of  
sieved microspheres was verified from SEM images. The results, summarized in 
Table 1, show that the 4 types of  micrspheres had comparable diameters. Surface 
morphology of  the microspheres was studied by SEM (Figure 2A1, B1, C1 and 
D1). PDLLA microspheres showed smooth surfaces. Surfaces of  Cisplatin 
microspheres were less regular compared to PDLLA microspheres with presence 
of  drug crystals located just near the vicinity of  the microsphere surface giving rise 
to a small roughness. ST microspheres had slightly porous surfaces with only few 
small pores, while Cisplatin + ST microspheres were highly porous. Cross-sections 
were made by cutting microspheres into two parts. Relatively large microspheres (> 
400 µm) were used to obtain cross-sections for practical reasons. SEM images of  
cross-sections (Figure 2 A2, B2, C2 and D2) revealed different internal structures 
for the 4 types of  microspheres. PDLLA and Cisplatin microspheres were non-
porous inside. ST microspheres showed some porosity for the cortical parts, but 
most area of  the cross-section was non-porous. Cisplatin + ST microspheres 
revealed a highly porous internal structure. 
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Table 1. Diameter of  the 4 microsphere types. 
Microsphere type 
Diameter [µm] 
(mean ± SD) 
PDLLA  280 ± 52  
Cisplatin  264 ± 50  
ST 278 ± 50  
Cisplatin + ST 259 ± 51  
 
Figure 2. Scanning electron images showing morphologies of  surface (A1 – D1) and 
cross-section (A2 – D2) of  4 types of  microspheres. (A1, A2) PDLLA; (B1, B2) Cisplatin; 
(C1, C2) ST; (D1, D2) Cisplatin + ST. Relatively large microspheres (> 400 µm) were used 
to obtain cross-sections for practical reasons.  
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Kinetics of  microsphere formation by emulsion/evaporation process is well-
known to be controlled by several formulation parameters such as temperature, 
agitation speed, nature of  the solvent and aqueous phase as well as molecular 
weight and nature of  the polymer adopted to form the microparticles [33]. 
Typically adopting PDLLA and classical emulsifiers, the phase separation leading 
to solid microparticles proceeds very quickly. The geometry, morphology and size 
of  the microparticles are, therefore, fixed some minutes after the onset of  the 
oil/water dispersion. The differences in surface and internal structures of  the 
microspheres as noticed by SEM could be assigned to the physical-chemical 
influence played by the drugs and the organic solvents used in their preparation. In 
view to promote drug encapsulation we have been obliged to adapt the 
composition of  the organic solvents in the oil phase of  the emulsion. Indeed 
dichloromethane, one of  the most popular organic solvents reported in the 
preparation of  poly (lactic acid)-based microspheres through solvent evaporation, 
has allowed us to prepare spherical placebo PDLLA and Cisplatin microspheres 
with a yield > 90%. However, this condition was unsuited for the preparation of  
ST and Cisplatin + ST microspheres. The presence of  sorafenib tosylate 
suspended in the oil phase has disturbed the interfacial/precipitation events, giving 
rise to irregular shaped particles. Spherical ST microspheres were obtained when 
using DMSO or DMF as the co-solvent of  dichloromethane. DMSO was finally 
chosen as preferred co-solvent for ST microspheres due to its safety and the higher 
yield noticed to generate spherical particles (> 90% vs. < 40% compared with 
DMF). Unfortunately DMSO could not be employed with cisplatin since this drug 
is known to be unstable in this solvent [34]. In the case of  Cisplatin + ST 
microspheres, a binary solvent made from DMF and dichloromethane was utilized, 
yielding spherical microspheres (> 85%). The porous structure (surface and cross-
section) of  ST and Cisplatin + ST microspheres might be attributed to the co-
solvents used (i.e. DMSO and DMF) in formulation. Due to their intermediate 
solvent characteristics, DMSO and DMF are known to facilitate uptake of  water 
into dichloromethane droplets, thus forming some water-filled-DMSO or -DMF 
regions which will become pores after solidification and evaporation of  the 
microspheres [35-36].  
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In Vitro Degradation of  the Microspheres 
The microspheres behaved differently with respect to wetting and aggregation 
behavior during degradation, as recorded by our visual examination. PDLLA and 
Cisplatin microspheres were rapidly wetted upon dispersion in the PBS. Their 
density, slightly above 1, promoted their settling in the physiological medium as 
well as their aggregation as already noticed before the end of  the first week of  the 
degradation study. Conversely, microspheres containing as low as 4.3% by mass of  
sorafenib tosylate were not totally wetted after one month of  incubation in PBS. 
These microspheres kept their original shape, being easily redispersed in PBS 
under manual agitation. The high hydrophobicity provided by sorafenib tosylate to 
the microsphere surface should account for their slow wetting and dispersibility. 
Aggregation of  microspheres was however reversible. After their washing and 
lyophilisation, SEM observations (Figure 3) clearly highlighted that the 
microparticles were well dispersed, and have kept their original shape and surface 
characteristics till the end of  9 months. 
  
  
Figure 3. SEM micrographies of  microparticle surface after 9 months of  in vitro 
degradation in PBS medium carried out at 37 oC. (A) PDLLA; (B) Cisplatin; (C) ST; (D) 
Cisplatin + ST. 
100 μm 
A 
100 μm 
B 
100 μm 
C 
100 μm 
D 
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Degradation kinetics was also investigated by monitoring changes in pH of  
the aqueous medium, in weight of  the microspheres and by following the 
evolution of  Mw and PDI of  the polyester during the degradation period of  9 
months (36 weeks; Figure 4). A mild weight loss (5.4% ± 2.9%) was observed for 
all 4 types of  microparticles, but which does not differ significantly for PDLLA, 
Cisplatin and ST microspheres after 9 months of  incubation. Cisplatin + ST 
microspheres showed the highest weight loss (12.1% in total) after 9 months. The 
variations in weight loss observed for this microparticle batch seems more likely 
related to methodological variations, in particular during the first period of  
incubation with the difficulty met when rinsing partly wetted microspheres in the 
PBS. Although buffered aqueous medium was used, variations in the pH were still 
observed compared to the PBS buffer adopted as a control. For all drug-carrying 
microspheres, pH increased to 7.54 ± 0.01 after 7 days of  incubation, compared to 
7.41 ± 0.01 of  the control PBS. Thereafter, pH leveled to 7.38 ± 0.04 at the end of  
two weeks and remained around this value till the end of  the ninth month.  
 
Figure 4. Changes of  weight loss, pH of  aqueous medium, Mw and polydispersity (PDI) 
of  the microspheres during in vitro degradation studies of  9 months (36 weeks).  
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By comparison to the PBS and PDLLA placebo, the slight increase in pH 
observed at the start might be attributed to alkalinization induced by the drugs 
released in the medium. Later on, the subsequent degradation of  PDLLA should 
progressively acidify the medium with the release of  hydrosoluble PDLLA 
oligomers or lactic acid. The long term follow-up of  the pH demonstrated that no 
major pH change has occurred after 9 months. This observation correlated with 
the very slight change in weight of  the microspheres, demonstrating that the 
reduction in molecular weight of  PDLLA was not enough significant to promote 
the release of  hydrosoluble oligomers or lactic acid in the medium. 
Meanwhile, the evolution with time of  the size exclusion chromatography 
traces of  PDLLA (Figure 4) clearly illustrates that a significant degradation of  
PDLLA has well proceeded during the incubation period. Degradation behavior 
of  this polyester appeared under a bi-phasic profile whatever the microparticle 
composition, with a relatively fast degradation phase extending up to the first three 
months. Later on, over the next 6 months, the drop in molecular weight is slower. 
PDLLA, Cisplatin and ST microspheres revealed comparable degradation rates. 
Their Mw changed from 3.29 (± 0.14) × 105 to 1.37 (± 0.16) × 105 Da after 3 
months and was further reduced to 7.96 (± 0.03) × 104 Da after 9 months of  
incubation. For the Cisplatin + ST microspheres, degradation was slower with Mw 
1.93 (± 0.19) × 105 Da after 3 months, and 1.39 (± 0.14) × 105 Da at the end of  
the study. 
Microspheres prepared in this work have a slow degradation profile, as can be 
deduced from weight loss and decrease in Mw during degradation. Degradation of  
poly(lactic acid) microspheres in aqueous medium involves typically three steps: (i) 
water absorption, (ii) hydrolysis of  ester bonds and (iii) erosion. Due to the 
insolubility of  poly(lactic acid) in aqueous medium with Mw above 1100 Da [37], 
erosion of  the polymer matrix with an accompanying weight loss and change in 
morphology, can only be expected by the end of  the degradation process if  it 
occurs in a homogeneous way. In this case, diffusion of  the degradation 
byproducts into the aqueous medium will only be observed when the Mw drop 
achieves a threshold around 1100 Da. 
It is interesting to remind that the degradation of  poly(lactic acid)-based 
materials can be auto-catalyzed by the limited diffusion of  the acidic degradation 
products entrapped inside the polymer matrix [38-39]. The higher degradation rate 
noticed within the core of  the material compared to the surface has been 
demonstrated for nonporous poly(lactic acid)-based materials whose thickness 
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should be above 100 µm to facilitate the establishment of  a pH gradient. 
Accordingly, the slower decrease noticed for Mw of  Cisplatin + ST microspheres 
might be assigned to a reduced auto-catalytic effect resulting from the porous 
structure specifically observed for these microspheres. Pores could therefore 
facilitate the diffusion of  degradation products, thereby reducing the auto-catalytic 
effect.  
Figure 5 shows the difference in PDI of  poly(lactic acid) molecular weight 
distribution of  4 types of  microspheres up to 9 months. A major broadening in 
molecular weight distribution was found for all microsphere compositions with a 
corresponding substantial increase in PDI over the 9 months of  incubation, 
starting from 2.1 ± 0.16 to 5.6 ± 0.45.  
 
Figure 5. Evolution of  the distribution of  molecular weight of  microspheres on a 9 
months incubation performed in PBS at 37 oC. 
Interestingly enough a low molecular species appeared in the SEC profiles of  
microparticles loaded with the drugs (Figure 5). Being absent at time 0, the relative 
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surface of  this peak compared to the main PDLA peak progressively increased 
with the duration of  degradation for all three drug formulations. Although this 
narrow peak, with an apparent Mw around 500 Da, is absent in placebo 
microparticles, it cannot be assigned to the drugs immobilized within the 
polymeric matrix. Indeed in the latter case, its corresponding surface should 
decrease with the incubation time, thus in contrast to our observations. Although 
that future chemical analysis would be needed to support our hypothesis, we could 
anticipate that this narrow peak could result from the formation of  PDLLA 
oligomers whose entrapment with the microparticles could be promoted by the 
presence of  the drugs. These changes in PDI of  the poly(lactic acid) chains with 
time and microspheres composition directly reflected the heterogeneity in this 
polymer degradation process, which might be explained due to variations in ions, 
pH, oligomers, and also drug(s) gradients within microspheres matrix. 
The slow degradation of  Cisplatin and ST microspheres also explained the 
slow in vitro drug release behavior of  these microspheres observed in our previous 
study [14]. After 15-days incubation in PBS (pH 7.4), 6.9% of  cisplatin and 9.3% 
of  sorafenib tosylate were released from microspheres loaded with single drug [14]. 
In degradation studies for Cisplatin and ST microspheres, no obvious polymer 
erosion was observed during the first 14 days. Therefore, the drug release in this 
stage was controlled by the diffusion of  drugs through the dense polymer matrix, 
causing the slow release. A tri-phasic release profile is mostly reported for 
poly(lactic acid)-based microspheres: (i) a burst release phase; (ii) a slow release 
phase or a lag phase; (iii) a faster release phase [40]. The third phase is often related 
to the onset of  erosion. As can be expected, with the degradation going on, Mw of  
the polymer will decrease and the polymer chains will be more flexible, which will 
facilitate the drug release process, showing the fast release phase. Cisplatin + ST 
microspheres showed slow degradation as well, but significant drug release 
occurred before the onset of  obvious polymer erosion. Specifically, after 14-days 
incubation in PBS (pH 7.4), 47.8 % of  cisplatin and 90.1% of  sorafenib tosylate 
were released from these microspheres [14]. This fast release was probably due to 
their porous structure, which enabled the transport of  drugs through water-filled 
pores. Quite similar results were reported by Kim et al. [41]. They used slow-
degrading poly(lactic acid) to prepare porous microspheres loaded with human 
growth hormone, which was completely released before significant erosion of  
poly(lactic acid) occurred. 
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In Vitro Cytotoxic Studies 
Cytotoxicity experiments were performed to determine the biofunctionality of  
drugs released from different microspheres. Cell culture medium incubated with 
microspheres for 1, 5 and 7 days were collected and further analyzed for 
cytotoxicity on HUVECs, PSFs and Renca tumor cells (Figure 6). Supernatants 
from ST microspheres were non-cytotoxic for all cell types tested, with cell viability 
comparable to PDLLA microspheres adopted as a control. Supernatants from 
Cisplatin microspheres caused a decrease in cell viability of  HUVECs (Figure 6A), 
while no effect was found on PSFs and Renca tumor cells (Figure 6B and 6C). This 
is probably due to the different sensitivity of  HUVECs, PSFs and Renca tumor 
cells to cisplatin. It has been reported that cytotoxicity induced by cisplatin is cell 
type and concentration dependent [42]. For example, Tardito et al. [43] studied the 
sensitivities of  23 different human cancer cell lines to cisplatin and the half-
maximal inhibitory concentration (IC50) of  the 23 cell types varied considerably 
with values between 2 - 50 µM. In contrast, and interestingly enough, a significant 
cytotoxic effect was found for all cell types that were treated with supernatants 
from Cisplatin + ST microspheres. The superiority of  Cisplatin + ST microspheres 
might relate to their porous structure (Figure 2) which facilitates the release of  
cisplatin in cell culture medium. The other explanation might be the synergistic 
effect induced by cisplatin and sorafenib tosylate, which has been reported recently 
[44]. The data presented in Figure 6 indicates that the formulation, Cisplatin + ST 
microspheres, could effectively be used in cancer treatment.  
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Figure 6. Cytotoxic effects of  microspheres supernatants obtained for different incubation 
time (1 day, 5 days and 7 days) on cell viability after 24 h of  culturing. (A) HUVECs; (B) 
PSFs; (C) Renca tumor cells. Numbers of  cells cultured in cell medium for 24 h are set at 
100% (control). Error bars represent standard deviation; * indicates a significant difference 
compared with PDLLA microspheres and # between conditions (n = 3; p < 0.05). 
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In Vitro Anti-angiogenic Studies 
To examine the anti-angiogenic action of  sorafenib tosylate released from the 
microspheres, supernatants of  different microspheres incubated for 5 days were 
studied in a classical matrigel tube assay, in which VEGFR2 inhibitor (SU5416) 
served as inhibition control and PDLLA microspheres as negative control. 
Supernatants from Cisplatin microspheres showed no inhibitory effect on tube 
formation (Figure 7A), with values of  total tube length, master segment length 
and junctions comparable with PDLLA microspheres (Figure 7B - 7D). 
Supernatants of  ST and Cisplatin + ST microspheres inhibited tube formation 
significantly (Figure 7A). Quantitative data (Figure 7B - 7D) further underlined 
their anti-angiogenic effect on VEGF-mediated angiogenesis. Notably, ST 
microspheres inhibited more strongly the angiogenesis compared to Cisplatin + ST 
microspheres. This difference in activity can be assigned to the pharmacological 
properties of  sorafenib tosylate which has been demonstrated to be dose-
dependent [22]. Higher anti-angiogenic efficacy of  ST microspheres may indicate 
that sorafenib tosylate was released faster from these microspheres than from 
Cisplatin + ST microspheres. This is probably due to the difference in aqueous 
solubility of  sorafenib tosylate between these two release systems. It is known that 
solubility of  sorafenib tosylate decreases at increased pH [45]. Cisplatin + ST 
microspheres released cisplatin and sorafenib tosylate simultaneously. The release 
of  cisplatin may increase the pH of  release medium and reduce the solubility of  
sorafenib tosylate thus decreasing its release rate. In general, the results compiled 
in Figure 7 demonstrate and confirm the anticipated anti-angiogenic effect of  
sorafenib released from the microspheres. 
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Figure 7. Anti-angiogenic effects of  SU5416 (VEGFR2 kinase inhibitor) and supernatants 
of  PDLLA, Cisplatin, ST, Cisplatin + ST microspheres on endothelial tube formation. (A) 
Representative transmission light microscopic images of  endothelial tube assay for 
HUVECs after 24 hours of  culture on hydrogels; (B) numeric data on total tube length; (C) 
numeric data on master segment length; (D) number of  junctions. Error bars represent 
standard deviation; * indicates significant difference compared with PDLLA control and # 
between conditions (n=5; p < 0.05). Scale bar is 1 mm. 
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In Vivo Evaluation of  the Microspheres in a Renca Tumor Model 
Based on our promising in vitro results we decided to evaluate the pharmacological 
efficacy of  different microspheres in an in vivo subcutaneous syngeneic renal tumor 
model (using Renca tumor cells) in mice [46-47]. 
 
Figure 8. Changes in animal weights during experiment. Blank PDLLA, Cisplatin, ST and 
Cisplatin + ST microspheres were intratumorally injected on day 14. Data are displayed as 
means ± SEM.  
During the course of  the study, animal weights of  all study groups remained 
stable and no major weight loss was observed (Figure 8). Drug efficacy analysis of  
microspheres was followed up till 14 days after microspheres injection due to large 
number of  animal drop-out at 28 days of  experiments. By day 28 (i.e. 14 days after 
the injection), 22 animals were aborted for ethical reasons with: 5 in the PDLLA 
group, 6 for the Cisplatin group, 5 in the ST group and 6 in the Cisplatin + ST 
group. Ulcerations were the main cause of  termination during the experiments. 
Compared to placebo, these ulcerations were assigned to tumor growth 
compromising skin perfusion. Tumor progress in our model was higher than 
expected. This might relate to increased tumor growth inflicted by damage of  the 
solid tumor capsule and integrity during microspheres injection (due to relatively 
large needle compared with the tumor size). 
Tumor volumes of  the animals were measured by calipering during the 
experiment. The results summarized in Figure 9A show an obvious retardation of  
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tumor growth for animals treated with Cisplatin + ST microspheres. No tumor 
inhibition was observed for the Cisplatin group, where the tumor growth was 
comparable with the control PDLLA group. ST microspheres significantly 
inhibited tumor growth during the period from day 14 to day 25. Thereafter, the 
effect diminished as tumor growth caught up with the PDLLA group at the end of  
14 days of  treatment. On day 28 (i.e. 14 days after the injection), animals in both 
PDLLA and Cisplatin group showed a high average tumor volume of  1141 and 
1090 mm3, respectively (Figure 9B). A lower overall mean tumor volume (786 mm3) 
was found for the animals treated with ST microspheres, and a significant lower 
mean tumor volume (262 mm3) was apparent for Cisplatin + ST group.  
 
Figure 9. (A) Tumor growth up to day 28 (14 days after injection of  microspheres) and the 
number of  animals alive on day 28 for each group is represented in the bracket. (B) Tumor 
volumes measured in vivo on day 28 (14 days after injection). Data are displayed both as 
means ± SEM. * indicates for significant difference compared with PDLLA group and # 
between drug-loaded groups (p < 0.05). 
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The data in Figure 9 support the hypothesis that the local sustained release of  
a combination of  an anti-angiogenic agent (i.e. sorafenib tosylate) and a cytostatic 
agent (i.e. cisplatin) inside a solid tumor provides an effective strategy to inhibit 
tumor growth in situ. The higher pharmacological potency exhibited by dual drug 
loaded microspheres could result from the complementary mode of  action of  
these two drugs. Indeed, tumor development depends first on an uncontrolled cell 
proliferation process giving rise to tumor invasion and eventually metastasis [48]. 
But angiogenesis is required for tumor progression and metastasis [49]. Figure 6A 
and 6C demonstrated the in vitro cytotoxic effect of  drugs released from Cisplatin 
+ ST microspheres on both HUVECs and Renca tumor cells, highlighting the 
synergic roles played by these two drugs. Therefore cytotoxicity of  these 
microspheres could not only impair the tumor cell growth but could also damage 
endothelial cells and suppress tumor vessel growth, thus inhibiting tumor 
development. This anti-angiogenic effect of  sorafenib tosylate released from 
Cisplatin + ST microspheres has been further demonstrated in our in vitro model 
(Figure 7). The synergistic effect on tumor inhibition offered by the combination 
of  these two drugs has been recently reported by Yang et al. [44] in a nude mouse 
model adopting human osteosarcoma cells. Another explanation might be that the 
porous structure of  Cisplatin + ST microspheres leads to relatively fast drug 
release rates in vivo. In vivo drug release study of  the microspheres should be 
performed in future to illustrate this point. 
Outlook: a Device for Transarterial Chemoembolization Therapy 
The drug-eluting biodegradable microspheres prepared in this study have been 
designed with transarterial chemoembolization (TACE) therapy in mind. They can 
pass a 4-Fr diagnostic catheter (Cobra, Cordis) [14], and microcatheters such as 
Progreat 2.7 (Terumo). This property is indeed essential to carry out a safe and 
efficient TACE where the particles should be administered in vivo through a 
catheter tube, and should follow the arterial blood flow in order to achieve a distal 
embolization of  the tumor’s arterial tree. The radiopacity given by cisplatin in 
cisplatin + ST microspheres [14] provides an additional benefit for TACE because 
this radiological intervention needs an imaging guidance (e.g. fluoroscopy and CT) 
to guarantee the safety and efficiency in the local targeting and release of  the 
microparticles within the vessels irrigating the solid tumor. This challenging clinical 
task will be facilitated by the visualization of  the local distribution of  the 
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microspheres during injection, in view to promote a distal embolization of  the 
tumor vessels and to limit any risk of  overflow in undesired surrounding tissues.  
Although performed adopting a different tumor model and a more simple 
administration, our preliminary in vivo results are encouraging and merit further in 
vivo investigations, in which the embolic drug-releasing microspheres will be 
introduced via TACE into animals carrying a solid tumor. For this purpose we will 
adopt larger animal model (i.e. rabbit VX2 tumor model [50-52]), which permits 
transarterial administration (TACE) of  the embolic particles via a microcatheter. 
It must be noted that the formulations as chosen in this work can be further 
optimized. Parameters, such as the loading percentages and ratio of  cisplatin and 
sorafenib tosylate could be future optimized. Degradation rate of  microparticles 
could be reduced by replacement of  the PDLLA with other biodegradable matrix 
(e.g. poly(lactic-co-glycolide)), showing faster degradation. This will lead to a 
plethora of  different formulations, which is of  interest in the context of  
personalized therapy concepts.  
5.4 Conclusions 
In summary, porous PDLLA microspheres loaded with cisplatin and sorafenib 
tosylate were developed. Bioactivity and therapeutic efficacy of  these microspheres 
were evaluated in vitro and in vivo. The experimental data from this study expanded 
our comprehension of  the drug release profile of  these microspheres. While it was 
observed that the PDLLA matrix was relatively stable (i.e. low degradation profile), 
significant release of  cisplatin and sorafenib tosylate occurred, both in vitro and in 
vivo. Microspheres containing cisplatin and sorafenib tosylate showed strong 
cytotoxic effect on cultured cells (HUVECs, PSFs and Renca tumor cells) and 
strong anti-angiogenic effect in vitro. Further, in vivo investigations in a mouse 
Renca tumor model evidenced that microspheres loaded with cisplatin and 
sorafenib tosylate had higher therapeutic efficacy than microspheres loaded with 
single drug. These results, taken together, underline the pharmacological potency 
of  the biodegradable microspheres containing cisplatin and sorafenib tosylate for 
localized drug delivery for tumor treatments as well as their adaptability to be used 
in TACE. 
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The last 2 - 3 decades have seen the introduction and emergence of  tissue 
engineering, regenerative medicine, gene therapy, controlled delivery of  drugs, and 
bio-nanotechnology as new technology fields in medicine. In many cases, these 
new technologies rely on the availability of  a biodegradable biomaterial. The 
success of  any tissue engineering strategy, for instance, depends on the availability 
of  a biodegradable porous scaffold structure that in the first instance provides the 
required physical strength and helps to introduce appropriate cells into the body, 
then facilitates healing, and finally “dissolves” from the site of  implantation.  
Remarkably, the development of  biodegradable biomaterials has been slow. 
This can be explained, in part, by the fact that engineering of  resorbable implant 
biomaterials poses unique challenges. First of  all, any biodegradable biomaterial 
must meet stringent requirements in terms of  biocompatibility, which is defined as 
the ability of  a material to perform with an appropriate host response in a specific 
application. We know now, that the “tissue response” of  a biomaterial per se is 
intimately related to a complex of  factors, such as stiffness and strength of  the 
biomaterial, its chemical (surface) properties, shape, structure, and texture. Another 
essential factor is the tissue response that is possibly triggered by the breakdown 
products of  the biodegradation process. In short, the most important properties 
of  a biodegradable biomaterial can be summarized as follows [1-3]: 
• The material should not evoke any inflammatory or toxic responses upon 
implantation in the body. 
• The material should have acceptable shelf  life.  
• The degradation time of  the material should match the healing or 
regeneration process.  
• The material should have appropriate mechanical properties for the 
indicated application and the variation in mechanical properties with 
degradation should be compatible with the healing or regeneration process.  
• The degradation products should be non-toxic, and able to get 
metabolized and cleared from the body.  
• The material should have appropriate permeability and processibility for 
the intended application. 
In view of  the fact that polymeric biomaterials are used in a variety of  
applications, there is no single polymer that could be considered as the “ideal 
biodegradable biomaterial”. Biodegradable polymers are found in the following 
applications [1, 4-8]:  
General Discussion 
143 
• Fixation devices (screws) in orthopedic and trauma surgery. 
• Implanted contraceptive reservoirs. 
• Small implats, e.g. sutures, staples, and microsized drug delivery vehicles. 
• Membranes and fibers for guided tissue regeneration. 
• Porous structures for tissue engineering. 
To meet the specific requirements of  these applications, a wide array of  
different biodegrable polymers has been developed. This is now, anno 2015, the 
basis of  an important industrial branch that bridges the traditional domains of  
chemical and medical device industries. Global sales of  medical devices based on 
biodegradble biomaterials has been estimated at 12 billion US$ in 2010. There is 
no doubt that this figure will grow substantially in the next decades.  
Most of  the biodegradable polymers that are used in clinical practice degrade 
through hydrolysis. An particularly important subclass comprises the poly(α-esters), 
such as poly(glycolide), poly(lactides), poly(lactide-co-glycolides), poly(dioxanone), 
poly(caprolactone), poly(trimethylene carbonate) and bacterial polyesters. Other 
important subclasses are: poly(ester amides), poly(ortho esters), poly(anhydrides), 
poly(phospazenes) and poly (phosphoesters). Over the years, advances in synthetic 
organic chemistry have provided the key to the development of  more and more 
sophisticated synthetic biodegradable implants. Moreover, some biodegradable 
polymers from a biological origin are used clinically. These materials comprise, for 
example, collagen, natural poly(amino acid)s, elastin, albumin, and fibrin.  
This thesis focuses on poly(lactide) (abbreviated as: PLA), i.e. macromolecules 
derived from D- and/or L-lactic acid. The ester linkages in PLA allows it to 
degrade through hydrolysis. PLA is probably the most widely accepted and most 
trusted synthetic biodegradabe polymer. The two most important features of  PLA, 
biodegradability and biocompatibility, make it a widely used material in various 
biomedical applications, e.g. sutures, implants and drug delivery system [4, 7, 9]. 
Interestingly, the aspect of  biodegradation has become an important avenue for 
innovation in various minimally invasive therapies [10-13]. This thesis focuses on 
the utilization of  biomaterials derived from PLA in two types of  minimally 
invasive treatment techniques. 
(i) Endovascular stenting. Biodegradable endovascular stents have been 
introduced approximately 10 years ago, and several devices have appeared on the 
market. PLA has been used to construct biodegradable stents. The main limitation 
of  current PLA stents is their X-ray translucency, which has led to the 
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development of  the iodine-containing radiopaque PLA in this thesis (Chapters 2 
and 3). We have proven that the iodine-containing PLA is X-ray visible, 
biocompatible as well as hemocompatible and that it has the potential for 
utilization in endovascular stents.  
(ii) Vascular embolization. Vascular embolization using biodegradable embolic 
particles is still in its infancy. This is remarkable, since the manufacture of  
biodegradable microparticles (microspheres) is well known. In this thesis 
(Chapters 4 and 5) we show that also biodegradable particles containing one or 
two pharmacologically active drugs can be manufactured. We furthermore proof  
biodegradation and functional release of  the embedded drugs, and that clever use 
of  these principles can retard growth of  subcutaneous tumours, at least in a mouse 
model.  
Below we describe the main conclusions of  the thesis as well as some 
outlooks for future research. 
6.1 Radiopaque PLA Blends for Medical Applications 
Approaches to Manufacture Radiopaque Polymers 
Radiopacity is an important and desirable property for polymeric materials used 
for medical implants, since this allows these implants to be detectable by 
fluoroscopy and X-ray imaging. Conventional hydrocarbon polymers (e.g. PLA) are 
hardly X-ray visible because they are primarily composed of  light elements such as 
carbon, hydrogen, oxygen and nitrogen.  
Radiopaque polymer blends with X-ray opacifiers like inorganic salts (e.g. 
barium sulfate) or organic and inorganic compounds containing heavy elements 
(e.g. iodine, bismuth and lead) have been developed [14-16]. However, because 
most of  the commercially available X-ray opacifiers are incompatible with 
polymers, the resultant polymer blends are heterogeneous. This heterogeneity is a 
major drawback, since it results in reduced mechanical properties of  the polymer 
blends [14]. Another important radiopaque polymer system is the polymerization 
product of  radiopaque monomers [17]. The monomer is usually produced by 
incorporation of  covalently bonded heavy elements. The disadvantage of  this kind 
of  systems is their relatively higher production cost compared with physical 
blending systems. 
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In this thesis we developed a new contrast agent that enabled physical 
blending to be used as a feasible and attractive method to manufacture radiopaque 
PLA-based materials (Chapters 2 and 3). Poly(D,L-lactic acid) (PDLLA) or 
poly(L-lactic acid) (PLLA) was blended with the new contrast agent, (S)-2-hydroxy-
3-(4-iodobenzyloxy) propanoic acid, using a twin-screw mini-extruder system. The 
resultant PLA blends were found to be homogeneous, optically transparent and 
radiopaque. The heterogeneity commonly observed in physical blending systems 
was overcome by using our new contrast agent. Besides physical blending, it was 
also possible to synthesize radiopaque polymers through ring-opening 
polymerization from the dimers of  the new contrast agent. Though in essence 
possible, this approach was found to be problematic in practice, i.e. low yield of  
the dimers (< 20%) and difficulty in preparing high molecular weight polymer. 
Considering the problems and complex procedures of  polymerization, we 
therefore consider physical blending to be a more attractive approach with easy 
procedures at low costs and with great practical value. 
Homogeneous and Heterogeneous Radiopaque Polymeric Systems 
In Chapters 2 and 3, two contrast agents were used to introduce radiopacity to 
PLA: (i) the new contrast agent developed in this thesis, (S)-2-hydroxy-3-(4-
iodobenzyloxy) propanoic acid, which is insoluble in water; (ii) a water-soluble 
commercial contrast agent, sodium diatrizoate. PLA (PDLLA or PLLA) blended 
with the new contrast agent was found to be homogeneous, while PLA blends 
containing sodium diatrizoate were heterogeneous. Considering the final 
biomedical application of  these radiopaque blends (e.g. coronary stents), i.e. these 
blends will be in direct contact with body fluids, heterogeneity is a great 
disadvantage that should be overcome. Mechanical failures are often found at the 
interface between polymer matrix and the X-ray opacifier. These fractures allow 
for penetration of  body fluid, and can lead to leakage of  the additive as well as to 
mechanical cracks and thereby to reduced mechanical properties [14]. It is also 
noted that the addition of  water soluble radiopacifiers to polymer can increase 
water absorption, thus reducing its mechanical properties [14, 17-18]. This might 
be especially critical for PLA, since water absorption significantly affects its 
degradation behavior [19-21]. Regarding these limitations of  heterogeneous 
radiopaque systems, it is worthwhile to develop homogeneous radiopaque PLA 
blends which will enable accurate engineering of  their mechanical properties and 
degradation kinetics. The concept of  homogeneity is in particular essential for 
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stent application due to the relatively large surface area of  this device. For stents 
made of  heterogeneous radiopaque PLA, e.g. PLLA/sodium diatrizoate blends, 
the large surface would greatly enhance water absorption and penetration, thus 
increasing the degradation rate and reducing mechanical properties of  the stents. 
Radiopacity of  Iodine-containing PLA Blends  
Radiopacity is one of  the key considerations in the design of  stents that are used 
during radiological intervention. In our study radiopacity of  iodine-containing 
PDLLA blends were quantified according to the Hounsfield scale (Chapter 2). 
Films (thickness: 500 μm) made from PDLLA blends (10 wt%) have a value of  
721 Hounsfield units (HU), while the value for PDLLA films is 340 HU. This 
indicated that incorporation of  the new contrast agent indeed improved the 
radiopacity of  PDLLA. We didn’t characterize the X-ray visibility of  these 
radiopaque PLA blends in vivo yet. If  the presence of  10 wt% new contrast agent 
turns out to be too low for PLA X-ray visibility in vivo, it will be necessary to 
increase the radiopacity of  PLA. It is known that radiopacity of  polymeric 
materials correlates positively with the content of  radiopaque elements [22]. 
Therefore, the X-ray contrast of  PLA can be further improved with increasing the 
content of  the new contrast agent. Meanwhile it is to be expected that increase in 
contrast agent content will influence other properties of  the polymer matrix as 
well, e.g. thermal behavior (like Tg), mechanical properties and degradation time. 
Hence it is important to find the optimal content of  the contrast agent to obtain 
blends with desirable properties.  
Outlook for Future Research on Radiopaque PLA Blends 
A new contrast agent, (S)-2-hydroxy-3-(4-iodobenzyloxy) propanoic acid, was 
designed and synthesized in this thesis. On the one hand, studies on this new 
contrast agent have shown promising results: PLA (PDLLA and PLLA) blends 
containing the new contrast agent (up to 10 wt%) were homogeneous, radiopaque, 
transparent, biocompatible (in vitro) and hemocompatible (in vitro). On the other 
hand, more research and development work should be performed to address the 
following issues:  
(i) Optimal content of  contrast agent. The content of  the new contrast will 
directly affect the mechanical properties of  the resulting blends. Therefore, it is 
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important to find the optimal content of  the new contrast agent, i.e., the content 
which is below the upper limit and gives the blends desirable properties, such as 
strength, fatigue, degradation profile, radiopacity, etc. 
(ii) In vivo biocompatibility and metabolism of  the new contrast agent. This study will 
provide us essential data to evaluate the in vivo safety of  the new contrast agent, 
which is essential for biomedical applications. 
(iii) In vitro and in vivo X-ray visibility. It is known that radiopacity of  a material 
is related to its thickness and imaging methods [14, 23]. An effective approach to 
investigate X-ray visibility of  the blends is to build stents from the blends and 
compare their visibility with other stents under the same condition in vitro and in 
vivo.  
(iv) In vitro and in vivo degradation kinetics. Degradation of  the PLA blends will 
directly influence its radiopacity. It is noted that the new contrast agent is not 
covalently bonded to PLA. With the degradation of  PLA, the new contrast agent 
will be released and radiopacity will reduce. Since the new contrast has good 
compatibility with PLA, radiopacity might even be employed as a parameter to 
monitor the degradation of  PLA, which will be of  great importance for in vivo 
studies. 
Research along these lines will give us more ideas of  the potentials of  our 
new contrast agent and also the resultant radiopaque PLA blends. It will also be 
interesting to study compatibility of  the new contrast agent with other degradable 
polyesters, e.g. poly(glycolic acid) and poly(lactic-co-glycolic acid), which will widen 
the application scope of  this new contrast agent. 
6.2 Embolic Drug-eluting Biodegradable PLA 
Microspheres for Medical Applications 
Drug Release Kinetics of  Biodegradable PDLLA Microspheres 
In this thesis, PDLLA was used as the polymer matrix to construct drug-loaded 
microspheres The PDLLA we used degraded very slowly with no significant 
weight loss (< 5%) after 9 months of  incubation.  
In general, four possible mechanisms for the drug release from PLA-base 
microspheres can be defined: (i) initial release from the surface of  the 
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microspheres; (ii) diffusion through water-filled pores; (iii) diffusion through the 
polymer matrix itself; (iv) polymer erosion and bulk degradation [24-25]. It is often 
said that the initial drug release is controlled by diffusion and that the release rate 
during the final stage of  the release period is controlled by degradation/erosion 
[26-27].  
For our PDLLA microspheres loaded with cisplatin and sorafenib tosylate, 
significant drug release occurred even before the onset of  obvious polymer 
erosion. This fast release might be attributed to their porous structure, which 
facilitated the diffusion of  drugs through water-filled pores. The formulation with 
sorafenib tosylate or cisplatin alone showed a typical entrapment of  drug into the 
matrix with non-significant release over two weeks (< 10%), i.e. the drug release in 
this stage is controlled by diffusion of  drug through dense polymer matrix. The 
slow drug release rates of  these two formulations may result in low therapeutic 
efficacy.  
 
Figure 1. Scanning electron images of  porous PDLLA microspheres. 
One approach to increase drug release rates is to create porous microspheres. 
Chung and Kim et al. [28-29] used Pluronic F127, a tri-block co-polymer 
composed of  poly(ethylene glycol)–poly(propylene glycol)–poly(ethylene glycol), as 
the water extractable porogen and prepared highly porous PLGA microspheres. By 
changing the weight ratio of  Pluronic F127/PLGA, a range of  PLGA 
microspheres with different porosity was obtained. We used Pluronic F107 as the 
porogen and prepared PDLLA microspheres by solvent evaporation. Figure 1 
shows the internal structure and surface morphology of  these microspheres. They 
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are highly porous inside and have some small pores on the surface. Hydrophobic 
drugs could be loaded to these microspheres during the preparation process, 
following up on the approach as we have used in Chapter 4. These porous 
microspheres could be used in future research for drug delivery. 
Biodegradable Drug-loaded Embolic Particles  
Transarterial chemoembolization (TACE) is a minimally invasive therapy used to 
treat primary tumors, especially tumors confined to the liver, e.g. hepatocelluar 
carcinoma. A variety of  embolic agents are now available in the market, such as 
gelatin sponge, polyvinyl alcohol (PVA) microspheres, coils and nonresorbable 
drug-eluting beads [30-31].  
Gelatin sponge (Gelfoam®) particles are the only biodegradable embolic 
particles that have been used extensively in treatment of  hepatocellular carcinomas. 
The gelatin particles mostly have an irregular shape (non-spherical), and small 
diameter (i.e., in the range 40 - 60 µm) [31]. Gelatin is a biodegradable material, i.e. 
the particles will dissolve and disappear in the course of  time; it is known from 
animal experiments that degradation takes approximately 1 – 3 weeks [32]. In 
Asian countries, gelatin is preferred as a temporary embolic agent to preserve 
patency of  the hepatic artery. On the other hand, however, it is also proved that 
gelatin sponge embolic particles can clump and associate after leaving the 
catheter’s mouth, thus leading to more proximal embolic occlusion than is 
intended. The latter phenomenon may explain why the use of  gelatin sponge 
embolic particles never became really widespread [31]. 
Apart from gelatin sponge particles, no biodegradable drug-eluting 
microspheres have been used in TACE to treat hepatocellular carcinomas. This 
thesis addresses the question whether embolic particles consisting of  PDLLA may 
provide alternatives to existing (biodegradable) materials and techniques. Our 
research was based on the premise that embolization, combined with local release 
of  one or more drugs, is of  particular interest in oncology, especially in the 
treatment of  hepatocellular carcinomas [33-35]. It is known that embolization per se 
is often not effective, as the formation of  new capillary arteries around the 
obstructing microparticles (local angiogenesis) can quickly restore the arterial 
blood supply [36-38].  It was decided, therefore, to manufacture and study PDLLA 
microparticles containing both a cytostatic (cisplatin) and an anti-angiogenic agent 
(sorafenib tosylate), so-called Cisplatin + ST microspheres. These Cisplatin + ST 
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microspheres could be evenly suspended in contrast agent mixture for a few 
minutes and were deliverable through a 4-Fr diagnostic catheter, indicating that 
they can be handled and administered according to standard TACE procedure. In 
addition, these Cisplatin + ST microspheres showed high therapeutic efficacy 
when intratumorally administered in vivo. Our results support that these Cisplatin + 
ST microspheres have the potential to be used as embolic agent for TACE.  
Radiopaque Embolic Microspheres 
Radiopacity of  microspheres is of  great interest for TACE, since this would enable 
real-time follow-up of  the particles during and after TACE procedure. Several 
types of  radiopaque microspheres that are detectable with X-ray-based imaging (e.g. 
fluoroscopy and CT) have been developed, in which X-ray contrast is introduced 
by incorporation of  contrast material within the microspheres or covalent 
attachment of  contrast to the polymer chains [39-41]. The PDLLA microspheres 
loaded with two drugs developed in Chapter 4 are radiopaque due to entrapping 
cisplatin within the microspheres. As can be expected, radiopacity of  these 
microspheres will decrease with the release of  cisplatin. This implicates that 
radiopacity might be monitored to obtain real-time feedback on drug release in vivo. 
Of  note is that the new contrast agent synthesized in Chapter 2 could be used to 
prepare radiopaque microspheres as well. 
Outlook for Future Research and Regulatory Hurdle 
In vitro and in vivo evaluations of  the microspheres loaded with cisplatin and 
sorafenib tosylate certificated their therapeutic efficacy and underlined the 
potential to use these microspheres as embolic agent for TACE. Future in vivo 
studies, which mimic the intra-arterial administration of  embolic particles in TACE 
(e.g. the rabbit VX2 tumor model [42-44]), should be performed to evaluate the 
therapeutic efficacy of  our newly developed drug-loaded microspheres. 
In addition, many parameters, such as loading percentages, ratio of  
cisplatin/sorafenib tosylate and drug categories could be changed and further 
optimized. Drug release kinetics of  microspheres can be tailored by adjusting their 
size, structure and degradation kinetics. This will lead to a plethora of  various 
formulations, which is of  great interest in personalized therapies.  
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Although the drug-loaded microspheres developed in this thesis showed 
promising results in vivo, we must recognize that the use of  preloaded microspheres 
implies that there will be significant regulatory issues, since this product will be 
classified as a medical device/drug combination. In addition, this kind of  device is 
used to treat cancer and regulators want to see survival benefits for patients treated 
with such a product. The level of  clinical evidence and the cost required to 
generate supportive data also provide hurdles to the development of  such products. 
This regulatory hurdle might also explain the absence of  a PLA-based drug-eluting 
microsphere on the market for treating hepatocellular carcinomas. However, 
considering the varying response rates in hepatocellular carcinomas treated by 
TACE with current drug-eluting microspheres (44% – 80.6%) [45], efforts to 
introduce new drug-carrying particles into the clinic are most likely to be 
worthwhile. 
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Summary 
Poly(lactic acid), which is a “green” and biocompatible material, has become an 
important polymeric construction material; it is eminently suitable for a wide range 
of  applications. In the last decades, considerable efforts from both academia and 
industry have been devoted to the utilization of  poly(lactic acid) in the biomedical 
field especially due to the material’s outstanding biocompatibility and 
biodegradability. For example, sutures, implants, scaffolds for tissue engineering 
and drug delivery systems have been manufactured out of  poly(lactic acid). This 
thesis describes novel approaches to formulate poly(lactic acid)-based biomaterials 
with two biomedical applications in mind, biodegradable vascular scaffolds and 
biodegradable embolic particles for anti-tumor therapy. Both applications are drug-
device combination products and have a primary mode of  action that is physical. 
The promising clinical results of  the ABSORB bioresorbable vascular scaffold 
(BVS) (a stent made of  poly(lactic acid), Abbott Vascular, Santa Clara, CA, USA) 
have indicated the safety and efficacy of  BVS and demonstrated the potential of  
BVS as an alternative for metal stents. Concerns about the radiolucency of  
poly(lactic acid) scaffolds led to the research of  a new contrast agent to impart 
radiopacity to poly(lactic acid) (Chapters 2 and 3). 
In Chapter 2, a new contrast agent, (S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid, is studied. This compound was synthesized from Boc-L-serine and 
4-iodobenzyl bromide. The new contrast agent was designed to bear structural 
resemblance to L-lactic acid and to contain covalently bound iodine. 
Characterization by proton nuclear magnetic resonance spectroscopy (1H NMR) 
and analysis of  the crystal structure (X-ray) certificated that the new contrast agent 
was pure and crystalline with extensive hydrogen bonding inside the crystal. The 
new contrast agent revealed no obvious cytotoxic effect on human coronary 
arterial endothelial cells (HCAECs), porcine skin fibroblast cells (PSFs) or porcine 
aortic smooth muscle cells (PSMCs) when these types of  cells were incubated in 
medium containing different concentrations of  the compound (0 to 10 mM). The 
new contrast agent also showed no clear negative effect on gene expression of  
HCAECs. Blends of  poly(D,L-lactic acid) (PDLLA, medical grade) with 5% or 10% 
of  the new contrast agent were prepared, using a twin-screw extrusion system. The 
thermal behavior, structure, and X-ray visibility of  these blends were investigated 
by differential scanning calorimetry (DSC), scanning electron microscopy (SEM, in 
backscatter mode), X-ray photoelectron spectroscopy (XPS) and a nanofocus X-
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ray inspection system. The results revealed that these blends were homogeneous 
and radiopaque; the new contrast agent acted as a plasticizer on PDLLA. For 
comparison, we also prepared PDLLA blends with the commercial contrast agent 
sodium diatrizoate. These materials appeared to have a phase-separated structure. 
We further studied the biocompatibility of  our blends with the new contrast agent 
in in vitro, using the MTT (triazolyl blue tetrazolium bromide) and live/dead assays; 
the blends exhibited no toxic effect in both tests. Data in this chapter certificate 
that it is feasible to manufacture radiopaque, biocompatible and homogenous 
PDLLA blends with the new contrast agent. Unfortunately, the glass transition 
temperatures (Tg) of  the 5% and 10% PDLLA blends are low (41 and 34 oC), 
indicating that these blends are too soft to use as stent building materials.  
Chapter 3 focuses on the preparation and characterization of  radiopaque 
poly(lactic acid) blends with higher Tg-values. In this chapter, a semi-crystalline 
poly(lactic acid), poly(L-lactic acid) (PLLA medical grade; Tg = 58 – 60 oC ), was 
used as the polymer matrix to build blends with (S)-2-hydroxy-3-(4-iodobenzyloxy) 
propanoic acid. These PLLA blends had higher Tg-values (55 and 47 oC for 5% 
and 10% blends, respectively) than PDLLA blends. SEM (in backscatter mode) 
images of  the blends certificated the good compatibility of  the new contrast agent 
with PLLA, i.e. these blends were homogeneous. PLLA blends containing sodium 
diatrizoate, prepared for comparison, had a heterogeneous structure. Addition of  
the new contrast agent did not have an obvious negative effect on the mechanical 
properties of  the polymer matrix. In addition, in vitro cytotoxicity and thrombin 
generation tests demonstrated the biocompatibility and hemocompatibility of  the 
blends containing the new contrast agent. The results in this chapter indicate the 
suitability of  these blends for the application of  bioresorbable vascular stents. 
Chapters 4 and 5 describe the formulation of  drug-loaded biodegradable 
microspheres composed of  PDLLA with the application transarterial embolization 
in mind. DC Bead® (Biocompatibles, Farnham, UK) is the most widely used non-
degradable embolic microspheres in this application. Concerns of  possible late 
inflammatory foreign-body response to the presence of  non-degradable particles 
and the fact that DC Bead® can’t control the release of  drugs lacking binds to the 
beads prompted the research on drug-eluting PDLLA microspheres. 
Chapter 4 is focused on PDLLA microspheres loaded with the anti-tumor 
drugs cisplatin and/or sorafenib tosylate. These microspheres with diameter 
ranging between 200 and 400 µm, were fabricated by a solvent evaporation method. 
SEM showed that: (i) cisplatin + sorafenib tosylate loaded microspheres were 
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porous; (ii) control PDLLA microspheres as well as cisplatin loaded microspheres 
had smooth surfaces; (iii) sorafenib tosylate microspheres were slightly porous at 
the surface. The drug release behavior of  all microspheres was studied in vitro in 
phosphate buffered saline (PBS) at two pH-values (pH 7.4 and pH 6.0). Drug 
release rates of  cisplatin + sorafenib tosylate microspheres were much faster than 
those of  micro-spheres containing single drug, which was ascribed to the different 
mechanisms controlling the drug release process. The fast release of  drugs from 
cisplatin + sorafenib tosylate microspheres results, most likely, from the porous 
structure which enabled fast diffusion of  drug molecules through water-filled 
pores. The drug release of  microspheres with single drug was probably controlled 
by the transport of  drug through the dense polymer matrix, thus resulting in slow 
release rates. Results of  in vitro cytotoxicity experiments and classical matrigel 
endothelial tube assay certificated the cytotoxic effect of  cisplatin and anti-
angiogenic effect of  sorafenib tosylate released from the microspheres, respectively.  
Chapter 5 further describes degradation (in vitro) of  the microspheres 
prepared in Chapter 4. Release profiles of  cisplatin and/or sorafenib tosylate from 
these microspheres (in vitro and in vivo) were measured. Degradation of  the 
microspheres was characterized in phosphate-buffered saline (pH 7.4). Results 
revealed that the microspheres degraded slowly during the test period of  9 months. 
On the one hand, the slow degradation explained the slow drug release rates of  
microspheres loaded with single drug. On the other hand, significant release of  
cisplatin and sorafenib tosylate from the microspheres containing both drugs 
occurred in vitro in spite of  the slow degradation, probably due to the porous 
structure of  these microspheres. Supernatants from cisplatin + sorafenib tosylate 
microspheres showed both strong toxicity to cells (i.e. endothelial cells, fibroblast 
cells and renal tumor (Renca) cells) and strong anti-angiogenic effect in matrigel 
endothelial tube assay. In vivo therapeutic efficacy of  the microspheres was 
evaluated using a mouse renal tumor (Renca) model. Microspheres loaded with 
both drugs showed the strongest anti-tumoral effect, indicating that administration 
of  both a cytostatic agent (i.e. cisplatin) and an anti-angiogenic agent (i.e. sorafenib 
tosylate) inside a solid tumor might be an effective approach to achieve tumor 
inhibition. The data in Chapters 4 and 5 underline the promise of  biodegradable 
drug-eluting microspheres containing cisplatin and sorafenib tosylate for 
intratumoral drug delivery and their potential in transarterial chemoembolization.  
Chapter 6 summarizes and discusses the main conclusions of  the thesis and 
provides outlooks for future research. 
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Samenvatting 
Poly(melkzuur), een groen en biocompatibel materiaal, is bij uitstek geschikt voor 
een uitgebreide reeks van toepassingen.  In de afgelopen decennia is, zowel in de 
academische wereld als in de industrie, gewerkt aan het gebruik van poly(melkzuur) 
op biomedisch gebied (bijvoorbeeld hechtdraden, implantaten, poreuze materialen 
voor weefsel-regeneratie en geneesmiddelafgifte systemen). De populariteit van 
poly(melkzuur) is terug te voeren op de uitstekende biocompatibiliteit en de 
voorspelbare gecontroleerde biologische afbreekbaarheid van het materiaal. Het 
onderzoek in dit proefschrift is verricht met het oog op de toepassing van 
poly(melkzuur) als constructiemateriaal voor endovasculaire stents, en als 
embolische deeltjes voor anti-tumor therapie. In beide toepassingen heeft het 
implantaat een primaire fysische functie.  
De veelbelovende klinische resultaten van de ABSORB (BVS) “scaffold”, een 
door Abbott Vascular (Santa Clara, CA, USA) gemaakte stent van, poly(melkzuur), 
bewezen de veiligheid en werkzaamheid van poly(melkzuur), en toonden het 
potentieel van BVS als een alternatief  voor metalen stents. De transparantie voor 
röntgenstralen van poly(melkzuur), leidde tot ons onderzoek naar een nieuw 
contrastmiddel waarmee radiopaciteit geintroduceerd kan worden in poly(melkzuur) 
(Hoofdstukken 2 en 3).  
In Hoofdstuk 2 wordt de synthese van een nieuw contrastmiddel (S)-2-
hydroxy-3-(4-iodobenzyloxy) propanoic zuur beschreven; start-materialen zijn Boc-
L-Serine en 4-iodobenzylbromide. Het nieuwe contrastmiddel was zo ontwikkeld 
dat de structurele gelijkenis met L-melkzuur werd behouden en jodium covalent 
werd gebonden. Proton kernspinresonantie en röntgendiffractie toonden aan dat 
het nieuwe contrastmiddel zuiver en kristallijn is (met waterstofbruggen binnen het 
kristal). Het nieuwe contrastmiddel was niet cytotoxisch voor humane coronaire 
arteriële endotheelcellen (HCAECs), varkenshuid fibroblastcellen, of  gladde 
spiercellen van de varkensaorta wanneer deze cellen werden geïncubeerd in 
medium met verschillende concentraties van het nieuw contrastmiddel (0 tot 10 
mM). Het nieuwe contrastmiddel toonde ook geen duidelijk negatief  effect op 
genexpressie van HCAECs. Door middel van extrusie, waarbij gebruik gemaakt 
werd van een extruder met een dubbele schroef, werden mengsels van poly(D,L-
melkzuur) (PDLLA) met 5% en 10% van het nieuwe contrastmiddel gemaakt. 
Thermisch gedrag, structuur en röntgenzichtbaarheid van deze mengsels werden 
onderzocht met ‘differential scanning calorimetry’ (DSC), ‘scanning electron 
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microscopy’ (SEM), ‘X-ray photoelectron spectroscopy’ (XPS) en een ‘nanofocus 
X-ray inspection system’. De analyses toonden aan dat de mengsels homogeen en 
radiopaak zijn, en dat het nieuwe contrastmiddel als weekmaker fungeert. Ter 
vergelijking werden PDLLA blends met natrium diatrizoaat (een commercieel 
contrastmiddel) gemaakt; maar dit resulteerde in fase-gescheiden structuren.  
Verder hebben we de biocompatibiliteit van de mengsels met het nieuwe 
contrastmiddel bestudeerd door middel van in vitro MTT en live/dead testen, 
waarbij er geen toxische effecten van de mengsels konden worden aangetoond. De 
gegevens in dit hoofdstuk bewijzen dat het mogelijk is om radiopake, 
biocompatibele en homogene PDLLA mengsels met het nieuwe contrastmiddel te 
vervaardigen. Echter, de glastransitietemperatuur (Tg) van de 5% en 10% PDLLA 
mengsels is erg laag (41 en 34 °C, respectievelijk). De verkregen materialen zijn dus 
te zacht (rubberachtig) om als poreus, biologisch afbreekbaar materiaal voor stents 
gebruikt te kunnen worden. 
Hoofdstuk 3 is gericht op de synthese en karakterisatie van radiopake 
poly(melkzuren) mengsels met hogere Tg-waarden. Het semi-kristallijne 
poly(melkzuur), poly(L-melkzuur) (PLLA, Tg = 58 – 60 oC ) is gebruikt als 
polymeermatrix om mengsels met het nieuwe contrastmiddel te maken. Deze 
PLLA mengsels hadden inderdaad hogere Tg-waarden (55 en 47 oC voor 5% en 10% 
mengsels, respectievelijk) dan PDLLA mengsels. SEM beelden toonden 
homogeniteit van de blends van het nieuwe contrastmiddel en PLLA. Ter 
vergelijking werden ook PLLA blends met natrium diatrizoaat gemaakt; deze 
materialen waren heterogeen (fase-gescheiden). Toevoeging van het nieuwe 
contrastmiddel heeft geen negatief  effect op de mechanische eigenschappen van 
de polymeermatrix. Ook toonden in vitro cytotoxiciteit- en trombinegeneratietesten 
de biocompatibiliteit en hemocompatibiliteit van het nieuwe contrastmiddel aan. 
De resultaten in dit hoofdstuk geven aan dat deze mengsels een hoge potentie 
hebben voor toepassing in bioresorbeerbare vasculaire stents. 
Hoofdstukken 4 en 5 gaan over biomedische toepassing van poly(melkzuur) 
als embolische deeltjes. DC Beads (Biocompatibles, Farnham, UK) is het meest 
gebruikte, niet afbreekbare product voor trans-arteriële embolisatie. De kans op 
een late ontstekingsreactie op vreemd materiaal door de aanwezigheid van niet-
afbreekbare deeltjes en het feit dat de afgifte van geneesmiddel door de DC Beads 
niet gecontroleerd kan plaatsvinden, vormden de aanleiding tot ons onderzoek 
naar bioresorbare microsferen die geneesmiddelen afgeven. 
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Hoofdstuk 4 beschrijft de productie van PDLLA microsferen met, een 
diameter tussen de 200 en 400 µm, geladen met anti-tumor geneesmiddel 
(cisplatine en/of  sorafenib tosylaat). De microsferen zijn gemaakt door middel van 
de oplosmiddel-verdampingsmethode. Uit SEM analyse bleek dat (i), cisplatine + 
sorafenib tosylaat microsferen poreus waren; (ii), PDLLA microsferen en cisplatine 
microsferen een glad oppervlak hadden; (iii), sorafenib tosylaat microsferen 
enigszins poreus waren aan het oppervlak. Van alle microsferen werd het 
geneesmiddelafgiftegedrag in vitro onderzocht in een fosfaat gebufferde 
zoutoplossing bij twee pH-waarden (pH 7,4 en pH 6,0). De geneesmiddelafgifte 
van cisplatine + sorafenib tosylaat microsferen bleek veel sneller te verlopen dan in 
het geval van microsferen met maar één enkel geneesmiddel. Dit is waarschijnlijk te 
wijten aan een verschil in afgiftemechanisme. De snelle geneesmiddelafgifte van 
cisplatine + sorafenib tosylaat microsferen kan voortvloeien uit de bijdrage die de 
poreuze structuur levert aan een snelle diffusie in een waterige omgeving. De 
geneesmiddelafgifte van microsferen met één enkel medicijn vond waarschijnlijk 
plaats door transport van het medicijn door een minder poreuze oppervlakte, 
resulterend in langzamere afgiftesnelheden. De resultaten van de cytotoxiciteit 
experimenten en de ‘classical matrigel endothelial tube assay’ test onderstreepten 
het cytotoxische effect van cisplatine en het anti-angiogenese effect van sorafenib 
tosylaat. 
In Hoofdstuk 5 wordt beschreven hoe de afbraak van de in hoofdstuk 4 
gesynthetiseerde microsferen in vitro onderzocht werd. Tevens wordt het in vitro en 
in vivo afgifteprofiel van cisplatine en/of   sorafenib tosylaat uit deze microsferen 
beschreven. Degradatie van de microsferen werd gedurende 9 maanden 
gekarakteriseerd in een fosfaat gebufferde zoutoplossing (pH 7.4). Het bleek dat de 
microsferen gedurende de gehele onderzoeksperiode langzaam afbraken. De 
traagheid van de degradatie verklaart de langzame geneesmiddelafgifte van de 
microsferen geladen met een enkel medicijn. Anderzijds werd waargenomen dat  
microsferen die zowel cisplatine als sorafenib tosylaat bevatten een significante 
geneesmiddelafgifte hebben in vitro, dit ondanks de langzame degradatie. 
Waarschijnlijk kan dit worden toegeschreven aan de poreuze structuur van deze 
microsferen. Supernatanten van cisplatine + sorafenib tosylaat bevattende 
microsferen vertoonden zowel hoge toxiciteit voor cellen (bijvoorbeeld 
endotheelcellen, fibroblastcellen en Renca tumorcellen) als sterke anti-angiogenese 
werking. De in vivo therapeutische werkzaamheid van de microsferen werd 
geëvalueerd met behulp van een muis niertumormodel (Renca tumormodel). 
Microsferen geladen met beide geneesmiddelen toonden het sterkste anti-tumor 
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effect. Dit geeft aan dat toediening van zowel een cytostatisch middel (bijvoorbeeld 
cisplatine) als een angiogenese remmer (bijvoorbeeld sorafenib tosylaat) binnenin 
een tumor een duidelijk remmend effect heeft op de tumorgroei. De gegevens in 
Hoofdstuk 4 en 5 benadrukken dat biologisch afbreekbare geneesmiddelafgevende 
microsferen die geladen zijn met cisplatine en sorafenib tosylaat, een hoge potentie 
hebben voor intra-tumorale geneesmiddelafgifte. 
In Hoofdstuk 6 worden de belangrijkste conclusies van het proefschrift en 
ook de toekomstige richtingen voor het onderzoek naar het gebruik van 
poly(melkzuur) als coronaire stents en embolische microsferen beschreven. 
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Valorization 
Social and Economic Relevance of  the Results 
The radiopaque polymeric blends, derived from poly(lactic acid) (PLA) and 
described in Chapters 2 and 3 of  this thesis, are innovative and new materials. 
They were not described in the scientific or patent literature hitherto. The key 
hypothesis behind this research- and development work was that these blended 
materials would uniquely combine: (i) controlled bio-degradation; (ii) sufficient 
strength; (iii) radiopacity. It was anticipated that this combination of  physical 
properties could provide the basis for the development of  a new type of  
biodegradable endovascular stents. These, in turn, could potentially be developed 
further to become the next generation of  the well-known biodegradable vascular 
stents. 
The results, as described in Chapters 2 and 3, were in line with our 
hypothesis. The blends derived from poly(L-lactic acid) (Chapter 3) appeared 
suitable for the construction of  endovascular stents. Most importantly, the feature 
of  X-ray visibility will contribute to the safety and accuracy of  endovascular 
stenting. Cardiologists are used to radiopaque stents (metallic stents can be 
monitored real time through X-ray fluoroscopy during the procedure). However, 
when using biodegradable stents, it is not possible to clearly visualize the stent: 
merely two metallic “contrast points” can be seen.  
Although there is still a long way to go, the results of  the thesis may provide 
the basis for this new generation of  biodegradable stents. On the one hand it is 
well imaginable that this can lead to new innovative products and new industrial 
activity. On the other hand, the new biodegradable radiopaque stents have the 
potency of  leading to improved clinical results, because stent placement can be 
monitored better than in case of  classical biodegradable stents, and because the 
degradation can – in principle - be monitored non-invasively during a post-
procedural X-ray investigation.  
Chapters 4 and 5 describe, for the first time, microspheres composed of  
poly(D,L-lactic acid) (PDLLA), which are suitable for transarterial embolization 
therapy. The microspheres had an additional feature: they contain one or two drugs, 
and these drugs are released in situ in a concerted fashion controlled by structure 
of  the microspheres and the breakdown of  the polymer matrix. The drugs that 
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were studied were cisplatin (a well-known cytostatic drug) and sorafenib tosylate (a 
relatively new drug that inhibits angiogenesis).  
It is clear that transarterial embolization will gain importance in oncology in 
the near future. Minimally invasive therapies will compete more and more with 
“classical” surgery. The research leading to Chapters 4 and 5 was conducted on 
the basis of  the hypothesis that drug-releasing embolic particles would be 
mandatory in order to enhance the efficacy of  embolization therapies in oncology. 
Chapters 4 and 5 describe the manufacture of  biodegradable embolic 
microspheres (consisting of  PDLLA as the polymer matrix), with either cisplatin 
or sorafenib tosylate embedded in them. In addition, PDLLA microspheres 
containing both cisplatin and sorafenib tosylate were developed. Although there is 
still a long way to go, it is clear that these particles can be developed further into 
new and innovative medical device/drug combination products for cancer therapy. 
This concept may lay the basis for new economic activities and new job 
opportunities. It is widely agreed that in the near future numerous patients will 
benefit from the development of  minimally invasive treatment modalities. This is 
particularly true for patients suffering from hepatocellular carcinoma, since 
transarterial chemoembolization is the most commonly offered therapy for these 
patients [1]. It must be noted that this is an emerging field of  research and 
development. Globally, at least 20 research groups work on the development of  
embolization particles that release drugs in situ. However, the combination of  
cisplatin and sorafenib tosylate in one microsphere, as reported in this thesis, is 
unique, and can be potentially translated into new business and improved therapies.  
Target Groups 
The groups that may interest in or can benefit from the valorization of  the results 
of  this thesis include companies, patients and the healthcare system as a whole. 
Companies 
Companies in biomedical field could be interested in valorization of  our results, 
since the impetus of  the thesis directly comes from the limitations of  some 
commercial products and thus have a high promise to be translated into medical 
products/devices. Research in Chapters 2 and 3 provides a novel solution to the 
translucency issues of  PLA-based stents currently available in the market, e.g. 
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ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA) and DESolve (Elixir 
Medical, CA, USA). Chapters 4 and 5 focus on biodegradable drug-loaded 
PDLLA microspheres. The impetus of  these two chapters comes from: (i) 
concerns over non-degradable embolic microspheres for transarterial embolization, 
such as DC Bead® (Biocompatibles, Farnham, UK); (ii) local delivery of  drug 
combinations (i.e. cisplatin and sorafenib tolylate). Valorization of  these results 
may lead to new competitive products and economic benefits. 
Patients 
A great number of  people nowadays suffer from coronary artery disease (CAD) 
and hepatocellular carcinoma. CAD is narrowing or blockage of  coronary arteries 
preventing adequate blood supply to the heart, which can lead to angina, 
arrhythmia, heart failure and heart attack. CAD is one of  the leading causes of  
death worldwide over the last decade. In 2013, CAD became the top cause of  
death, responsible for 16.8% (8.14 million) of  all deaths worldwide [2]. In the light 
of  these numbers, it can easily be appreciated that treatment of  CAD is high on 
the agenda. Coronary angioplasty with a stent is one of  the most commonly used 
interventional procedures to treat CAD. Hepatocellular carcinoma is the sixth most 
frequent cancer and the third top cause of  cancer-related death globally [3]. 
Transarterial chemoembolization is the standard care of  patients with 
hepatocellular carcinoma, in particular those at the intermediate stage [4]. The 
incidence and mortality rates of  hepatocellular carcinoma have been reported to 
increase, primarily resulting from the rise in hepatitis C virus infections [5-6]. 
Valorization of  our results may lead to new medical devices (radiopaque 
biodegradable stents and biodegradable microspheres for transarterial 
chemoembolization), which could be transformed into better therapeutic 
performance and finally benefit patients.  
Healthcare System  
Minimally invasive procedures such as stenting and transarterial 
chemoembolization are generally cheaper and faster than the corresponding 
surgical counterpart procedures (bypass surgery and surgical tumor resection). The 
choice between minimally invasive therapy or surgical intervention primarily 
depends on the patients’ conditions. For patients with complex CAD (e.g. 3-vessel 
or left main coronary artery disease), bypass surgery is cost-effective. For patients 
Appendix 
166 
with less complex CAD (e.g. low SYNTAX scores for 3-vessel disease), coronary 
angioplasty with a stent is found to be attractive [7-8]. Transarterial 
chemoembolization is the recommended procedure to treat hepatocellular 
carcinoma for patients not amenable to curative therapies, i.e. tumor resection, 
ablation and liver transplantation [9]. Our results and the possible valorization of  
our results might contribute to the evolution of  the safety and efficacy of  these 
two minimally invasive procedures. More patients with CAD or hepatocellular 
carcinoma could become candidates to these less costly treatments with the 
advance in therapeutic technologies, which will benefit the whole healthcare system. 
Products and Innovation 
Valorization of  the results of  this thesis will lead to new innovative products, 
which are medical device/drug combinations. These are: biodegradable radiopaque 
endovascular stents, or biodegradable drug-releasing embolic microspheres.  
The results of  the thesis and the foreseen products are certainly innovative. 
With respect to the results of  Chapters 2 and 3, this is clear from the fact that the 
blend materials introduce a new feature that is not encountered in any of  the 
existing biodegradable PLA-based stents. This feature is X-ray visibility. Presently 
ABSORB BVS and DESolve are the only two CE mark approved PLA-based 
bioresorbable drug-eluting coronary stents available in the market. One important 
difference between these two stents and metal stents is that the struts of  these 
PLA-based stents are translucent. As a result, two metal markers are incorporated 
at both ends of  ABSORB BVS and DESolve. These metal markers allow 
interventionalists to navigate the stent, i.e. monitor the location of  the stent by X-
ray imaging and deploy the stents precisely. However, it is impossible to monitor 
expansion of  the stent or detect fracture of  the stent with these markers. Whole 
stent X-ray visibility may improve safety and accuracy of  stent implantation. 
The results as described in Chapters 4 and 5 are innovative as well. The 
microspheres loaded with cisplatin and sorafenib tosylate reported here have not 
been described previously. Furthermore, the combination of  cisplatin and 
sorafenib tosylate, showing high therapeutic efficacy in our in vivo experiments, 
could be considered as an example of  “inventive step”. DC Bead® is the most 
widely used drug-eluting microsphere product in transarterial chemoembolization. 
Compared with DC Bead® composed of  non-degradable poly(vinyl alcohol), one 
important feature of  the foreseen product based on our results would be the 
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degradability. This feature could avoid the risk of  late foreign-body reactions to 
non-degradable microspheres. In addition, the drug loading and releasing of  DC 
Bead® depend on the binding between the drug and the poly(vinyl alcohol) matrix; 
drugs that lack binding will be released uncontrollably [10]. For the PDLLA 
microspheres we presented, drugs are physically incorporated inside the polymer 
matrix, i.e. the drug loading or release kinetics is not related to the binding between 
the drug and the polymer matrix. This indicates that more options of  drug or drug 
combinations could be loaded to these PDLLA microspheres as compared to DC 
Bead®. Moreover, drug release of  these PDLLA microspheres is determined by 
structure, as well as the degradation process of  the microspheres, which could 
provide a fine-tuning of  the drug release kinetics. 
Market, Schedule and Implementation 
The foreseen radiopaque PLA-based bioresorbable stents present a promising 
innovation with a large potential market. According to a report on coronary stents 
from Globaldata, the global stents market for CAD was $4.89 billion in 2013 and is 
expected to increase to $5.62 billion by 2020 [11]. The market growth is attributed 
to the rising prevalence of  CAD due to aging of  the population as well as to the 
epidemic of  obesity and diabetes [12]. The stents currently used in clinic include 
bare metal stents, drug-eluting stents (DES) and bioresorbable stents. Lots of  
efforts have been devoted to the design of  DES to improve their efficacy and 
safety over the last decade. DES have become the first choice in coronary 
angioplasty to treat CAD. In 2010, DES held 55% - 60% of  the global coronary 
stents market and the share is expected to increase considering the high-adoption 
rate of  DES [13]. In contrast to DES, the market of  bioresorbable stents is still in 
its infancy. The small market share of  bioresorbable stents is directly associated 
with their availability in the market. Abbott Vascular is the leader in the 
bioresorbable stent market. Their product, ABSORB BVS, leads the market and is 
authorized for sale in Europe, parts of  Asia Pacific and Latin America. ABSORB 
BVS is still not approved for sale in some countries that hold large stent market, 
e.g. the USA, Japan and China. In the USA, ABSORB BVS is a device still under 
investigation and will probably be the first bioresorbable stent approved in the near 
future. Meanwhile, in countries where bioresorbable stents are approved for sale, 
these stents still have not received as high acceptance as DES in clinical practice. 
The reason for this is the limited knowledge regarding the very long-term results 
for bioresorbable stents as compared to DES. Several clinical trials and registries 
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currently running for further evaluating the safety and efficacy of  bioresorbable 
stents [14] will help to achieve high-adoption of  bioresorbable stents in the future. 
Unlike biodegradable stents, we must admit that the foreseen embolic 
biodegradable drug-eluting microspheres do not have a really large market, which 
is also the case for the commercial drug-eluting beads, e.g. DC Bead®. The reason 
for this is the limited number of  patients suitable for transarterial embolization. 
Although hepatocellular carcinoma is the sixth most frequent cancer worldwide, 
only less than 15% of  the patients are ideal candidates for transarterial 
embolization [15].  
The pathways to commercialization and clinical use of  any of  the foreseen 
products as described above will typically last several years at least or even decades. 
This is especially true since the anticipated products are medical device/drug 
combinations, which implies that there will be numerous strict regulatory 
requirements to be met on the route to CE certification. The most straightforward 
way to accomplish the development of  such products is to establish one or more 
high-tech companies with a specific mission to translate the current findings into 
one or more products. Financing of  such an endeavor will be critical and risky, 
since this is a highly competitive research & development area. In addition, there 
are already products that dominate the market, such as ABSORB BVS and DC 
Bead®. Nevertheless, there are huge potential benefits, since the foreseen products, 
emerging from this thesis research could provide ample opportunities for new 
business and improved therapeutic techniques.  
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